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Abstract 
This thesis evaluated supplementation with two components of flaxseed during exercise 
training on inflammation in older adults. 
Experiment 1: This experiment assessed secoisolariciresinol diglucoside (SDG) 
supplementation during aerobic exercise training on inflammation in older adults.  Methods:  
One hundred subjects aged 50y or older were randomized to receive either SDG or placebo 
before completing a 6-month walking program.  Fasting concentrations of interleukin-6 and 
tumor necrosis factor-α, glucose, triacylglycerol (TAG), high density lipoprotein (HDL), low 
density lipoprotein, and total cholesterol as well as leukocyte cell count were measured every 
two months while body composition, resting blood pressure, and a composite Z-score of six 
metabolic syndrome risk factors were assessed at baseline and 6 months.  Results: Men on 
placebo increased metabolic syndrome composite Z-score (p<0.05).  TAG increased (p=0.017) 
in men on placebo relative to men on SDG and men on SDG decreased (p=0.045) DBP relative 
to men on placebo.  Conclusions:  SDG had no effect on inflammation while it is effective in 
attenuating risk factors associated with metabolic syndrome in older males but not females. 
Experiment 2: This experiment evaluated alpha-linolenic acid (ALA) supplementation during 
strength exercise training on inflammation in older adults.  Methods:  Fifty-one healthy older 
adults (65.4±0.8y) were randomized to receive ALA or a placebo before completing a 12 wk 
strength training program.  Subjects were evaluated at baseline and 12 weeks for TNF-α and IL-
6, muscle strength, body composition, and muscle thickness.  Results:  Males supplementing 
with ALA decreased IL-6 concentration (p=0.003).  The female placebo and male ALA group 
had a significant increase in knee flexor thickness (p<0.05).  Chest and leg press strength, lean 
tissue mass, and muscle thickness significantly increased, while percent fat and total body mass 
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decreased with training (p<0.05), with no difference between ALA and placebo. Conclusions:  
ALA lowers IL-6 in older men, but has minimal effect on muscle mass and strength during 
resistance training. 
General Conclusion:  A composite score of metabolic syndrome is attenuated in males 
supplementing with SDG.  ALA reduces IL-6 in older men.  Older men, but not older women, 
derive specific health benefits from increased consumption of components of flaxseed consumed 
during an exercise program. 
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Chapter 1: Introduction and Review of Literature 
 
1.1 General Introduction 
 Aging is associated with biological changes that may increase the risk of developing 
chronic disease.  Of the various biological changes, decreased immune system function has been 
postulated to increase the risk of many diseases (Candore et al. 2006).  Cytokines are peptide 
mediators of the immune system and influence local and systemic control of the immune system 
and other regulatory systems of the body by binding to cytokine receptors located on cell 
membranes.  Aging results in a hyper-inflammatory state that is associated with an increased 
amount of pro-inflammatory circulating cytokines and a decreased production of anti-
inflammatory cytokines (Gomez et al. 2005).  The imbalance between pro- and anti- 
inflammatory cytokines is theorized to result in an increased susceptibility to infection and 
changes in tissue structure and function.  Cardiovascular disease, auto-immune diseases, type-II 
diabetes, sarcopenia (loss of muscle mass), and osteoporosis are all considered diseases or 
conditions which may be linked by chronic dysregulated inflammatory processes (de Rekeneire 
et al. 2006; Figaro et al. 2006; Prelog 2006; Stoll and Bendszus 2006; Yun and Lee 2004).  
Although changes in the homeostatic balance between too much and not enough inflammation 
may be influenced by numerous environmental and genetic factors, eating a proper diet and 
regular physical activity seem to play an important role in reducing the amount of inflammation 
associated with aging (Nettleton et al. 2006; Nieman 2001; Shinkai et al. 1997; Yan et al. 2001a).  
Evidence suggests that older adults who have healthy diets and participate in regular physical 
activity have decreased markers of inflammation and thus, may be at a decreased risk for the 
development of chronic inflammatory disease associated with aging (Nicklas et al. 2004).  
Further, women tend to have a reduced risk of chronic disease compared to men until 
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menopause.  At menopause, the risk of chronic disease increases in women to a level similar to 
and possibly greater than men.  The differences noted in disease risk at menopause are largely 
attributable to changing hormonal concentrations which will also influence immune system 
function.  There may be a difference in inflammatory responses in older women versus men, 
especially if women are post-menopausal (Kuller and Meilahn 1996; Maturana et al. 2007). 
 Physical activity is an important behavior that will reduce the risk and modify the 
outcome of chronic disease.  Exercise immunology is a growing area of research that has 
revealed many benefits to immune system function with moderate exercise training.  For 
example, natural killer (NK) cell activity is improved and T-cell function is maintained in older 
exercising adults, both of which may aid in defense against viral and bacterial pathogens 
(DiPenta et al. 2004; Ferrandez and De la Fuente 1996; Shinkai et al. 1997; Venjatraman and 
Fernandes 1997).  Also, the homeostatic balance between pro- and anti-inflammatory cytokines 
is maintained in older adults who have participated in exercise training (Shephard and Shek 
1995a). 
Recently, Linum usitatissimum or flaxseed and its components  have shown great promise 
as a nutraceutical (Bloedon and Szapary 2004; Hasler et al. 2000; Lee 2006; Nestel et al. 1997; 
Rajesha et al. 2006; Ranich et al. 2001; Velasquez et al. 2003).  Flaxseed is composed of three 
main components: the fatty acid α-linolenic acid, the lignan secoisolaricresinol diglucoside, and 
fibre (Muir and Westcott 2003).  Alpha linolenic acid (ALA) is considered an ω-3 fatty acid and 
is the precursor for the production of eicosapentaenoic acid (EPA) which has profound effects on 
inflammation by altering the production of pro-inflammatory eicosanoids and cytokines 
(Alexander 1998; James et al. 2000; Simopoulos 1999; Simopoulos 2002b).  Also, the flaxseed 
lignan, secoisolaricresinol diglucoside (SDG), may exert anti-inflammatory effects via its action 
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as an anti-oxidant (Kitts et al. 1999; Prasad 1997b; Prasad 1999; Prasad 2000a; Prasad 2000b; 
Prasad 2000c; Prasad 2001; Prasad 2005b; Prasad et al. 2000).  Increased consumption of SDG 
may down-regulate the production of reactive oxygen species resulting in a decreased amount of 
pro-inflammtory cytokines produced via the nuclear signaling pathway identified as nuclear 
factor kappa B (NFκB). 
Flaxseed consumption added to a program of exercise will, theoretically, result in a 
reduction of markers of inflammation in older adults.  Reducing the hyper-inflammatory state in 
older adults should result in an improvement of risk factors associated with cardiovascular 
disease and musculoskeletal health.  This thesis was designed to evaluate the effect of 
supplementation with components of flaxseed during exercise training on inflammatory 
cytokines in older adults.  In particular, the main objective was to evaluate whether the flaxseed 
lignan and the main fatty acid of flaxseed (alpha-linolenic acid) would reduce the hyper-
inflammatory state often observed as a process in aging. To answer this question, two studies 
which involve interventions aimed at improving cardiovascular health (Experiment I) and 
musculoskeletal health (Experiment II) were utilized.  For improving cardiovascular health, the 
literature supports the use of the lignan component of flaxseed as it is thought to act as an anti-
oxidant/anti-inflammatory and improves lipid profiles. For musculoskeletal health, the literature 
supports the use of α-linolenic acid because it is the stronger anti-inflammatory component of 
flaxseed and theoretically would be more beneficial for reducing sarcopenia (i.e. muscle 
wasting).  These flaxseed interventions will be combined with exercise programs deemed most 
beneficial for cardiovascular and musculoskeletal fitness so that Experiment I will involve flax 
lignan combined with a walking/jogging program (cardiovascular exercise), and Experiment II 
will involve flax oil (α-linolenic acid) combined with resistance training (musculoskeletal 
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exercise).  The exercise components used in this research were applied to all study participants as 
a means to establish a ―standard of care‖ that is most appropriate for reducing morbidity related 
to cardiovascular disease and musculoskeletal disease based on current available evidence.  The 
main purpose of the studies was to evaluate the efficacy of supplementation with either the main 
lignan or the main fatty acid found in flaxseed on inflammatory cytokines in older exercising 
adults.  The main hypotheses of the studies in this thesis were that each component of flaxseed 
would decrease markers of inflammation in older exercising adults.  The following section will 
provide an overview of immune system function to aid in understanding how flaxseed and 
exercise may affect inflammation during aging.  This will be followed by a review of the 
literature on the effects of exercise, secoisolariciresinol diglucoside, and alpha-linolenic acid on 
inflammation. 
 
1.2  Overview of the Immune System 
In humans, the immune system is a complex series of interactive humoral and cellular 
components which functions as a defense system against pathogenic attack and infectious agents 
that may cause disease.  In general, the immune system protects the body from viral, bacterial, 
parasitic, and fungal infections by mounting attacks via the innate (or nonspecific) and/or the 
adaptive (or specific) components of the immune system (Mak and Saunders 2006).  The 
immune system is also responsible for the inflammatory process which will heal damaged tissues 
(Mackinnon 1999).  The innate immune system has cells present and ready to attack invading 
pathogens if the organism is to become infected at any time.  The adaptive immune system 
requires time to develop via its recognition of antigen specificity and thus will only attack 
foreign cells that are specific to the antigen present from previous exposure (Eales 2003).  This is 
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in contrast to innate immunity which will react equally to a variety of pathogens and thus lacks 
specificity.  Also, the adaptive component of the immune system will develop memory cells, 
which function to recognize foreign organisms from previous exposure and mount a quick and 
rapid attack against the organism (Eales 2003).  The innate immune system is composed of: 
physical barriers (skin, mucus), chemical barriers (pH of body fluids, complement, acute phase 
proteins), and cells (monocytes/macrophages, granulocytes, and natural killer cells).  The 
adaptive branch of the immune system is composed of a humoral component, which includes 
memory cells and antibodies, and a cellular component which is composed of T cells 
(Mackinnon 1999).  
The immune response happens in three stages with varying amounts of time between 
each stage (Mak and Saunders 2006).  Phase I is the immune reaction that immediately happens, 
from 0-4 hours, and is termed the non-induced innate, non-specific response.  This phase is 
regulated by the defenses of the body that include the skin, pH, and saliva proteases (Mak and 
Saunders 2006).  The second phase is termed the induced innate, broadly specific response and 
usually occurs from 4-96 hours following a pathogenic attack.  In this phase, the innate immune 
system is largely responsible for attacking a broad variety of pathogens by phagocytosis, 
activation of complement, and cytokine release.  If a former pathogen is detected by memory 
cells of the adaptive immune system i.e. an antibody recognizes an antigen, the adaptive 
response will remove the pathogen from the host (Mak and Saunders 2006).  Phase III of the 
immune response is termed the induced adaptive, highly specific response and usually takes over 
96 hours to become fully functional after initial infection.  During this phase, the pathogen must 
be processed by the innate system cells and presented to the T-cells to ensure a fully stimulated 
response.  If the third phase is fully activated it will result in the production of T and B memory 
6 
 
cells which will aid in producing a more rapid response if the host is exposed to the same 
pathogen again (Mak and Saunders 2006). 
Cells of the immune system all originate in stem cells found in bone marrow and are 
differentiated into the myeloid cell line and the lymphoid cell line (Eales 2003).  The myeloid 
cell line includes monocytes which differentiate into macrophages, Kupffer cells, and dendritic 
cells as well as granulocytes which differentiate into neutrophils, basophils, and eosinophils 
(Mak and Saunders 2006).  Cells coming from the lymphoid cell line include T-cells, B-cells, 
and natural killer (NK) cells.  T-cells will differentiate into T-helper, T-suppressor, and T-
cytotoxic cells while B-cells will differentiate into plasma cells which are responsible for 
secreting antibodies (the immunoglobulins) (Eales 2003).  T-cells are so named due to the fact 
that they must migrate to the thymus gland to mature and differentiate into the various sub-types 
of T-cells.  Once in the thymus gland, the T-cells will differentiate into 2 distinct cell types with 
a specific protein marker termed the cluster of differentiation (CD)4
+
 T helper cells and CD8
+
 
pre-cytotoxic cells (Mak and Saunders 2006).  T-helper 1 (Th1) cells will aid pre-cytotoxic cells 
to differentiate into cytotoxic T-cells and T-helper 2 (Th2) cells aid B-cells in differentiating into 
plasma cells (Mak and Saunders 2006). 
 
1.2.1  Myeloid Immune Cells 
 The general purpose of monocytes and macrophages in the immune system is to 
phagocytose foreign organisms and act as antigen-presenting cells (APCs) for the lymphoid cell 
line (Eales 2003).  These cells are found predominantly in the circulation but will migrate to 
various types of tissue when infection, inflammation, or injury occurs.  Monocytes and 
macrophages are involved in the production of cytokines including IL-1α, IL-1β, IL-1ra, IL-6, 
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and TNF-α, which help stimulate the adaptive immune response (Eales 2003).  These cells 
produce proteases from lysosomes and produce oxygen free radicals as well as nitric oxide which 
are all toxic to microorganisms, particularly bacteria (Mackinnon 1999). 
 Granulocytes, another type of myeloid immune cell, are large immune cells that 
differentiate into three types of cells including neutrophils, basophils, and eosinophils.    
Neutrophils are phagocytic cells which release proteases, phospholipases, and generate oxygen 
radicals which all destroy microorganisms (Eales 2003).  Eosinophils function by phagocytosis 
and function to destroy parasitic infections while basophils are mostly involved in allergic and 
inflammatory reactions (Mackinnon 1999). 
 
1.2.2  Lymphoid Immune Cells 
 The lymphoid cells include T-cells, B-cells, and NK-cells.  T and B-cells are part of the 
adaptive immune system while NK-cells function in the innate immune system.  The T-cells are 
distinguished from other cells by the T cell receptor (TCR or CD3) located on the cell membrane 
(Eales 2003).  The main function of T-cells is to control the adaptive immune response via 
various subsets of T-cells.  Helper and inflammatory T-cells are identified by the cell surface 
protein CD4 and cytotoxic T-cells are identified by the CD8 cell surface protein (Eales 2003).  
All T-cells are able to distinguish between self and non-self by a protein complex termed the 
major histocompatibility complex (MHC), which aids T-cells in identifying foreign antigens on 
infectious cells, and then produces an immune response via T-cell activation (Eales 2003).  Also, 
cytokines, such as IL-2, IL-3, IL-4, and IL-6, are released by T-cells which are responsible for 
regulating and coordinating further immune cell function.  CD8
+
 cells will seek out virally 
infected cells, which have viral proteins on the cell surface, and release chemicals inside the 
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infected cell to destroy DNA and prevent further replication (Mak and Saunders 2006).  CD4
+
 
cells are further subdivided into helper T-cells and inflammatory T-cells.  The helper T-cells 
activate B-cells to produce an antibody to a specific antigen and are responsible for killing 
extracellular immunogens (Mak and Saunders 2006).  Intracellular pathogens are destroyed by 
inflammatory T-cells where they activate monocyte/macrophage phagocytic activity as well as 
antibacterial activity (Mak and Saunders 2006). 
 The B-cells of the lymphoid cell line are responsible for bearing antibody on the cell 
surface.  The unique feature of B-cells is their ability to produce antibody from previous 
exposure to some pathogen and thus, maintain memory of previous exposure to antigens that 
invade the system (Mak and Saunders 2006).  The B-cells, in combination with activation from 
T-helper cells, will produce a faster immune response to invading antigens if the system has been 
‗primed‘ by previous exposure to the same antigen (Eales 2003).  This feature of the immune 
system is what the immunization process is based upon and has resulted in a reduction in 
infectious disease in the developed world (Mak and Saunders 2006). 
 Natural killer (NK) cells are part of the innate immune system and are identified by the 
cell surface markers CD16
+
 and CD56
+
 but lack the CD3
-
 marker of T-cells (Eales 2003).  The 
main function of NK cells, as their name would suggest, is to kill tumor cells and cells infected 
with viruses.  They do so by discharging toxic enzymes into infected cells after binding with 
them (Eales 2003).  NK cells are also mediators in antibody-dependent cell-mediated 
cytotoxicity, which means they act to aid in recognition of antibody coated cells that require 
destruction (Mak and Saunders 2006). 
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1.2.3  Soluble Mediators of the Immune System 
 Many mediators of immunity are found in blood and other body fluids.  The different 
types of soluble mediators include: immunoglobulins, acute phase proteins, complement, and 
cytokines.  Immunoglobulins (Ig) are glycoproteins that are produced by plasma cells in response 
to an immunogen and which produce antibodies (Eales 2003).  The primary function of 
immunoglobulins is to bind to one specific antigen producing an antigen-antibody complex 
which will protect the host species from attack by the antigen by stimulating plasma cells to 
produce more antibodies to the specific antigen infecting the host (Mackinnon 1999).  Acute 
phase proteins, such as C-reactive protein and serum amyloid-A, are released from the liver on 
stimulation by pro-inflammatory cytokines (Eales 2003).  The purpose of acute phase proteins is 
to bind to a wide variety of microbes (i.e. acute phase proteins have the ability to recognize self 
from non-self) on their cell surfaces which will activate the complement cascade of events (Mak 
and Saunders 2006).  Complement represents a series of 30 serum and membrane proteins that 
when activated will induce cell lysis, opsonization, clearance of antigen-antibody complexes, 
enhance antigen presentation, enhance B-cell activation, and generate by-products that signal a 
number of cellular events related to the immune and inflammatory response (Eales 2003; Mak 
and Saunders 2006).  Each mediator has a specific function in the immune response but this 
review will focus on the effects cytokines have on immune system regulation, and specifically 
the inflammatory process. 
 
1.2.3.1  Cytokines 
 Cytokines are peptide or glycoprotein molecules that influence a wide variety of cell 
functions but whose primary role is intercellular communication (Mak and Saunders 2006).  
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Cytokines, hormones and growth factors are similar in that they are all soluble and they need to 
be bound by receptors on cells to exert their influence (Eales 2003).  The site of production, 
mode of operation, and range of influence are what distinguishes cytokines from hormones or 
growth factors.  Cytokines exert regulatory function by controlling innate and adaptive immunity 
as well as the growth and differentiation of hematopoietic cells (Mak and Saunders 2006).  
Cytokines are involved in a number of cellular events related to immune function including: pro-
inflammation, anti-inflammation, antiviral replication, growth of cells, differentiation of cells, 
cell-mediated immunity, humoral mediated immunity, Ig isotype switching, and chemotaxis 
(Mak and Saunders 2006). They exert their effects by binding to specific receptors on cell 
membranes to produce intracellular signaling that results in gene transcription or changes in the 
cell‘s activity (Mak and Saunders 2006).  The cytokine network is complex and it is reasoned 
that the complexity exerts exacting control over the cells of the immune system which, if left 
unchecked, could produce extreme tissue damage or auto-immune disease (Mak and Saunders 
2006). Currently, there are more than 100 cytokines identified; this review will focus on the 
cytokines that are involved in inflammation.   
The interleukin (IL) cytokines are produced by leukocytes including T-cells, 
monocytes/macrophages, and NK cells.  These cytokines are not structurally related but share 
function by influencing immune cell operation (Mackinnon 1999). 
 Interleukin-1 is present in two isoforms, IL-1α and IL-1β, but IL-1β is found in greater 
amounts than IL-1α (Mak and Saunders 2006).  The prominent role of IL-1 is to increase 
inflammatory events in innate defense.  At low concentrations, IL-1 will promote the expression 
of adhesion molecules and induce the production of other pro-inflammtory cytokines including 
IL-6, IL-8, and TNF-α.  If the concentration of IL-1 is moderate, it will induce fever, the acute 
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phase response of the immune system, and may be cachexic.  High concentrations of IL-1 may 
result in endotoxic or septic shock in which the circulatory and metabolic systems collapse 
possibly resulting in death (Mak and Saunders 2006).  IL-1 also functions to induce 
hematopoietic growth factors and is involved in bone remodeling by increasing bone resorption 
by osteoclasts and decreasing bone deposit by osteoblasts (Mak and Saunders 2006). 
 Recent debate has suggested that interleukin-6 may act either as a pro or anti-
inflammatory cytokine but general nomenclature still considers it a pro-inflammatory cytokine 
(Starkie et al. 2003).  IL-6 exerts a strong influence on B-cell differentiation, especially at the 
end stages of B-cell production.  It is produced by mononuclear phagocytes, fibroblasts, and 
vascular endothelial cells in response to stimulation by IL-1 and TNF-α, thus, it usually exerts it 
effects in conjunction with other inflammatory cytokines (Mak and Saunders 2006).  Some 
activated T-cells will produce IL-6 and it has recently been demonstrated that skeletal muscle 
acts as an endocrine organ by releasing IL-6 which may influence adipose, hepatic, and arterial 
tissue (Febbraio and Pedersen 2002; Febbraio and Pedersen 2005; Mak and Saunders 2006). 
 Interleukin-8 is considered a chemokine, which is a cytokine that exerts chemoattraction 
of leukocytes, and not an interleukin (Mak and Saunders 2006).  IL-8 is a mediator that 
selectively allows passage of leukocyte subsets between the blood and various types of tissue 
compartments as well as influences the actions of endothelial and nervous system cells (Mak and 
Saunders 2006).  In general IL-8 acts as a powerful attractor for neutrophils and will promote the 
inflammatory response (Mak and Saunders 2006). 
 Interleukin-12 is a cytokine that plays a pivotal role in linking the activation of 
macrophages by bacteria to the activation of NK and Th1 outcome functions (Mak and Saunders 
2006).  Thus, IL-12 is a key cytokine that links innate and adaptive immunity because it 
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stimulates the production of interferon γ (IFNγ), a cytokine involved in suppressing viral 
replication, and is responsible for defense against a number of intracellular pathogens as well as 
activation of the adaptive immune response (Mak and Saunders 2006). 
 Interleukin-17 is produced by CD4
+
 T-cells and induces the production of other pro-
inflammatory cytokines including IL-6, IL-8, and granulocyte-colony stimulating factor (G-CSF) 
(Mak and Saunders 2006).  High amounts of IL-17 will induce IL-6 reliant neutrophilia which 
may increase resistance to bacterial infections.  Also, IL-17 up regulates the production of 
intercellular adhesion molecule (ICAM-1), a cell surface ligand, which plays a role in leukocyte 
adhesion and the inflammatory response (Mak and Saunders 2006). 
 There is an overlap of activities between IL-1, IL-12 and IL-18.  Interleukin-18 
stimulates the propagation of IFNγ and IL-2 receptor from Th1 cells, stimulates the release of IL-
2 and granulocyte-monocyte colony stimulating factor (GM-CSF) from activated T-cells, and 
will promote natural cytotoxicity  by release of IFNγ and TNF-α from NK cells (Mak and 
Saunders 2006). 
 In general, interleukin-22 is considered pro-inflammatory due to its ability to stimulate 
acute phase protein release from hepatocytes (Mak and Saunders 2006).  IL-22 will increase the 
numbers of platelets and basophils as well as decrease the number of erythrocytes (Mak and 
Saunders 2006).  Interleukin-24 is found in high levels in some tumors and promotes the 
induction of apoptosis in tumor cells.  Also, IL-24 may be responsible for aiding wound healing 
by increasing fibroblast proliferation or supporting the inflammation associated with wound 
healing (Mak and Saunders 2006).  Interleukin-27 promotes the Th1 response, increases the 
amount of pro-inflammatory cytokines, decreases the Th2 response, and has powerful anti-tumor 
effects (Mak and Saunders 2006). 
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Interferons (IFN) are so named due to the discovery that primary viral infection will 
induce interferon release from cells resulting in resistance to infection by a second virus thus, 
interfering with viral infection (Eales 2003).  There are four types of interferons found in humans 
including: IFNα, IFNβ, IFNγ, and IFNω.  All interferons share antiviral and antiproliferative 
properties but IFNγ alone has effects on the immune system cells and adaptive immunity (Mak 
and Saunders 2006).  IFNγ is considered pro-inflammatory since it stimulates the secretion of IL-
1β, IL-12, IL-18, and TNF-α from macrophages and thus, promotes the inflammatory response 
(Eales 2003).  Also, IFNγ effectively eliminates intracellular-replicating pathogens by 
upregulating the expression of inducible nitric oxide synthase (iNOS) and reactive oxygen 
intermediates to eliminate pathogenic organisms (Mak and Saunders 2006). 
 Tumor necrosis factor (TNF), which is also known as TNF-α, is a very pleiotropic (i.e. 
has multiple systemic roles) cytokine that exerts effects on many tissue types (Mak and Saunders 
2006).  In low concentrations TNF-α functions to upregulate adhesion molecules on cell surfaces 
to stimulate the movement of leukocytes from circulating blood into surrounding tissue that may 
be under pathogenic attack or damaged due to injury or insult.  TNF-α also promotes 
granulocytes to destroy invading microbes as well as stimulating the release of IL-1, IL-6, IFNγ, 
chemokines, and TNF-α itself.  At moderate concentrations TNF-α will enter the blood and begin 
acting like a hormone where it affects cells of many tissue types throughout the body.  At high 
concentrations, TNF-α may be lethal as it may stimulate endotoxic shock (Mak and Saunders 
2006).  In addition, TNF-α has been implicated in the proliferation of fibroblasts which may 
result in the infiltration of fibrous tissue and fibrous degeneration observed in chronic 
inflammation of various tissue types (Mak and Saunders 2006).  TNF-α has immunoregulatory 
roles, similar to IL-1 and can promote both apoptosis and cell survival depending on the TNF-α 
14 
 
receptor that is engaged as well as the cellular milieu present on binding (Eales 2003).  TNF-α is 
used to facilitate the response of B and T-cells to antigenic presentation, may induce tumor cell 
death by necrosis or apoptosis, may act in an antiviral fashion, and aids in the activation of the 
blood clotting cascade of events (Mak and Saunders 2006). 
 Lymphotoxin α (LTα), which was formerly known as TNF-β, is also considered a pro-
inflammatory cytokine related to the TNF family of cytokines (Eales 2003).  Its main role is to 
promote inflammation, kill tumor cells by apoptosis, stimulate neutrophil activity, and act as an 
antiviral.  Thus, LTα has very similar roles to TNF-α but its potency is only a fraction of that of 
TNF-α (Mak and Saunders 2006). 
Interleukin-4 is a very potent, pleiotropic cytokine that exerts it effects on most cell types. 
The role of IL-4 in inflammation is to inhibit the secretion of pro-inflammatory chemokines and 
cytokines (TNF-α and IL-1β) from macrophages as well as impair the ability of macrophage 
cells to produce reactive oxygen species (Eales 2003).  Other roles of IL-4 include: 
differentiation and growth of Th2 subsets, which aid in the humoral response to combat 
extracellular pathogens, upregulation and formation of major histocompatibility complex II, 
regulation in allergic reactions, and stimulatimg the synthesis of  IL-12 from dendritic cells and 
macrophages thus, acting in a negative feedback method (Mak and Saunders 2006). 
 Interleukin-10 has a regulatory function in both innate and adaptive immunity which 
demonstrates the cross-talk between both branches of the immune system (Eales 2003).  IL-10 
can act to slow down inflammation by targeting granulocytes and mast cells to inhibit the release 
of massive amounts of IL-1 and TNF-α to reduce the risk of endotoxic shock (Eales 2003).  Also, 
IL-10 inhibits activation of NFκB, a transcription factor that upregulates the production of TNF-
α, IL-1, IL-6, IL-8, and IL-12 therefore reducing the amount of pro-inflammatory cytokines 
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produced.  IL-10 also operates to inhibit the respiratory burst and nitric oxide (NO) dependent 
killing of microbes associated with macrophage activity (Mak and Saunders 2006). 
 Anti-inflammatory effects are exerted by interleukin-11 due to the inhibition of pro-
inflammatory cytokines and NO production by macrophages (Mak and Saunders 2006).  IL-11 is 
similar to IL-6 and is redundant with some of its function.  IL-11 will stimulate hematopoietic 
cells, growth of T and B-cells, and promote collagen deposits by fibroblasts (Mak and Saunders 
2006).  IL-13 is considered anti-inflammatory as it inhibits the production of TNF-α, IL-1β, and 
pro-inflammatory cytokines secreted by macrophages (Mak and Saunders 2006).  However, IL-
13 may upregulate the synthesis of IL-12 from dendritic cells and macrophages (Mak and 
Saunders 2006). 
 Transforming growth factor β (TGF-β) is a pleiotropic cytokine vital to cell growth and 
the adaptive immune response (Mak and Saunders 2006).  It is considered anti-inflammatory due 
to the decreased production and effect of IL-1, IL-2, IL-6, IFNγ, and TNF-α exerted by TGF-β.  
Further, TGF-β will decrease the release of NO by macrophages consequently acting to decrease 
the inflammatory response (Mak and Saunders 2006). 
 The purpose of this project was to evaluate the effect of flaxseed supplementation 
interventions during exercise training on IL-6 and TNF-α in older adults.  These two cytokines 
are considered pro-inflammatory, although IL-6 possesses anti-inflammatory functions as well. 
There is evidence that IL-6 and TNF-α are elevated by 2-4 fold in older adults which may 
increase the risk of various diseases associated with aging (Krabbe et al. 2004).  These pro-
inflammatory cytokines have been studied extensively in relation to the development of 
dysregulated inflammation.  The evidence gathered from this project will aid in determining the 
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efficacy of supplementation with components of flaxseed while exercise training on the 
amelioration of diseases associated with increased amounts of IL-6 and TNF-α.  
 The following sections discuss the inflammatory response and how inflammation is 
related to the development of atherosclerosis and sarcopenia.  The studies completed for this 
thesis project were designed to investigate how flaxseed supplementation may reduce 
inflammation associated with the development of these two diseases associated with the aging 
process. 
 
1.2.4  Inflammatory Response 
 Inflammation is the term given to the immune response that results from tissue damage or 
pathogenic attack.  It is a series of events that comprises the second and third phase of the 
immune response and thus, is an essential component of both adaptive and innate immunity 
(Eales 2003).  The clinical signs of inflammation include redness, swelling, heat, and pain.  The 
redness and heat accompanying inflammation is a direct result of the vasodilation of blood 
vessels in the involved area.  The swelling that accompanies inflammation is largely a result of 
increased amount of leukocytes that are coming to the affected area (i.e. chemoattraction).  The 
augmented number of leukocytes occurs in response to increased adhesion of white blood cells to 
endothelial blood cells and increased permeability of local blood vessels (Eales 2003).  Pain is 
felt due the release of bradykinin, which is a plasma enzyme that stimulates pain receptors of the 
nervous system, induces vasodilation, smooth muscle contraction and increases permeability 
(Mak and Saunders 2006). 
 Leukocytes that migrate to a site of infection or injury will be attracted initially by 
chemotaxis, which is a process whereby injured cells release chemokines. The leukocytes are 
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attracted via a chemical gradient.  Some chemokines that are released include: macrophage 
activating factor, macrophage inflammatory protein-1α , interleukin-8, and neutrophil activating 
protein (Eales 2003).  Each of these chemokines will be released by cells from the myeloid and 
lymphoid cell lines as well as platelets and the endothelium of damaged tissue (Mak and 
Saunders 2006).  During this part of the inflammatory response, the innate effector cells are 
largely responsible for phagocytosis of the infected or injured tissue.  Cells of the innate system 
will release factors that will attract effector cells of the adaptive immune response and stimulate 
the process whereby antigen recognition results in a more rapid attack if infected in the future 
(Mak and Saunders 2006). 
 The inflammatory response is also mediated by the cytokines TNF-α and IL-6, which are 
released by activated macrophages in response to infection or injury (Mak and Saunders 2006).  
TNFα and IL-6 stimulate the liver to release acute-phase proteins that act in a manner similar to 
antibodies, by activating the complement cascade, but are non-specific and will bind to a vast 
array of bacterial pathogens.  In the beginning stages of inflammation, the concentration of the 
acute-phase proteins will increase rapidly which results in an increased activation of complement 
(Eales 2003).  One type of acute-phase protein is C-reactive protein (CRP) which when bound to 
cell walls of bacteria and fungi can activate the complement cascade of events resulting in the 
destruction of the agent (Mak and Saunders 2006).   
Another group of inflammatory mediators are collectively known as eicosanoids and 
include prostaglandins, thromboxanes, and leukotrienes (Eales 2003).  These lipid-based 
molecules are derived from the degradation of phospholipids in the membranes of cells in the 
myeloid cell line (Eales 2003).  Degradation of the phospholipids results in the production of 
arachidonic acid which can be metabolized to the various eicosanoids by the enzymes 
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phospholipase A, cyclooxygenase and lipoxygenase (Eales 2003).  In general, activation of 
arachidonic acid metabolism will result in an increased inflammatory environment by: inducing 
leukocyte chemotaxis and aggregation, proliferating T-cell formation, increasing the release of 
pro-inflammtory cytokines (such as TNF-α and IL-6), and increasing platelet aggregation 
(Alexander 1998; James et al. 2000; Mak and Saunders 2006). 
During inflammation there is an upregulation of cell adhesion molecules (CAMs) on the 
activated endothelial cells which are responsible for increasing the leukocyte migration to a place 
of injury (Eales 2003).  CAMs are responsible for binding leukocytes and allowing them entry 
from the blood into the tissues that are affected.  The leukocytes will then follow the chemotactic 
signals to the site of injury and begin phagocytosing the infected cells.  Eventually, if the 
pathogen is not destroyed by complement, bound to acute-phase proteins, or phagocytosed, 
macrophages will release TNF-α and IL-1 to attract T-cells to the area thereby activating the 
adaptive branch of the immune system (Mak and Saunders 2006).  Thus, the interaction between 
the innate and adaptive system is again intermingled and the two systems should not be thought 
of as separate entities but fully functional and synergistic branches that aid in host defense. 
The inflammatory process would not be complete without the repair of tissue damaged 
during the assault on the host.  The increase in permeability of blood vessels allows enzymes of 
the fibrinolytic system to enter into the damaged area and begin the blood clotting cascade of 
events by building up a network of fibrin to aid in clotting and initiating wound healing (Eales 
2003).  Platelets and mast cells are also involved in the inflammatory healing process.  Platelets 
are needed to complete wound healing, while mast cells release heparin, histamine, and 5-
hydroxytryptamine to cause vasodilation and ―speed up‖ the healing of the wound (Mak and 
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Saunders 2006).  In general, a complete inflammatory response involves both the destruction of 
foreign pathogens and/or the repair of damaged tissue (Mak and Saunders 2006).   
In older adults, it is hypothesized that chronic low-grade levels of inflammation result in 
a hyper-active inflammatory response whereby complete wound healing or defense against 
foreign pathogens is compromised due to elevated levels of pro-inflammatory cytokines and a 
decreased amount of anti-inflammatory cytokines (Bruunsgaard and Pedersen 2000; Kohut and 
Senchina 2004; Shinkai et al. 1997).  The main purpose of this thesis was to evaluate 
supplementation with components of flaxseed during exercise training on cytokines related to 
inflammation in older adults. 
 
1.3 Review of Literature 
1.3.1 Aging and Inflammation 
 One theory explaining the development of chronic disease with age is that the amount of 
inflammation progressively increases.  The terms ―inflamm-aging‖ or ―hyper-inflammation‖ 
have been used to describe the physical characteristics associated with immunosenescence 
(Franceschi et al. 2000).   As individuals age, there is an increased amount of antigenic 
presentation, which alters the capability of the innate and adaptive immune system.  The inability 
to combat antigenic challenge, due to changes to both innate and adaptive immunity during 
aging, may be responsible for increased incidence of infectious, auto-immune, and chronic 
diseases (Punzi et al. 1996; Roubenoff et al. 1998; Sindermann et al. 1993).  One study evaluated 
the immune response to novel antigenic challenge and found that older sedentary men have less 
of a response on stimulation versus younger and older physically active men suggesting a 
depression of acquired immunity with age (Smith et al. 2004).  Also, T-cell function is depressed 
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in aged sedentary males when compared to aged active males (Yan et al. 2001b).  In this cross-
sectional study there was an increase in helper T-cells with a corresponding decrease in 
cytotoxic/supressor T-cells which accounted for an increase in the CD4
+
:CD8
+
 ratio in older 
sedentary males when compared to younger controls and older exercising men.  Further, NK cell 
function was reduced in older sedentary men when compared to older active men suggesting a 
preservation of both adaptive and innate immunity with moderate physical exercise into old age.  
In an animal model of sepsis, old rat myocardium responded with increased expression of 
components of the innate immune system (CD14 and nitric oxide synthase) and a reduced β-
adrenergic response to stimulation when compared to young rat hearts (Rosas et al. 2001).  This 
study suggests a role for altered innate immune system function in old age that may increase 
mortality during septic shock due to altered hemodynamic properties associated with normal 
heart function.  The authors of this study suggested that increased cytokine concentrations may 
be the stimulus for the altered immue response and it has recently been demonstrated cross-
sectionally that older adults maintain the ability to produce high amounts of cytokines during 
septic shock (Marik and Zaloga 2001).  Evidence for the role cytokines play in the process of 
―inflamm-aging‖ is growing and indicates a increase in pro-inflammatory cytokines and a 
decrease in anti-inflammatory cytokines as part of the aging process (Shinkai et al. 1998).  Also, 
due to alterations in T-cell, B-cell, and NK-cell concentrations with aging, there is a 
corresponding alteration in the inflammatory milieau present in older adults promoting an 
increased amount of inflammation (Rosas et al. 2001; Smith et al. 2004; Yan et al. 2001b; Zanni 
et al. 2003). 
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1.3.2 Cytokines and Aging 
 In general, there are some differences in the type of cytokines predominantly expressed 
between in vitro and in vivo studies in older adults; various studies indicate both an increased 
amount of pro-inflammatory or anti-inflammatory cytokines (Franceschi et al. 2000; Gomez et 
al. 2005; Krabbe et al. 2004).  Possible explanations for the differences between in vivo and in 
vitro research are: additional immune cells or tissue cell types producing pro-inflammatory 
cytokines than those assessed in vitro; the variety of inclusion/exclusion criteria used in human 
aging studies (possibly masking underlying inflammatory events); or alteration of cell function in 
vitro as compared to in vivo due to a change in phenotype caused by differing environmental 
conditions (Gomez et al. 2005).  Nonetheless, there is disparity between studies utilizing 
different methodologies as to the immune response with aging.   
Comparative research of young and old individuals examining the effects of in vitro 
cytokine release from whole blood found a trend toward increased levels of IL-6 in older adults 
but no differences between the levels of IL-2 or IFNγ (Sindermann et al. 1993).  The researchers 
also found a higher ratio of CD4
+
/CD8
+ 
cells in the older adults which might explain the 
increased incidence of infection in older versus younger adults.  Another cross-sectional study, 
which compared 742 elderly (average age 79 years) adults from the  Framingham study to 21 
younger (average age 39 years) adults, examined the production of cytokines from monocytes 
(Roubenoff et al. 1998).  The elderly group had higher levels of IL-6 and IL-1ra than the young 
group.  Also, there was a direct correlation between higher concentrations of C-reactive protein 
and IL-6 in the elderly but no similar relationship in the young group.  Conversely, the results 
indicated no difference in TNF-α or IL-1β between the young and elderly subjects.  The authors 
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indicated that there does seem to be dysfunction arising in inflammatory mediators with age but 
would not speculate on the function inflammation plays in the aging process. 
 In another study examining the effects of the acute phase response of young versus old 
subjects to endotoxin injection, the elderly had greater increases in TNF-α, soluble TNF 
receptors, and a prolonged increase in soluble TNF receptors when compared to the young 
participants (Krabbe et al. 2001).  The elderly participants in the study also exhibited a prolonged 
fever response and had a more rapid increase in CRP than the younger control group.  The 
conclusion of the research indicated aging is associated with an increased inflammatory 
response, a heightened acute phase response, and an extended fever reaction. 
 An in vitro study examining the cytokine profile of T-cells isolated from individuals of 
varying ages indicated a significant increase in the production of IFNγ, IL-2, and TNF-α in all 3 
sub-type T-cells while IL-4, IL-6, and IL-10 were only increased in memory CD8
+
 T-cells of 
older adults (Zanni et al. 2003).  The authors concluded that the results give evidence for the 
―inflamm-aging‖ hypothesis.  In contrast, IL-1 and TNF-α production from monocytes was not 
altered in vitro when a group of malnourished elderly nursing home patients, an age-matched 
control group, and a group of young healthy adults was compared (Bradley et al. 1990).  This 
disparity between the two studies is likely due to the various cell types used in each 
investigation.  Another study examining the effects of in vitro stimulation by 
phytohemagglutinin, a mitogen to lymphocytes, of human peripheral mononuclear cells from 
young (average age 27 years) and old (average age 80 years) found significant increases in the 
production of IL-1β, IL-6, and TNF-α in the old subjects (Fagiolo et al. 1993).  The authors 
suggested that the increased production of these cytokines in response to stimulation may 
increase the risk of some pathology such as atherosclerosis, dementia, and osteoporosis. 
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 In vitro research of lipopolysaccharide (LPS) stimulated monocytes shows lower amounts 
of TNF-α, IL-1β, and IL-6 production in older (> 65 years) versus younger (< 39 years) cell 
cultures (Bruunsgaard et al. 1999b; Gabriel et al. 2002; Gon et al. 1996; McLachlan et al. 1995).  
Other in vitro research indicates an increased release of IL-1β, IL-6, or TNF-α from 
polymorphonuclear (i.e. leukocytes with varied nuclei structure) cells or whole blood stimulated 
with LPS or phytohemagglutinin in cells donated by old versus young adults (Born et al. 1995; 
Fagiolo et al. 1993; Gabriel et al. 2002; McNerlan et al. 2002; O'Mahony et al. 1998; Riancho et 
al. 1994; Sandmand et al. 2003; Saurwein-Teissl et al. 2000).  Furthermore, there is research 
indicating no difference between the release of pro-inflammatory cytokines from various types of 
leukocyte cultures between older and younger adults (Beharka et al. 2001; Gabriel et al. 2002; 
O'Mahony et al. 1998; Riancho et al. 1994; Roubenoff et al. 1998; Rudd and Banerjee 1989).  A 
conclusion is difficult to draw given the evidence from various types of studies evaluating the 
cytokine changes with aging.  Higher levels of circulating inflammatory mediators such as IL-6, 
TNF-α, and acute phase proteins have each been associated with increased morbidity and 
mortality in the elderly (Harris et al. 1999; Krabbe et al. 2004; Taaffe et al. 2000).  Broadly, one 
hypothesis is that the systemic circulating levels of IL-6 may represent the level of inflammation 
in younger and healthy older populations whereas TNF-α levels would represent the level of 
inflammation in frail elderly populations (Krabbe et al. 2004).  The authors postulate that TNF-α 
would not be released systemically by varying tissue types, such as adipocytes and endothelial 
cells, until a certain threshold in terms of age and disease activity was met.  Once the threshold 
was met, the result would be a systemic increase in TNF-α concentration resulting in increased 
morbidity and mortality.  In general, it is not known whether increased amounts of pro-
inflammatory cytokines are a cause of the chronic diseases associated with aging or a 
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consequence of the events surrounding the pathological and/or physiological changes associated 
with the aging process (Petersen and Pedersen 2005).  Nonetheless, quantifying soluble markers 
of inflammation, such as cytokines, is one strategy that, in the future, may aid clinicians in 
determining disease morbidity and mortality.  In general, the consensus seems to be that aging is 
associated with decreased amounts of IL-2 and increasing amounts of TNF-α and IL-6 
(Bruunsgaard and Pedersen 2000; Kohut and Senchina 2004; Shinkai et al. 1998). 
 
1.3.3 Cytokines in Diseases of Aging 
 Chronic low grade inflammation has been implicated in a number of disease processes 
and is associated with the aging process (Petersen and Pedersen 2005). The purpose of the 
following two sections is to draw a link between the inflammatory processes and the 
pathogenesis of atherosclerosis, metabolic syndrome, and sarcopenia.  The studies in this thesis 
determined the effects of supplementation with components of flaxseed during exercise training 
on pro-inflammatory cytokines, with a focus on prevention of metabolic syndrome and 
sarcopenia in older individuals.   The theoretical link between altered inflammatory processes 
and the development of these two diseases is outlined below. 
 
1.3.3.1 Atherosclerosis/Metabolic Syndrome and Inflammation 
 Atherosclerosis is considered a chronic inflammatory disease of the arteries (Stoll and 
Bendszus 2006; Tedgui and Mallat 2006).  For most of the 20
th
 century, the lipid hypothesis of 
atherosclerosis was widely accepted which suggested that smooth muscle cells proliferate in 
response to high blood lipid levels causing arterial narrowing.  It was later suggested that 
atherosclerosis involves a response to injury whereby monocytes and lymphocytes adhere to 
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endothelial cells to induce a chronic inflammatory reaction (Raines and Ross 1993; Ross 1979; 
Ross 1986; Ross 1987; Ross 1999; Ross and Glomset 1976a; Ross and Glomset 1976b).  Indeed, 
current evidence indicates that the concentration of CRP is a better predictor of cardiovascular 
disease than low-density lipoprotein (LDL) cholesterol (Ridker et al. 2002).  It is acknowledged 
that high concentrations of blood lipids, especially LDL, have a clear role in the development of 
atherosclerosis, as atherosclerosis usually does not occur in those with normal blood cholesterol 
concentrations; however, oxidized LDL seems to be the initial activator of the inflammatory 
process in vascular cells (Stamler et al. 1986; Tedgui and Mallat 2006).  Once macrophages and 
lymphocytes are recruited, due to oxidized LDL activation, they will secrete numerous 
cytokines, including TNF-α and IL-6, which stimulate inflammation resulting in increased 
atherosclerotic lesions (Tedgui and Mallat 2006).    
Metabolic syndrome is defined as a group of risk factors (elevations in each of central 
adiposity, serum triacylglycerol, serum glucose, blood pressure, inflammation, and lowered high 
density lipoproteins) that increase the risk of developing atherosclerosis and may lead to insulin 
resistance and cardiovascular disease (Wassink et al. 2007).  Recently, higher concentrations of 
inflammatory proteins and cytokines have been linked to the development of metabolic 
syndrome (Wassink et al. 2007).  Increased adipose tissue deposits will increase the amount of 
TNF-α and decrease the concentration of adiponectin, an anti-inflammatory adipokine, released 
into circulation which may stimulate the development of insulin resistance (Petersen and 
Pedersen 2005; Wassink et al. 2007).  Once the inflammatory mediators are up-regulated 
systemically, there is an increased risk of pathology related to metabolic syndrome (Trayhurn 
and Wood 2004).  Increasing obesity results in higher amounts of inflammatory mediators and it 
seems metabolic syndrome diagnosis, with concomitant higher concentrations of pro-
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inflammatory cytokines, may further perpetuate the risk of developing cardiovascular disease 
(Lago et al. 2007; Wu et al. 2007).  Although not conclusive, there is strong evidence suggesting 
a role for cytokines in the development of metabolic syndrome and atherosclerosis leading to 
clinical end-points of cardiovascular disease (Trayhurn and Wood 2004). 
Higher concentrations of TNF-α were observed in a group of centenarians when 
compared to younger counterparts and the higher levels were associated with atherosclerosis 
(Bruunsgaard et al. 1999a).  This suggests that underlying alterations in inflammatory processes 
precludes the development of clinical end-points of the atherosclerotic process.  TNF-α 
concentrations in apparently healthy men (mean age 50 years) were associated with the 
development of early atherosclerotic risk factors in terms of metabolic and cellular disturbances 
(Skoog et al. 2002) and higher concentrations of TNF- α and IL-6 are associated with a poorer 
result in terms of the clinical outcome of individuals suffering strokes (Castellanos et al. 2002; 
Leira et al. 2006).  The role TNF-α has in the development of atherosclerosis has recently been 
questioned as TNF receptor (TNFR) levels were associated with carotid plaque thickness but 
TNF-α was not (Castellanos et al. 2002).  This suggests that the cytokine receptor density and 
affinity may be more important in the development of atherosclerosis than the amount of 
cytokine being produced.  However, the concentration of IL-6 is also related to mortality from 
coronary artery disease and is higher in those individuals with uncontrolled angina when 
compared to those with controlled angina (Biasucci et al. 1996; Harris et al. 1999).  Interventions 
aimed at those individuals with high levels of IL-6 on admission for treatment, due to coronary 
artery disease, dramatically reduced mortality in a one-year follow up (Lindmark et al. 2001).  
Thus, utilizing interventions aimed at reducing pro-inflammatory cytokines in a preventative 
27 
 
manner may be an effective strategy for decreasing the pathological changes associated with the 
inflammatory atherosclerotic process.  
The first study proposed in this thesis will use the lignan component of flaxseed 
(combined with a walking exercise program) because the lignan is the component that has the 
most potential for acting as an anti-oxidant and favorably changing the blood lipid profile.  If 
LDL levels can be reduced by supplementation with flaxseed lignan, this may lead to a smaller 
LDL-stimulated inflammatory response and lower levels of the inflammatory cytokines.  Also, if 
the lignan or its metabolites are able to scavenge reactive oxygen species in vivo, there would 
likely be a down-regulation of inflammatory cytokine production from NFκB.  Further, 
cardiovascular exercise training is considered the most appropriate type of exercise for altering 
the blood lipid profile by raising high density lipoprotein cholesterol and lowering triacyglycerol 
(Paterick and Fletcher 2001).  Thus, the combination of these two interventions should produce 
favorable results in ameliorating the increased amount of inflammation observed in older adults 
who may be at risk of developing metabolic syndrome and atherosclerotic pathologies. 
 
1.3.3.2 Sarcopenia and Inflammation 
Sarcopenia refers to the age related loss of muscle mass and strength and the derivation of the 
word comes from Greek meaning ‗poverty of flesh‘ (Borst 2004).  Sarcopenia is not considered a 
disease but a condition of the normal aging process.  Recently, it has been determined that the costs 
associated with health-care due to sarcopenia are 1.5% of the total health care costs for one year in 
the United States (Janssen et al. 2004).  It is estimated that this cost will continue to rise as the 
population ages.  Chronic low grade inflammation is related to decreasing muscle mass and strength 
with age (Borst 2004; Crepaldi and Maggi 2005; Roubenoff 2001).   
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High levels of IL-6 (>5 pg·mL
-1
) and C-reactive protein (>6.1 µg·mL
-1
) in older adults (mean 
age 76.4 years) increase the risk of muscle strength loss by 2-3 times that of older adults without high 
amounts of these inflammatory mediators (Schaap et al. 2006).  In addition to lower strength, IL-6 
has been associated with a decrease in muscle mass, and fiber number in older adults (Bautmans et 
al. 2005; Deschenes 2004; Ferrucci et al. 2002; Payette et al. 2003; Roubenoff 2003; Roubenoff et al. 
2003).  Thus, it is apparent that IL-6 plays a role in the relationship between muscle mass and 
strength loss due to aging.  
Modest concentrations of IL-6, mimicking the amount of IL-6 observed post-exercise and in 
older adults with chronic low-grade inflammation, infused into the tibialis anterior muscle of rats 
demonstrated a catabolic effect on the muscle as it significantly lowered the mass of the tibialis 
anterior muscle compared to saline infused animals (Haddad et al. 2005).  The growth hormone - 
insulin like growth factor-1 (GH-IGF-1) axis and IL-6 may have similar signaling mechanisms 
related to the Janus kinase-signal transducer activator of transcription (JAK/STAT) pathway (De 
Benedetti et al. 1997; Lieskovska et al. 2002).  It is theorized that IL-6 stimulates suppressors of 
cytokine signaling (SOCS) expression via JAK activation and that SOCS activation will decrease the 
GH-IGF-1signaling associated with their respective receptors ultimately resulting in a down-
regulation of anabolic stimulus for muscle hypertrophy.  Evidence in animals has suggested that 
SOCS activation from IL-6 infusion resulted in a change in the balance of STAT signaling proteins 
that favored catabolism in muscle (Haddad et al. 2005).  Also, a recent human study with 
recombinant IL-6 infusion, at a concentration of 140 pg·mL
-1
, demonstrated a greater decrease in 
muscle protein synthesis than muscle protein breakdown resulting in an increased net muscle protein 
breakdown (van Hall et al. 2008).  The authors found that rhIL-6 infused skeletal muscle 
significantly increased the release of amino acids with a corresponding decrease in arterial amino 
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acid concentration suggesting other tissues were utilizing the amino acid acid release from the 
skeletal muscle (van Hall et al. 2008).  This may be one mechanism whereby moderate 
concentrations of IL-6 result in loss of skeletal muscle amino acids eventually resulting in loss of 
myocytes and eventually muscle function. 
TNF-α is considered a catabolic signaling agent and increasing levels with age result in a 
decreased amount of muscle mass and strength (Ladner et al. 2003).  Aged skeletal muscle displays a 
higher amount of TNF-α and mRNA for TNF-α than young skeletal muscle (Greiwe et al. 2001).  
Apoptosis, or programmed cell death, has been implicated as a possible contributor to the etiology of 
sarcopenia (Leeuwenburgh 2003; Phillips and Leeuwenburgh 2005; Roubenoff 2001).  It is 
postulated that as people age increases in TNF-α will inundate apoptotic death receptors in aged 
skeletal muscle fibers.  TNF-α will up-regulate the NFκB signaling pathway leading to increased 
production of pro-inflammatory cytokines and the progressive deterioration of myocytes via 
apoptosis.  Over time, this will result in a decrease in total muscle mass and a corresponding loss of 
strength (Ladner et al. 2003; Phillips and Leeuwenburgh 2005).  It is unclear whether strength 
training can reduce the concentration of TNF-α.  In one study, very old adults were unable to reduce 
TNF-α with resistance training but muscle strength was still improved after 12 weeks (Bruunsgaard 
et al. 2004) and in another study of identical length resistance training reduced the amount of skeletal 
muscle expressing TNF-α (Greiwe et al. 2001).  Interventions aimed at reducing chronic low-levels 
of inflammation may be beneficial for improving muscle strength and muscle size in older adults.  
High concentrations of TNF-α will signal the extrinsic pathway for apoptotic signaling in 
aging muscle by binding to the tumor necrosis factor receptor 1 associated death domain on the cell 
membrane.  This will signal an activation of procaspase-8 which will then cleave resulting in 
caspase-8 activation of caspase-3.  The activated caspase-3 results in proteolytic activity which 
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eventually culminates in cellular collapse.  TNF-α may also contribute to apoptosis by increasing the 
intracellular signaling of B-cell leukemia/lymphoma-2 associate-X protein which will signal the 
release of cytochrome c from the mitochondria.  Cytochrome c will signal proapoptoic events by 
binding 2‘-deoxyadenosine 5‘-triphosphate and apoptosis protease activiating factor-1which forms 
an apoptosome that cleaves caspase-9 increasing caspase-3, and the corresponding proteolytic 
activity associated with this protein, eventually resulting in apoptosis (Alway and Siu 2008; 
Leeuwenburgh 2003).  TNF-α has also been shown to inhibit protein synthesis induced by insulin 
like growth factor-1 in myoblast cell cultures suggesting another mechanism whereby protein 
degradation of skeletal muscle may occur in old age (Broussard et al. 2003). 
Another possible cause of myocyte loss in old age is myocyte death induced by other factors 
such as poor nutrition and alteration in immune system function related to adaptive immunity.  These 
factors stimulating myocyte death could promote an inflammatory response thus signaling 
chemokines to attract neutrophils and monocytes/macrophages to the area which would release 
inflammatory cytokines in the area of myocyte death, thus promoting an inflammatory environment 
to clear the cellular debris resulting from the myocyte death.  Recent evidence in old rats subjected to 
endotoxemia and nutritional deficiencies found that even though the old rats had low-grade 
inflammation as a result of endotoxin and nutrient deficiency, there was not a corresponding increase 
in muscle loss (Mayot et al. 2007a; Mayot et al. 2007b).  These results suggest that myocyte 
apoptosis as a result of increased inflammatory cytokines may not be the only possible mechanism 
whereby skeletal muscle is decreased in old age.  It is probable that many factors contribute to 
myocyte loss with old age and inflammation may be either a causative factor or consequential to 
increased inflammation as a result of an inflammatory response to necrosis of old tissue. 
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The purpose of the second study of this thesis was to evaluate the effects of flaxseed oil, 
which is high in alpha-linolenic acid, on IL-6 and TNF-α concentrations during progressive 
resistance training in older adults.  Alpha-linolenic acid (ALA) is considered the most potent anti-
inflammatory component of flaxseed and will likely exhibit the greatest potential for reducing the 
amount of muscle wasting by reducing concentrations of TNF-α and IL-6.  Also, resistance training 
has been shown to be the most effective method of exercise training to reverse the loss of muscle 
mass and strength associated with the aging process (Roubenoff 2003). 
 
1.3.4 Exercise and Inflammation 
 It is theorized that chronic exercise training has beneficial effects on immune system 
function as people age (Malm 2004).  Exercise results in: a reduced stress response via 
modulation of sympathetic nervous system activity and reduced catecholamine release; assists 
sleep, which is when NK cell activity is highest; reduces cross-linkage formation, which reduces 
damage to the ability of DNA to replicate; maintains T-cell function; restores a homeostatic 
balance between pro- and anti-inflammatory mediators; and lessens the damaging effects of free 
radicals (Shinkai et al. 1997).  Although the theory seems plausible, there is debate as to whether 
or not the beneficial effect of exercise will translate into improved immune system function or 
that exercise is anti-inflammatory in older individuals.   
Epidemiological data indicates that individuals who are physically active have a reduced 
amount of inflammation (Colbert et al. 2004; King et al. 2003; Panagiotakos et al. 2005; Pitsavos 
et al. 2005; Reuben et al. 2003).  A large cross-sectional study of older adults (n = 3,075; age = 
70-79 years) determined that those who perform ≥ 180 min·wk-1 of physical activity have lower 
amounts of inflammatory markers (i.e. CRP, IL-6, and TNF-α) when compared to their non-
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active counterparts (Colbert et al. 2004).  Another cross-sectional study compared young active, 
young inactive, old active, and old inactive adults for in vitro stimulated release of IL-1β, IL-6, 
TNF-α and CRP analyzed from plasma (McFarlin et al. 2006).  Inactive subjects had higher 
amounts of IL-6 and TNF-α, by 24% and 21% respectively, than the active groups.  Also, IL-1β 
was 14% higher in the old-inactive group versus the young-active group.  Overall, physically 
active subjects had 60% lower CRP than their inactive counterparts while the older subjects had 
a 53% higher CRP than the younger participants.  It was concluded that being physically active 
has anti-inflammatory effects which may be beneficial for lowering chronic inflammation 
observed with aging. The two studies in this thesis involve cardiovascular (―aerobic‖) and 
musculoskeletal training; therefore, both types of training and their influence on inflammatory 
cytokines will be reviewed. 
Relatively few prospective trials have been completed on the effects of cardiovascular 
training on the inflammatory response in healthy older adults.  The majority have evaluated the 
beneficial effects of cardiovascular training on inflammatory markers in adults at risk of 
cardiovascular disease (Adamopoulos et al. 2001; Conraads et al. 2002; Gielen et al. 2003; 
Goldhammer et al. 2005; Larsen et al. 2001; Rauramaa et al. 2004; Smith et al. 1999; Tisi et al. 
1997).  All of these studies have shown that inflammation, analyzed by acute phase proteins and 
pro-inflammatory cytokines, is reduced by cardiovascular exercise training.  Also, a trial 
performed on healthy adults, who were recruited to train with endurance exercise for 9 months, 
found a significantly lower amount of CRP in the trained versus untrained control condition 
(Mattusch et al. 2000).  Further, a retrospective trial found that healthy older men who were 
physically active had a lower degree of inflammatory markers than those men who were inactive 
(Jankord and Jemiolo 2004).  These results indicate that chronic cardiovascular exercise training 
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is anti-inflammatory in nature for diseased populations and perhaps for healthy populations.  
More research on the anti-inflammatory nature of cardiovascular exercise is warranted, 
especially from a preventative viewpoint.   
Experiment I in this thesis employed cardiovascular training to establish a standard of 
care that would be appropriate for reducing the risk of atherosclerosis and metabolic syndrome, 
which includes inflammation as one of a cluster of risk factors. The cluster of risk factors 
associated with metabolic syndrome, as classified by WHO or ATP III guidelines, indicates that 
the risk of cardiovascular disease is increased in older adults diagnosed with metabolic syndrome 
(Scuteri et al. 2005) and that metabolic syndrome is more common in old versus young adults 
(Meigs 2002).  Longitudinal data has indicated that 10 years of cardiovascular exercise training 
(30-45 min·session
-1
, 3 d·wk
-1
, 75-85% of VO2max) improved the cardiovascular fitness level and 
decreased metabolic syndrome risk factors in older adults (Petrella et al. 2005) and 6 years of 
low to moderate intensity aerobic exercise for 45-60 minutes, 5 times per week slowed the 
progression of atherosclerosis in men (Rauramaa et al. 2004). To date, one exercise trial has 
indicated that a combination of cardiovascular and resistance exercise training is effective at 
lowering metabolic syndrome risk in older adults (Stewart et al. 2005a).  However, another trial 
determined that cardiovascular exercise training and resistance exercise training had similar 
effects in enhancing glucose metabolism but cardiovascular training was the only effective 
method of improving insulin activation of glycogen synthesis in older men which could decrease 
risk of metabolic syndrome (Ferrara et al. 2006).  Furthermore, 2 days per week of moderate 
intensity aerobic exercise for 6 months significantly decreased cell adhesion molecules and the 
atherogenic lipid profile in older, overweight, type II diabetics (Zoppini et al. 2006) while 
epidemiological evidence suggests that 30 minutes of moderate intensity aerobic exercise lowers 
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the risk of type II diabetes by 30-50% (Bassuk and Manson 2005).  For Experiment I it was 
deemed that cardiovascular exercise training would be the most appropriate recommendation to 
give to older individuals as this mode of exercise is effective at decreasing metabolic syndrome 
risk (Meigs 2002; Pitsavos et al. 2005) and reducing the risk of atherosclerosis (Rauramaa et al. 
2004; Smith et al. 1999) most likely by modifying the inflammatory milieau, insulin sensitivity, 
and the blood lipid profile thus, reducing cardiovascular disease development (Ford 2002; 
Goldhammer et al. 2005). 
Resistance training studies are mixed on whether they reduce inflammation. Evaluation 
of the effects of 12 weeks of resistance training in older and younger women indicated that there 
was no effect on IL-1β, TNF-α, IL-6, or IL-2 levels (Rall et al. 1996).  Ten weeks of resistance 
training in older women had no effect on cytokine mRNA expression; however, IL-6 and TNF-α 
release from LPS-stimulated blood monocytes were significantly lower in resistance trained 
women than controls (Flynn et al. 2003).  These two studies should be interpreted with caution as 
the first study contained women with rheumatoid arthritis which has known effects on cytokine 
proliferation and the second study utilized some pharmacological agents in different groups 
which may influence the cytokine response.  Additional studies indicated 12 weeks of resistance 
training in a very old population of nursing home residents (age 85-96 y) had no effect on  
circulating IL-6, TNF-α or soluble TNF receptors (Bruunsgaard et al. 2004), but 6 weeks of 
intensive training in older adults (average age 68 y) tended to decrease circulating concentrations 
of IL-6 and increase IL-10 and TGF-β (Bautmans et al. 2005).  The effect of resistance training 
on inflammatory markers requires further study before specific conclusions can be made. 
Acute exercise (i.e. muscle contraction) is associated with a substantial increase and 
release of IL-6 and a minor increase in TNF-α content in skeletal muscle which would seem a 
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paradox for promoting muscular growth or metabolic adaptations to improve exercise ability 
(Steensberg et al. 2002).  Both of these cytokines induce the acute phase inflammatory response 
and TNF-α is known to be a catabolic cytokine (Bautmans et al. 2005).  The tissue site of origin 
of IL-6 may be an important regulator of its physiological action and a local release of IL-6 from 
muscle may have some beneficial effects (Fischer 2006).  The purpose of IL-6 release from 
skeletal muscle seems to be for metabolic regulation.  When glycogen content of muscle is low 
or exercise intensity or duration is increased, higher amounts of IL-6 are released from muscle 
(Chan et al. 2004; Helge et al. 2003).  IL-6 release from skeletal muscle appears to promote a 
catabolic environment by increasing fat oxidation, lipolysis, glucose output, and energy 
expenditure from adipose and liver tissue so the increased substrate release may be utilized by 
contracting skeletal muscle to maintain exercise (Febbraio and Pedersen 2002).  IL-6 may also 
stimulate some anti-inflammatory mediators. For example, IL-6 stimulates the release of IL-1 
receptor antagonist (IL-1ra), a cytokine that will attenuate the pro-inflammatory effects of IL-1β. 
IL-6 also stimulates the release of IL-10, a potent anti-inflammatory cytokine, as well as soluble 
TNF receptors which would attenuate the effects of TNF-α (Steensberg et al. 2003; Tilg et al. 
1994).  Cortisol, a known anti-inflammatory hormone (Barnes 1998) is released when 
recombinant IL-6 is infused (Steensberg et al. 2003).  IL-6 release from contracting skeletal 
muscle is maintained into old age which may be one mechanism whereby exercise is anti-
inflammatory in older adults (Pedersen et al. 2004).   
Toll-like receptors (TLR) are trans-membrane signaling receptors that respond to 
lipopolysaccharide (LPS), a component of gram-negative bacteria, and stimulate an innate 
inflammatory reaction by releasing pro-inflammatory cytokines and proteins (Gleeson et al. 
2006).  Those who are physically active or participate in resistance exercise training have shown 
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down-regulation of a specific TLR called TLR4 (Flynn and McFarlin 2006; Flynn et al. 2003).  
Individuals that have high expression of TLR4 also have higher LPS-stimulated production of 
pro-inflammatory cytokines (Flynn et al. 2003; McFarlin et al. 2004).  Therefore, a down-
regulation of TLR4 is a possible mechanism whereby exercise training reduces the concentration 
of inflammatory cytokines such as IL-6 and TNF-α (Gleeson et al. 2006; Stewart et al. 2005b).   
The underlying theme of this thesis was to provide evidence for the anti-inflammatory 
effects of flaxseed components during standardized exercise training.  Many conditions are 
associated with the hyper-inflammatory state often observed in older adults, including 
sarcopenia.  Experiment II is designed to utilize progressive resistance training as the mode of 
exercise and standard of care for older adults in an attempt to reduce the risk of sarcopenia.  
Sarcopenia has been defined as a loss of muscle mass equal to or greater than 2 standard 
deviations below the young reference mean and its development is associated with physical 
disability and other chronic diseases (Castillo et al. 2003).  Various methods have been employed 
to reverse sarcopenia in older adults, including testosterone and human growth hormone, but 
high intensity progressive resistance training remains the most effective method of decreasing 
the risk of sarcopenia, increasing lean tissue mass, and increasing strength in the elderly (Binder 
et al. 2005; Borst 2004; Charette et al. 1991; Fiatarone et al. 1994; Frontera et al. 1990; 
Hakkinen et al. 2002; Ivey et al. 2000; Lemmer et al. 2000; Roubenoff 2000; Yarasheski et al. 
1999).  As discussed above, resistance training may be effective for lowering inflammatory 
markers but by having each subject in the study complete the same resistance training program, 
this thesis establishes a standard of care that would reduce the incidence of sarcopenia and 
thereby evaluate if an anti-inflammatory nutritional supplement (ALA) will improve skeletal 
muscle mass to a greater extent than resistance training alone.  Experiment II utilized a different 
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mode of exercise than Experiment I as secondary hypotheses of each study were that the exercise 
mode utilized would be most appropriate as a clinical prescription for the condition of interest 
(sarcopenia for Experiment II and metabolic syndrome/atherosclerosis for Experiment I). 
From the above review it is difficult to speculate on the effects exercise has on the entire 
cytokine network during the aging process.  Studies to date indicate that exercise training is 
either anti-inflammatory or has no effect on inflammation.  The research done on the response of 
cytokines to physical activity or exercise in older adults is limited and it is probable that the type, 
duration, intensity, and volume of the exercise task all influence the response of cytokines.  One 
study has indicated that prolonged exercise (2 hours) significantly increased IL-6 and TNF-α 
when compared to either 5 minutes of high intensity exercise (90% VO2max) or circuit training 
(Brenner et al. 1999).  Also, light volume aerobic exercise training (70-85% heart rate maximum, 
3 d·wk
-1
 for 12 weeks) was suggested to be optimal for immune system function when compared 
to moderate volume training (same intensity but 4-5 d·wk
-1
) (Shore et al. 1999).  It is important 
to note that eccentric exercise tasks (i.e. when muscle is forced to lengthen, such as when 
walking or running downhill) will result in localized skeletal muscle inflammation in response to 
the stimuli of the exercise task (Hamada et al. 2005; Toft et al. 2002).  Older adults‘ ability to 
respond to an eccentric exercise task may be compromised due to changes in the cytokine milieu 
after the exercise task but recent evidence suggests that an inflammatory event is not necessary 
for anabolism in older adults completing eccentric muscle exercise (LaStayo et al. 2007).  The 
type and intensity of exercise influences the cytokine response and very intense forms of exercise 
(i.e. eccentric loading or long duration high intensity cardiovascular exercise) may not result in 
the same cytokine response as moderate exercise intensity.  Thus, although evidence from cross-
sectional, retrospective trials seems to increasingly favor the anti-inflammatory effects of 
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physical activity, it seems necessary to perform more prospective randomized controlled trials on 
the cytokine response to chronic exercise training to determine the effectiveness of exercise for 
ameliorating the increase in low-grade chronic inflammation associated with aging.  Exercise 
prevents many diseases; a reduction in inflammation is likely one mechanism whereby exercise 
training maintains health into old age (Salvioli et al. 2006). 
 
1.3.5 Flaxseed and Inflammation 
 The anti-inflammatory potential of many food compounds may lead to novel approaches 
in preventative and therapeutic care of pathological conditions related to inflammation 
(Murakami and Ohigashi 2006).  Components of flaxseed, specifically the oil and lignan, hold 
potential for reducing inflammation when consumed in higher amounts.  The following section 
reviews the anti-inflammatory potential of these two components of flaxseed. 
 
1.3.5.1  Secoisolariciresinol Diglucoside 
 Lignans are a group of polyphenolic compounds in plants that share structural similarities 
with estrogen and thus have been classified as phytoestrogens.  Bacterial flora in the colon are 
able to metabolize various plant lignans, including flaxseed lignans, to the mammalian lignans 
enterodiol and enterolactone (Borriello et al. 1985; Heinonen et al. 2001; Wang et al. 2000).  The 
flaxseed lignan, secoisolariciresinol diglucoside (SDG), has received research interest due to its 
potential to reduce the risk of chronic health conditions including cancer, cardiovascular disease, 
diabetes, and osteoporosis (Thompson and Ward 2002).  There is no established Dietary 
Reference Intake for SDG and currently in Canada it is termed a natural product and is 
considered a phytochemical.  SDG is first metabolized to secoisolariciresinol (SECO), which is 
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its aglycone, and then further metabolized to the mammalian lignans enterodiol and 
enterolactone.  SECO shares structural similarity with nordihydroguaiaretic acid, which is a 
antioxidant, and various lignans have been shown to bind to sex hormone binding globulin in in 
vitro studies (Schottner et al. 1997; Schottner et al. 1998).  The possible mechanisms whereby 
SDG may exert its health effects are: 1) acting as an anticancer agent in hormone dependent 
cancers such as breast and prostate cancer (Lin et al. 2002; Rickard et al. 1999; Thompson et al. 
1996) or colon cancer (Jenab and Thompson 1996; Sung et al. 1998); 2) modifying lipid 
metabolism to reduce the risk factors associated with cardiovascular disease (Hallund et al. 
2006a; Hallund et al. 2006b; Prasad 1999); 3) exerting an estrogenic-like effect which may have 
positive effects on bone metabolism (Ward et al. 2001a; Ward et al. 2001b); or 4) acting as an 
antioxidant which may have beneficial effects for a number of disease processes related to 
inflammation (Kitts et al. 1999; Prasad 1997b; Prasad 2000a; Prasad 2000c).  Of the various 
effects SDG is proposed to exert on health, this review will focus on its ability to reduce 
inflammation especially in relation to cardiovascular disease. 
 In response to inflammation, activated immune cells respond to injury or microbe 
invasion by phagocytosis which involves the respiratory burst.  The respiratory burst is a time of 
increased oxygen consumption whereby the oxidation of molecules foreign to the organism 
occurs.  During this time, NADPH-dependent oxidases catalyze the conversion of oxygen to the 
superoxide (O2
-
) anion and produce a number of reactive oxygen and nitrogen intermediates that 
result in the degradation of the foreign material (Mak and Saunders 2006).  One of the reactive 
oxygen intermediates formed in this process is the hydroxyl radical (OH
-
) which breaks 
hydrogen bonds and is associated with damage to nucleic acids.  In vitro analysis of the OH
- 
scavenging ability of SDG was determined by HPLC when hydrogen peroxide was subjected to 
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photolysis by UV light (Prasad 1997b).  This study also utilized another in vitro measure in liver 
homogenate to evaluate if lipid peroxidation was reduced in the presence of SDG.   The results 
indicated that OH
- 
radical was scavenged by SDG in the first model and assessment of 
malondialdehyde, a measure of lipid peroxidation, was reduced by SDG in the second model.  
One other study has confirmed the antioxidant effect of SDG, and its metabolites enterolactone 
and enterodiol in vitro (Kitts et al. 1999).  It was concluded in both studies that SDG had 
antioxidant properties which may be the mechanism whereby it exerts anti-cancer effects.  
Another in vitro study of the effects of SDG and its metabolites SECO, enterodiol (ED), 
and enterolactone (EL) was performed to analyze the scavenging activity of each substance on 
zymosan-activated polymorphonuclear (PMNL) leukocytes (Prasad 2000a).  The results 
indicated that all metabolites were able to scavenge reactive oxygen species but ED and SECO 
displayed the greatest scavenging ability by reducing PMNL chemiluminescence by 94.2% and 
91.2% respectively.  The author speculated that the antioxidant ability of SDG is a function of 
the scavenging ability of its metabolites and may be effective in inhibiting and treating various 
inflammatory diseases including cardiovascular disease and auto-immune disease.  Recent in 
vitro examination of the antioxidant properties of SDG and SECO at concentrations likely 
achievable in vivo, within the gastrointestinal tract,  indicates they are effective in a dose 
dependent-manner while ED and EL did not show as much scavenging efficacy (Hosseinian et 
al. 2007; Hu et al. 2007).  The direct scavenging ability of SDG and SECO at concentrations 
achievable in vivo in other tissue types is unknown at this time. 
In an animal model representative of Type I diabetes, confirmation of the above in vitro 
result was obtained in vivo (Prasad 2000c).  Rats were divided into three groups: a control group 
not prone to developing diabetes, a group that was untreated and prone to developing type I 
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diabetes, and a group treated with SDG who were prone to developing type I diabetes.  The 
incidence of diabetes development in the SDG group was 21.4% whereas the non-supplemented 
group‘s incidence of developing diabetes was 72.7%.  Also, results indicated that serum 
malondialdehyde levels were lower when comparing the SDG treated versus untreated animals.  
Pancreatic chemiluminescence was reduced in the SDG treated group when compared to the 
untreated group.  The author concluded that type I diabetes may be mediated by reactive oxygen 
species and SDG supplementation may be effective in lowering the incidence of this auto-
immune disease.  Results from the same laboratory in relation to the development of type II 
diabetes, in an animal model, also indicate that SDG is effective in reducing the incidence of this 
disease by reducing oxidative stress (Prasad 2001).  Further, a study in type II diabetic humans 
indicated improved glycemic control but no difference in glucose, insulin, or blood lipids after 
12 weeks of SDG supplementation (Pan et al. 2007). 
The effects of a flaxseed lignan complex containing SDG on the development of 
atherosclerosis in rabbits fed a high cholesterol diet produced conflicting results (Prasad 2005b).  
In this study, female rabbits were separated into four groups: a control group, a group fed lignan 
complex, a group fed a high cholesterol diet, and a group fed a high cholesterol diet as well as 
lignan complex.  Antioxidant reserve was increased in the SDG group on the high cholesterol 
diet whereas it was decreased in the SDG only group.  Also, aortic malondialdehyde 
concentration was lower in the cholesterol/lignan group compared to the cholesterol only group 
but the lignan complex increased aortic malondialdehyde in the lignan supplemented group when 
compared to the control group.  Serum malondialdehyde concentration was 35.7% less after 2 
months in the cholesterol/lignan group as compared to the cholesterol diet group.  Prasad (Prasad 
2005b) stated that a reduction of oxidative stress was seen in this animal model which reduced 
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the extent of atherosclerosis.  These results suggest SDG has beneficial effects when animals are 
fed a high cholesterol diet but may have pro-oxidant effects in those consuming a normal diet 
which could be an indicator of future health detriments if supplementation was continued. 
 Supplementation with flaxseed (7.5 g·kg
-1
) over 8 weeks reduced polymorphonuclear 
leukocytes (PMNL) production of oxygen free radicals in rabbits who were either on normal or 
high-cholesterol diets (Prasad 1997a). It was not known whether the α-linolenic acid or the SDG 
found in flaxseed exerted the decrease in free radical production.  Other studies out of the same 
laboratory indicated that SDG was the effective component; flaxseed with low α-linolenic acid 
content reduced atherosclerotic plaque formation in animals on a high cholesterol diet (Prasad et 
al. 1998) and direct SDG supplementation increased antioxidant capacity and decreased lipid 
peroxidation in animals on a high cholesterol diet (Prasad 1999).  
SDG was shown to prevent the development of streptozotocin-induced diabetes in a rat 
model (Prasad et al. 2000).  In this study rats were divided into four groups: a control group, a 
group supplementing with SDG for 24 days, a group injected with streptozotocin, and a group 
supplementing with SDG before and after streptozotocin injection.  The rats supplemented with 
SDG and injected with streptozotocin, that did not develop diabetes, showed a link with 
decreases in the amount of serum and pancreatic malondialdehyde and an increase in pancreatic 
antioxidant reserve.  Further analysis revealed that leukocyte chemiluminescence was decreased 
in the SDG-streptozotocin group when compared to the streptozotocin group, which suggests 
SDG may scavenge reactive oxygen species produced during inflammatory reactions.  The 
authors speculated that a reduction of hydrogen peroxide by SDG scavenging could decrease the 
activation of the complement cascade of events and possibly delay the development of diabetes. 
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 A cross-over human study investigating the effect of defatted flaxseed on indicators of 
oxidative stress found contrasting results (Jenkins et al. 1999).  Serum protein thiol and carbonyl 
groups were measured to assess oxidative stress.  Protein carbonyl concentrations did not differ 
between the control and flaxseed supplement conditions but protein thiol concentrations were 
significantly lower at the end of the flaxseed trial in comparison to the control trial.  Increased 
oxidative stress with defatted flaxseed consumption may or may not be harmful depending on 
perspective.  If the increased oxidative stress results in the degradation of lipids and proteins 
necessary for tissue function it could be considered harmful but, if the increase was due to an 
improvement in innate immune function against foreign pathogens it could be beneficial (Jenkins 
et al. 1999). 
 In contrast to the above animal research, the first human study to evaluate the effects of 
supplementation with a flaxseed lignan complex found no changes in oxidative stress or 
measures of inflammation in 22 healthy post-menopausal women who supplemented for 6 weeks 
(Hallund et al. 2006a; Hallund et al. 2006b).  In this study the researchers employed a cross-over 
design where women consumed a muffin containing 500 mg·d
-1
 of lignan complex for 6 weeks, 
followed by a 6 week wash-out period, and then a 6 week consumption of a placebo muffin.  
Serum lipoprotein resistance to oxidation, Trolox-equivalent antioxidant capacity, and ferric 
reducing ability of plasma did not differ significantly between the placebo and lignan complex 
intervention suggesting no effect of lignan complex on oxidative status (Hallund et al. 2006a).  
Further results revealed no effect on plasma markers of NADPH oxidase and endothelin-1, 
which indicates endothelial relaxation and constriction respectively, as well as asymmetric 
dimethylarginine, which is an endogenous inhibitor of endothelial derived nitric oxide synthase 
and is implicated in endothelial dysfunction (Hallund et al. 2006b).  Also, Pan et al. (Pan et al. 
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2007) found improved glycemic control with 12 weeks of SDG supplementation in type II 
diabetic patients but no improvement in blood lipids, glucose control or insulin sensitivity.  
Furthermore, 8 weeks of flaxseed lignan complex (600 mg·d
-1
) supplementation significantly 
reduced total cholesterol and glucose concentrations in a group of hypercholesterolaemic 
subjects (Zhang et al. 2007). 
 There is the possibility of a sex difference when supplementing older adults with flaxseed 
lignan.  Women who are post-menopause will have a decreased production of estrogen and 
possibly a down-regulation of estrogen receptors whereas this change would not be as dramatic 
in men (Castelo-Branco and Rostro 2006).  Although speculative, the flaxseed lignan or its 
metabolites may not bind as effectively in the women versus the men due to a lack of receptors.   
This may result in less of a potential health benefit in women versus men.  Recent work in post-
menopausal women has indicated no effect of SDG supplementation for 6 weeks on blood lipids 
or antioxidant status (Hallund et al. 2006a).  The first study in this thesis addressed this issue by 
supplementing men and women with SDG for 6 months.  Experiment I was designed to evaluate 
the sex differences in the dependent variables.  It was also designed to evaluate if supplementing 
with SDG for a longer time period (6 months versus 6 weeks) would have an effect on the 
dependent variables measured. 
 There is a possibility of age-specific effects on lignan metabolism.  Older individuals 
have a decrease in bacterial flora which may affect the conversion of SDG to SECO and the 
mammalian lignans enterodiol and enterolactone (He et al. 2001; Leibovici 1995).  It has been 
theorized, from in vitro models, that the conversion of SDG to the mammalian lignans may be 
the mechanism driving the beneficial lipid lowering effects of SDG as enterolactone may act 
similarly to estrogen by stimulating  hepatic and macrophage cells to increase uptake of LDL 
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(Owen and Abbey 2004; Owen et al. 2004).  If the conversion of SDG to the mammalian lignans 
is compromised due to reduced bacterial flora in old age then there may not be the same 
purported health effects in older adults.  Also, recent evidence has found that prebiotic and 
probiotic ingestion will positively influence bacterial flora (Bartosch et al. 2005), possibly 
enhancing immune function and reducing inflammation in older adults (Schiffrin et al. 2007).  A 
synergistic effect of probiotics and a high soy diet on the bioavailability of active isoflavones 
(daidzein, genistein) in older adults was not observed (Larkin et al. 2007).  It is not known if 
prebiotic or probiotic ingestion will influence the gut metabolism of flaxseed lignans.  The 
design of Experiement I did not directly test this relationship but it is worth mentioning the 
possibility of an age and nutritional effect in this review. 
 In general, research completed so far on the anti-oxidant or anti-inflammatory effect of 
flaxseed lignan in humans is in its initial stages.  There is potential for this phytochemical to aid 
in health promotion given the evidence from animal models, but the paucity of information 
surrounding the health effects of SDG supplementation in humans definitely requires a more 
thorough investigation.  Theoretically, if SDG or its metabolites act as anti-oxidants, and 
decrease the amount of reactive oxygen species generated due to their scavenging ability, SDG 
supplementation may be an effective means to down-regulate NFκB‘s production of pro-
inflammatory cytokines such as TNF-α and IL-6 and may be an effective nutritional strategy to 
combat the hyper-inflammation associated with the aging process.  The purpose of the first study 
of this thesis was to evaluate the efficacy of supplementation with a flaxseed lignan complex 
during cardiovascular training on inflammatory status and blood lipid profiles in older adults at 
an increased risk of developing cardiovascular disease.  It was theorized that increased oxidative 
stress, from oxidized LDL, and increased inflammation, due to more circulating pro-
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inflammatory cytokines, will intensify the risk of metabolic syndrome and cardiovascular disease 
due to atherosclerosis in older adults.  Experiment I hypothesized that standardized exercise 
designed to decrease blood lipid profiles (walking 6 d·wk
-1
, 30-60 min·d
-1
) and a nutritional 
intervention designed to decrease oxidative stress and inflammation (flaxseed lignan complex 
supplementation) would decrease the inflammatory process and reduce the development of 
metabolic syndrome.  
 
1.3.5.2  Alpha-Linolenic Acid 
The purpose of this section is to summarize the effects of supplementing with α-linolenic 
acid from flaxseed on immune function with a focus on cytokine production in humans.  Alpha-
linolenic acid (18:3ω-3; ALA) is an 18 carbon fatty acid with the last of the carbon-to-carbon 
double bonds located 3 carbon atoms before the methyl end.  It is considered an essential ω-3 
polyunsaturated fatty acid and the parent to longer carbon chain ω-3 fatty acids.  Flaxseed oil is 
composed of between 45-60% ALA (Cunnane 2003).  Currently, the Dietary Reference Intake 
has an established adequate intake of ALA which is 1.6 and 1.1 g·d
-1
 for men and women 
respectively with no upper limit set.  One metabolic function of ALA in humans is incorporation 
into the structure of cell membranes.  Also, ALA functions as a precursor to other ω-3 fatty acids 
(eicosapentaenoic acid and docosahexaenoic acid) via carbon chain elongation and further 
desaturation (Burdge 2004).  Supplementation with ω-3 fatty acids has been used to decrease the 
amount of inflammation associated with various disease processes (Simopoulos 1999; 
Simopoulos 2002b).  It is theorized that a high ratio of ω-6 to ω-3 fatty acids in the normal 
western diet increases risk for the development of many chronic diseases (Simopoulos 2002a).  
The main type of ω-6 fatty acid, derived from linoleic acid, is arachidonic acid (AA) which is the 
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precursor for various inflammatory eicosanoids and cytokines (Darlington and Stone 2001).  
Most research utilizing supplementation with ω-3 fatty acids shows a change in the ratio of ω-
6:ω-3 fatty acids with numerous biologic effects.  Decreasing the ratio of ω-6:ω-3 fatty acids will 
result in a decreased amount of inflammatory eicosanoids and cytokines because the ω-3 fatty 
acid, eicosapentaenoic acid (EPA), competes with AA metabolism along the same enzymatic 
pathways (cyclooxygenase and 5-lipoxygenase) (James et al. 2000).  ALA is the precursor or 
―parent‖ fatty acid to EPA (Cunnane 2003).  The specific change that occurs to mediate the 
inflammatory response is a change in the lipid bilayer of most human cells to a decreased amount 
of ω-6 fatty acids and an increased amount of ω-3 fatty acids (Alexander 1998).  Increasing 
consumption of ALA will increase EPA concentration in men and women but the conversion is 
lower in men than women (Burdge 2004; Burdge et al. 2003; Burdge and Wootton 2003).   
A dietary intervention, which had men (ages 21-37 years) eat all their meals at a 
nutritional test center for 126 days, evaluated the effects of a diet high (21% of the total fatty 
acids) and low (1% of the total fatty acids) in ALA on various parameters of both cellular and 
humoral immunity (Kelley et al. 1991).  There were no changes in the number of circulating T-
cells, T-cell subsets, or B-cells with the intervention.  In vitro analysis of mitogen stimulated 
peripheral blood mononuclear cells revealed a suppression of T-cell proliferation with no change 
in the secretion of IL-2 or IL-2r when the ALA group was compared to the control group.  
Further results of B-cell function indicated no change in serum concentrations of 
immunoglobulins or complement components.  The results suggest a suppression of T-cell 
function but no effect on B-cell function or cytokines in young men supplementing with large 
amount of ALA.  
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Research in a population diagnosed with rheumatoid arthritis, to evaluate the effects of 
ALA supplementation on markers of inflammation, revealed mixed results (Nordstrom et al. 
1995).  In this study patients were split into a group receiving 30 grams of flaxseed oil (~9.6 
grams ALA) or 30 grams of safflower oil for 3 months.  Serum ALA concentration as well as 
bleeding time was significantly increased in the patients consuming flaxseed while C-reactive 
protein, erythrocyte sedimentation rate and clinical data of disease activity were not significantly 
different between the two groups post-intervention.  The interpretation of this study is difficult 
due to the fact that all patients were taking various pharmaceutical agents known to affect 
immune system function, to control their disease activity. 
An evaluation of a 4 week flaxseed oil based diet on TNF-α and IL-1β was performed in 
healthy male subjects (Caughey et al. 1996).  In this design, subjects were randomized to a 
flaxseed oil group who consumed an average of 13.7 g·d
-1
 of ALA or a sunflower oil group who 
consumed an average of 1.1 g·d
-1
 ALA.  In vitro analysis of stimulated mononuclear cell 
production of cytokines before and after the supplementation period revealed a significant 
decrease of 30% and 31% in TNF-α and IL-1β respectively.  Also, the high ALA group had 
decreased amount of inflammatory eicosanoids and increased amounts of ALA and EPA in 
mononuclear cell membranes when compared to the sunflower oil group.  Another study from 
the same laboratory analyzed the changes in in vitro cytokine and eicosanoid production in a 
group of young men (average age 37 years) eating a diet high in ALA (~9.2 g·d
-1
) over 4 weeks 
(Mantzioris et al. 2000).  The results indicated a 20% significant decrease in IL-1β after 2 and 4 
weeks compared to baseline while TNF-α significantly decreased by 40% after 2 weeks but was 
not significantly different than baseline at 4 weeks.  Eicosanoid production was decreased at 2 
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and 4 weeks when compared to baseline.  This suggests that diets high in plant-based ω-3 fatty 
acids can effectively inhibit TNF-α and IL-1β production.   
A larger (n = 48) randomized controlled trial has evaluated the effects of supplementation 
with moderate levels of different types of fatty acids on immune system function in healthy male 
and female participants over a 12 week period (Thies et al. 2001b).  The purpose of the research 
was to evaluate any detrimental effects to immune system function in those following current 
dietary recommendations to increase consumption of ω-3 fatty acids.  One of the groups in this 
study consumed an extra 2.0 g·d
-1
 of ALA.  There was no effect of ALA supplementation on NK 
cell activity although a decrease in NK cell function was found in a group supplementing with 
EPA (Thies et al. 2001b).  There were no significant effects of time, treatment or the interaction 
on TNF-α and IL-6 production in any of the groups (Thies et al. 2001a).  The study also 
evaluated the effects that ALA supplementation had on the production of IL-2 and IFN-γ from in 
vitro stimulated lymphocytes and found no effect on these two cytokines (Thies et al. 2001c).  At 
low levels of supplementation there seems to be no adverse effects of ALA although a criticism 
could be made, depending on perspective, that the low amount of ALA given may not be enough 
to produce a biological effect. 
Another randomized, double blind, placebo controlled trial (n = 150) evaluated the 
immune function of participants ingesting a low or high ALA and EPA/DHA supplement in a 
broad group of adults (age range 25-72 years) over a 6 month time period (Kew et al. 2003).  In 
this research, there was a group consuming a low amount of ALA (4.5 g·d
-1
) and a high amount 
of ALA (9.5 g·d
-1
).  Cytokine response to LPS and Con A stimulation in cultured peripheral 
blood mononuclear cells resulted in no change in TNF-α, Il-1β, IL-6, IL-2, IL-4, and IFN-γ 
between groups at baseline or after the dietary intervention.  Although there were no changes in 
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cytokine production between the groups, there was a significant difference in the composition of 
fatty acids incorporated into mononuclear cell phospholipids which reflected the dietary 
interventions.  Thus, it seems that increased consumption of ALA may not affect cytokine 
production but will change the fatty acid composition of immune cell phospholipids.  Additional 
study confirmed that ALA supplementation (3.5 g·d
-1
) for 12 weeks had no effect on TNF-α, IL-
1β, or IL-6 (Wallace et al. 2003).  In contrast, the results indicated that supplementation with 
medium and high amounts of fish oil (EPA and DHA) resulted in a decreased production of IL-6. 
 A double blind trial randomized hypercholesterolaemic men and women (mean age 55 
years) to an ALA group (5.9 g·d
-1
) or a linoleic acid group (Bemelmans et al. 2004).  The study 
analyzed the effects of ALA intake on C-reactive protein, IL-6 and IL-10 over a 2 year time 
period and found that CRP was reduced in the ALA group when compared to the linoleic acid 
group but no differences were found for IL-6 or IL-10.  The study is limited in its interpretation 
because very few blood samples were within the detection limits of the ELISA kits used to 
analyze IL-6 and IL-10.  Another study, in dyslipidaemic male patients (n = 76, mean age 51 
years), found that supplementation with 15 mL·d
-1
 of ALA versus 15 mL·d
-1
 of linoleic acid over 
3 months resulted in a significant decrease in CRP, serum amyloid A, and IL-6 (Rallidis et al. 
2003).   
 A four day clinical intervention analyzed the effects of a low (0.5% of total energy 
intake) and high (5.0% total energy intake) amount of ALA on soluble markers of IL-6 receptor 
(sIL-6R) and TNF-α (sTNFR1, sTNFR2) in nine normal weight and seven overweight males 
(Nelson and Hickey 2004).  There were no significant changes in sTNFR1 and sTNFR2 between 
the control and ALA diet although a 12% decrease in sTNFR2 was noted in the overweight 
group.  The levels of sIL6R decreased significantly by 11% and 12% in the normal weight and 
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overweight males, respectively, who were on the ALA diet when compared to the control group.  
The results may have important clinical implications in reducing sub-clinical inflammation, 
especially in overweight/obese individuals. 
 A diet with moderate amounts of ALA may reduce inflammatory cytokine production in 
chronic obstructive pulmonary disease (Matsuyama et al. 2005).  In this study, patients were 
randomized to either a ω-3 group (n = 32; 1.4% of diet ALA) or a ω-6 group (n = 32; 0.18% of 
diet ALA) and were evaluated for leukotriene B4 (LTB4), TNF-α, and IL-8 levels in the sputum 
and serum over a 2 year time period.  The levels of serum LTB4 decreased in the ω-3 group at 15 
months when compared to the ω-6 group but no changes were seen in levels of TNF-α or IL-8.  
Sputum levels of LTB4, TNF-α, and IL-8 were all decreased in the ω-3 group when compared to 
the ω-6 group.  The authors recommended nutritional support with ω-3 fatty acids as a strategy 
in treatment of COPD. 
 The effects of ALA supplementation on inflammatory markers may vary between males 
and females.  Burdge and colleagues (Burdge 2004; Burdge 2006; Burdge and Calder 2005; 
Burdge et al. 2003; Burdge et al. 2002; Burdge and Wootton 2002; Burdge and Wootton 2003) 
have investigated the metabolism of ALA in men and women and found that the conversion of 
ALA to EPA is higher in young women than in young men and that this relationship is mediated 
by estrogen.  One purpose of Experiment II was to evaluate sex differences in the anti-
inflammatory effects of ALA supplementation.  The sample included post-menopausal women, 
who may convert less ALA to EPA as estrogen concentration is reduced, thus potentially 
reducing the anti-inflammatory effect of ALA supplementation.  Therefore, Experiment II 
included an evaluation of differences between males and females in the dependent variables 
measured.   
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The research performed by Burdge et al. (Burdge 2004; Burdge 2006; Burdge and Calder 
2005; Burdge et al. 2003; Burdge et al. 2002; Burdge and Wootton 2002; Burdge and Wootton 
2003) on ALA conversion to longer chain fatty acids was done in young healthy males and 
females.  In Experiment II, we recruited old healthy males and females.  It is not known if age 
influences the conversion of ALA to EPA or if older adults will experience the same anti-
inflammatory benefits as younger adults from consuming ALA as this hypothesis has not been 
directly tested.  The available data seems to indicate that ALA is anti-inflammatory across age 
ranges (21-72 years) but the majority of this data was in patients with blood lipid abnormalities 
(Bemelmans et al. 2004; Kew et al. 2003; Rallidis et al. 2003; Thies et al. 2001b; Zhao et al. 
2007; Zhao et al. 2004).  The design of Experiment II will not test differences across age-ranges 
in terms of inflammatory cytokines but it is suggested that a difference may exist in the 
effectiveness of ALA to reduce inflammation in older versus younger adults. 
 In summary, the evidence for the effectiveness of ALA to decrease markers of 
inflammation seems conflicting but may reflect the differences in study design, methodology, 
and populations analyzed.  Very few studies have evaluated the effects of ALA supplementation 
on the inflammatory process in older adults.  There is more information in regards to the health 
effects of ω-3 fatty acids derived from fish oils than of those derived from plant-based sources 
such as flaxseed.  As ALA is seen as the ―parent‖ fatty acid to EPA, and EPA has known effects 
on the inflammatory process, it is sensible to evaluate the effects of supplementation with ALA 
on health and the inflammatory process.  It seems evident that ALA supplementation does have 
an effect on the inflammatory response and immune function but more information in regards to 
its role in ameliorating the hyper-inflammatory response in aging is warranted. 
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1.3.6 Nutritional Considerations 
 Habitual diet may have a profound effect on the immune system and inflammation, 
especially in the elderly (Fernandes 2008).  The experiments in this thesis attempted to control 
for nutrition by evaluating the typical self-reported dietary intake of subjects both before and 
after the interventions with a food frequency questionnaire.  The Dietary Reference Intakes are 
comprised of reference values for specific macronutrients and micronutrients established by the 
National Academy of Sciences in collaboration with Health Canada.  Specific dietary 
recommendations are made for individual nutrients, based on sex and age, in an attempt to 
optimize the health and reduce the risk of deficiency disease of almost all healthy individuals 
(Trumbo et al. 2002).  A specific lack of certain nutrients can have a profound effect on immune 
system function.  The elderly may be at increased risk of malnourishment from specific nutrient 
deficiencies but this seems to be more prevalent in older adults with a lower socio-economic 
status who are in poor health (Payette and Shatenstein 2005) while Canadian adults may not be 
eating the recommended servings of specific food groups (Starkey et al. 2001).  In this regard, a 
short description of some nutrients that have an important function in immune regulation will 
now be addressed. 
 Protein ingestion plays an essential role in the regulation of the immune system.  
Unavailability of essential amino acids will decrease protein synthesis of immunoglobulins, 
complement, and cytokines as well as affect the proliferation and development of immune cells.  
The current recommended daily allowance (RDA) for protein is 0.8 g protein·kg·d
-1
 with an 
Acceptable Macronutrient Distribution Range (AMDR) of between 10-35% of the total energy 
intake per day (Trumbo et al. 2002).  Seminal research on healthy adults given 0.1, 1.0, or 2.0 g 
protein·kg·d
-1
 demonstrated impaired antibody action in the group consuming the lowest amount 
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of protein (Hodges et al. 1962).  A recent review of the subject has concluded that protein energy 
malnutrition is a major factor in reducing immune function in elderly, undernourished 
individuals as they are already at risk of decreased immune function due to age alone (Lesourd 
2004).  In particular, protein energy malnutrition significantly increases the inflammatory 
processes in older adults caused by loss of homeostasis of macrophage function and decreased T-
cell function (Lesourd 2004). 
 The AMDR for fat intake in healthy adults is between 20-35% of total energy intake 
(Trumbo et al. 2002).  The consumption of adequate amounts of fat is also essential to proper 
immune system functioning.  In particular, the consumption of essential fatty acids (ω-6 and ω-3) 
has a strong relationship in modifying inflammatory processes.  The RDA established for ω-6 
fatty acids is 11 g·d
-1
 and 14 g·d
-1
 for women and men older than 50 years respectively and for 
ω-3 fatty acids is 1.1 g·d-1 and 1.6 g·d-1 for women and men over 50 years respectively (Trumbo 
et al. 2002).   In general, the consumption of high amounts of ω-6 fatty acids is associated with a 
pro-inflammatory environment while the consumption of high amounts of ω-3 fatty acids is 
associated with an anti-inflammatory environment (Simopoulos 1999; Simopoulos 2002b).  
Also, consumption of mono-unsaturated fats, such as oleic acid, is associated with less 
inflammation and improved health into old age (Perez-Jimenez et al. 2005).  High amounts of 
saturated fat consumption is associated with an increased amount of inflammation (Giugliano et 
al. 2006; Han et al. 2002; Lennie et al. 2005; Lopez-Garcia et al. 2005; Mozaffarian et al. 2004).   
Fats are essential to the immune system and inflammation as changing dietary fat intake will 
result in hormonal, metabolic, prostaglandin, and cell signaling changes, mostly mediated by the 
compositional change of cellular membranes with varying fat ingestion, that will either improve 
or wane immunological function.   
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 The AMDR for carbohydrate ingestion is between 40-65% of total energy intake with a 
minimum intake of 130 g·d
-1
 (Trumbo et al. 2002).  Low amounts of carbohydrate consumption 
may have an effect on the immune system by lowering blood glucose concentration which could 
stimulate a hypothalamic-pituitary-adrenal response causing an increased amount of 
adrenocorticotrophic hormone, cortisol, growth hormone, and a decrease in insulin.  Increased 
amounts of stress hormones are known to increase immune stress (Flint et al. 2007; Lundberg 
2005) but recent evidence suggests that a low carbohydrate diet may reduce inflammation 
(Forsythe et al. 2008) while high kilocalorie, nutrient poor carbohydrate consumption will 
increase inflammation (O'Keefe et al. 2008).  It is likely that food choice in relation to 
carbohydrate is vital in regulating immune system function.  Food choice in relation to 
carbohydrate consumption was not analyzed as part of this thesis but it is acknowledged that the 
type of carbohydrate consumed may have an effect on inflammatory markers. 
 Certain micronutrient deficiencies will affect immune system function and inflammation, 
especially in older adults who are immuno-compromised (High 1999; Lesourd 1997; Miquel 
2001; Wintergerst et al. 2007).  Vitamin A deficiency has a profound effect on infection by 
decreasing serum concentrations of IgG antibody (Bendich 1992; Bloem et al. 1990; Coutsoudis 
et al. 1992; Hussey and Klein 1990).  B-vitamin deficiency results in lymphoid atrophy and 
vitamin B6, folate, and pantothenate deficiency are associated with reduced immune function and 
decreased production of antibodies (Cramer et al. 1921; Rall and Meydani 1993).  Vitamin B6 is 
utilized in the development and function of T-cells which controls antibody production by B-
cells. Older adults deficient in vitamin B6 have decreased lymphocyte numbers and mitogen 
stimulated lymphocyte response (Ha et al. 1984; Meydani et al. 1991; Miller and Kerkvliet 
1990).  Sufficient intake of vitamin C stimulates proliferation of T-cells, prevents a suppression 
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of neutrophil activity, and directly protects phagocytes against auto-oxidation (Anderson 1982; 
Anderson and Lukey 1987; Evans et al. 1982; Frei et al. 1989; Frei et al. 1990; Herbaczynska-
Cedro et al. 1994).  Adequate vitamin D, or more specifically its active metabolite 1,25-dihyroxy 
vitamin D3, is associated with a down-regulation of inflammatory markers and may have an anti-
proliferative effect on immune cells; however, inadequate amounts of vitamin D are associated 
with increased incidence of auto-immune diseases (Chen et al. 2007; Lips 2006; Staud 2005).  
Vitamin E deficiency is quite rare but would have a great effect on immune function by 
decreasing T-cell function; conversely, vitamin E supplementation may have a beneficial effect 
on immune function in older adults (Meydani and Beharka 2001; Serafini 2000). 
 The major elements that may have the most extreme effect on immune function include 
zinc and iron (Chandra 1997).  Iron overload is associated with several chronic inflammatory 
diseases and coronary heart disease risk increases with high iron intake most likely due to 
increased production of reactive oxygen species (Ascherio et al. 1994; Cardier et al. 1997; 
Shephard and Shek 1995b; van Asbeck et al. 1984).  Alternatively, iron deficiency is known to 
suppress lymphocyte proliferative response to mitogen stimulation, decrease the release of IL-1 
from macrophages, decrease NK-cell cytotoxic activity, and impair phagocytic activity of 
neutrophils (Chandra 1991; Cunningham-Rundles 1982; Helyar and Sherman 1987; Scrimshaw 
and SanGiovanni 1997; Sherman 1992).  Thus, iron overload or deficiency harms the immune 
system.  Zinc deficiency affects immune function by reducing thymulin effectiveness thus 
resulting in lymphoid atrophy, decreasing the production of the anti-inflammatory cytokine IL-2, 
impairing the proliferative response of lymphocytes to mitogen stimulation, as well as reducing 
NK-cell cytotoxic activity (Chandra 1997; Cunningham-Rundles 1982; Prasad 1993; Sherman 
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1992).  High doses of zinc supplementation may be detrimental to immune function by impairing 
T-cell and polymorphonuclear cell activity (Chandra 1984). 
 In summary, diet does influence immune function as deficiencies in macronutrients and 
micronutrients result in deleterious changes to immunity, especially in older adults, while 
supplementation may aid immune system operation.  The studies presented in this thesis 
attempted to control for the nutritional influence on inflammation by having subjects record their 
typical dietary intake with food frequency questionnaires both before and after the intervention 
time period.  This was done to control for possible changes in the subjects‘ typical diets that may 
influence immunological parameters, thus, influencing cytokine production (the primary 
dependent variables in both studies). 
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1.4 Statement of the Problem 
Dysregulation of inflammation is considered a contributor to the metabolic syndrome and 
atherosclerotic process leading to cardiovascular disease in aging individuals (Wassink et al. 
2007).  Supplementation with the flaxseed lignan SDG ameliorates the atherosclerotic process 
and decreases the amount of oxidative stress in in vitro and in in vivo animal models (Prasad 
1997b; Prasad 1999; Prasad 2000a; Prasad 2000c; Prasad 2001; Prasad 2005b).  One human 
study has indicated no beneficial effect in reducing oxidative stress in post-menopausal women 
supplemented with a flax lignan complex containing SDG over a 6 week period of time (Hallund 
et al. 2006a) while another in type II diabetics resulted in improved glycemic control but no 
other health benefit (Pan et al. 2007).  Recent evidence from hypercholesterolaemic subjects 
indicates SDG supplementation for 8 weeks effectively lowered TC, LDL and fasting glucose 
versus placebo (Zhang et al. 2007).  No study has evaluated the effect of SDG supplementation 
during cardiovascular exercise training on inflammation or blood lipid profiles in healthy older 
males and females.  One study has evaluated flaxseed lignan complex supplementation in post-
menopausal women (Hallund et al. 2006a) and another in type II diabetics with neither study 
indicating any differences between the placebo and lignan groups in relation to blood lipid 
profiles (Pan et al. 2007).  Also, a recent study in hypercholesterolaemic subjects demonstrated 
efficacy with higher dose flaxseed lignan supplementation in reducing total cholesterol and 
glucose (Zhang et al. 2007). 
Supplementation with ALA decreased pro-inflammatory cytokines and eicosanoids in 
some studies (Babu et al. 2003; Bemelmans et al. 2004; Caughey et al. 1996; James et al. 2000; 
Rallidis et al. 2003; Wallace et al. 2003).  Theoretically, this could reduce the amount of skeletal 
muscle wasting associated with aging by reducing the pro-inflammatory cytokine TNF-α which 
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may act as a signaling mechanism for skeletal muscle apoptosis (Leeuwenburgh 2003; Phillips 
and Leeuwenburgh 2005; Roubenoff 2003; Schaap et al. 2006).  No research has evaluated the 
effect of supplementation with ALA during a strength training exercise program on 
inflammatory cytokines in older adults. 
The purpose of this thesis was to evaluate the effects of supplementation with 
components of flaxseed on inflammatory cytokine concentrations of older healthy adults 
completing exercise training programs prescribed for the secondary conditions of interest 
(metabolic syndrome and sarcopenia).  The research was designed to determine whether 
supplementation with either secoisolariciresinol diglucoside or α-linolenic acid from flaxseed 
and added to standard exercise prescriptions effectively lowers the concentrations of IL-6 and 
TNF-α in the blood of older humans.  As individuals age concentrations of pro-inflammatory 
cytokines increase.  There are no previous studies evaluating the effects of the above components 
of flaxseed during exercise on the blood concentration of IL-6 and TNF-α.  This thesis includes 
two studies to elucidate the effects of SDG and ALA supplementation on the inflammatory 
response in healthy older humans.  One study was an intervention with SDG supplementation 
during cardiovascular exercise training while the other was an intervention with ALA 
supplementation during strength exercise training. 
 
1.5 Experiment I Hypotheses 
The primary hypothesis of Experiment I was: 
1. TNF-α and IL-6 concentrations will be reduced in elderly female and male SDG 
supplemented groups compared to  elderly female and male placebo groups completing a 
6 month cardiovascular exercise training program. 
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The secondary hypotheses of Experiment I were: 
1. A composite score of metabolic syndrome will be reduced in elderly female and male 
SDG supplemented groups compared to elderly female and male placebo groups 
completing a 6 month cardiovascular exercise training program. 
2. Triglyceride, total cholesterol, low-density lipoprotein cholesterol, and total cholesterol: 
high-density lipoprotein cholesterol ratio will be reduced in elderly female and male SDG 
supplemented groups compared to elderly female and male placebo groups completing a 
6 month cardiovascular exercise training program. 
3. There will be a significantly greater decrease in TNF-α, IL-6, triglyceride, total 
cholesterol, and low-density lipoprotein cholesterol concentrations as well as total 
cholesterol: high-density lipoprotein cholesterol ratio concentrations in the elderly male 
SDG supplemented group compared to the elderly female SDG supplemented group. 
 
1.6 Experiment II Hypotheses 
The primary hypothesis of Experiment II was: 
1. TNF-α and IL-6 concentrations will be reduced in elderly female and male ALA 
supplemented groups compared to elderly female and male placebo groups completing a 
12 week resistance training exercise program. 
The secondary hypotheses of Experiment II were: 
1. One-repetition maximum chest press and leg press strength will increase more in elderly 
female and male ALA supplemented groups compared to the elderly female and male 
placebo groups completing a 12 week resistance training exercise program and, 
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2. Lean tissue mass and muscle thickness will increase more in elderly female and male 
ALA supplemented groups compared to the elderly female and male placebo groups 
completing a 12 week resistance training exercise program. 
3. There will be a significantly greater decrease in the TNF-α and IL-6 concentrations in the 
elderly male ALA group compared to the elderly female ALA group. 
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Chapter 2: Experiment I 
2.1 Introduction 
  Chronic low grade inflammation has been implicated as a component of the metabolic 
syndrome and the development of atherosclerosis which are associated with the aging process 
(Paoletti et al. 2006; Rana et al. 2007).  Metabolic syndrome is characterized by risk factors (i.e. 
elevations in each of central adiposity, serum triacylglycerol, serum glucose, blood pressure, and 
inflammation, and lowered high density lipoproteins) which in combination lead to increasing 
risk of developing insulin resistance, atherosclerosis and cardiovascular disease (Rana et al. 
2007).  Lifestyle interventions including dietary modification and aerobic exercise can reverse 
metabolic syndrome risk factors (Roberts et al. 2006). Interventions using components of 
flaxseed have demonstrated health benefits in relation to cardiovascular disease risk factors 
(Jenkins et al. 1999; Mozaffarian 2005; Psota et al. 2006).   
 The flaxseed lignan secoisolariciresinol diglucoside (SDG) is a phytoestrogen which 
exerts weak estrogenic or antiestrogenic effects in mammalian tissue, depending on the estrogen 
receptor (Dixon 2004).  Evidence from in vitro and animal studies indicate that SDG has lipid 
lowering and anti-inflammatory potential (Hosseinian et al. 2007; Prasad 1999; Prasad 2000a; 
Prasad 2005b).  Currently, there is a paucity of information surrounding the potential of the 
lignan component of flaxseed to act in a similar manner in humans.  One study in healthy 
postmenopausal women found no effect of supplementation with a flaxseed lignan complex on 
lipid profiles, antioxidant capacity, and endothelial function (Hallund et al. 2006a; Hallund et al. 
2006b).  SDG supplementation had no effect on blood lipids, glucose, or insulin although it did 
improve glycemic control as measured by HbA1c in type II diabetic patients (Pan et al. 2007).  
Also, 8 weeks of SDG supplementation in hypercholesterolaemic subjects lowered total 
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cholesterol, LDL cholesterol and glucose concentrations (Zhang et al. 2007).  There has been no 
assessment of supplementation with SDG on the prevention of alteration to lipid profiles that 
would pose a health risk in healthy older men or inflammatory cytokines or leukocytes in healthy 
older adults.  The primary purpose of this study was to assess the efficacy of supplementation 
with flaxseed lignan complex on the inflammatory cytokines interleukin-6 and tumor necrosis 
factor-α as well as leukocyte cell number in healthy older men and women completing an 
exercise program designed to improve blood lipid profile.  A secondary purpose was to evaluate 
the effects of flaxseed lignan complex on a composite score of metabolic syndrome which 
included measures of inflammatory cytokines.  The hypothesis was that older adults completing 
a standardized cardiovascular exercise program and supplementing with the flaxseed lignan 
polymer would decrease serum concentration of IL-6 and TNF-α as well as reduce risk factors 
associated with the development of metabolic syndrome more so when compared to those taking 
a placebo. 
 
2.2 Subjects and Methods 
2.2.1 Subjects 
One hundred men and postmenopausal women were recruited from the general 
population by newspaper advertisement from a single centre (all subjects were residents of 
Saskatoon, Saskatchewan, Canada and vicinity and were recruited through the University of 
Saskatchewan).  For study inclusion, subjects were required to be at least 50 years of age.  This 
age was chosen as epidemiological evidence indicates that those over 50 years of age are at 
increased risk of developing cardiovascular disease due to abnormal blood lipid profiles (Reeder 
et al. 1997).  Subjects were excluded from the study if they 1) were taking pharmaceutical agents 
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that lower cholesterol levels; 2) had type I or II diabetes; 3) were smokers; 4) were diagnosed 
with inflammatory bowel disease; 5) were taking hormone replacement therapy; 6) ingested 
flaxseed supplements (flaxseed, flax oil, flax lignan, or flax fibre) within the previous 2 months; 
or 7) were involved in vigorous exercise training (≥3 times·wk-1). A sample size of n = 39 per 
treatment group was calculated by using previous research (Huang et al. 2005) demonstrating a 
decrease in serum TNF-α from 36.3±14.0 pg·mL-1 to 27.2±10.3 pg·mL-1 with phytoestrogen (soy 
isoflavone) supplementation in post-menopausal women at 80% power and an alpha level of 
0.05. (Statistica version 7, StatSoft Inc., Tulsa, Oklahoma).  A baseline TNF-α concentration of 
36.3±14.0 pg·mL
-1
 was entered as the population mean and standard deviation.  The post-
intervention TNF-α concentration of 27.2 pg·mL-1 was entered as the expected mean in the 
intervention group after supplementation.  Sample size recruitment was increased to n = 50 per 
group due to an expected drop-out rate of 25%.  Ethical approval for the study was received from 
the Biomedical Research Ethics Board at the University of Saskatchewan and a certificate of 
approval (Bio# 04-169) was issued (see appendix A).  Also, all subjects were informed of the 
intent of the study and signed a consent form before beginning participation in the study (see 
appendix B). 
 
2.2.2 Study Design 
 This study was double-blind, randomized, and placebo-controlled, with subjects 
randomized to supplement with a flax lignan complex (lignan group) or a placebo (placebo 
group) for 6 months.  The trial was conducted as intent-to-treat and missing data points from 
individual cases for blood work were accounted for by carrying over the last data point if the 
subject had at least the baseline and 2 month data point assessed. Subjects were recruited in a 
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staggered fashion in four blocks.  The first block of subjects was recruited in March 2005 and 
had follow up testing in October 2005.  The second block of subjects was recruited in April 2005 
and had follow up testing in November 2005.  The third block of subjects was recruited in June 
2005 and had follow up testing in January 2006.  The final block of subjects was recruited in 
August 2005 and had follow up testing in March 2006. The randomized allocation sequence, 
with subjects stratified by sex (male/female), was computer generated by a research assistant 
who had no other involvement in the study.  A random number generator (Microsoft Excel) was 
used to randomize individuals to either the flaxseed lignan or the placebo treatment group. This 
was done in blocks of 2, so if one subject was randomized to flaxseed lignan complex, the next 
person was randomized to placebo and vice-versa.  Subjects were enrolled into the study by the 
principal investigator and assigned to groups by a research assistant who had no other 
involvement with the study.   Subjects were considered part of the study once they had been 
interviewed and initially assessed on all dependent variables at baseline.  Participants, those 
administering the intervention, and those evaluating the outcomes were blinded to group 
assignment. 
 
2.2.3 Exercise Protocol 
All subjects completed the same exercise protocol which involved cardiovascular training 
(walking) between 30-60 min·d
-1
, 6 d·wk
-1
 (Monday-Saturday) during the 6 month supplement 
intervention.  The program initially prescribed 30 min·d
-1
 and progressed by 4 minutes per week 
until 60 minutes of walking was done per day (see appendix C).  This volume of exercise is 
appropriate for raising high density lipoprotein cholesterol (HDL) levels and lowering 
triacylglycerol (TAG) levels (Durstine et al. 2002).  The exercise program was semi-supervised; 
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that is, subjects had the option of attending a daily supervised walking session with a Certified 
Exercise Physiologist (Canadian Society for Exercise Physiology) or completing the walking 
program on their own.  Subjects were instructed to complete the walking program at an intensity 
corresponding to 50-65% of their predicted maximal heart rate (220-age).  Subjects were 
instructed on how to find a radial or carotid pulse and how to correctly count the number of beats 
in a 15 second span of time.  Subjects were then instructed to multiply their 15 second count by a 
factor of 4 to calculate heart rate beats per minute.  They were also instructed to take a pulse 
count approximately 10 minutes into their exercise session and towards the end of their exercise 
session.  If intensity was found to be too low or too high, participants were instructed to modify 
their walking speed accordingly.  If subjects desired to exercise at a higher intensity they were 
allowed to do so as long as they were able to complete the same duration of exercise.  All 
subjects were given data sheets to record the total exercise time with each walking session for 
compliance monitoring.  The data sheets were collected from the participants at the end of the 6 
month intervention to monitor study compliance (see appendix C).   
 
2.2.4 Supplementation 
 The subjects consumed the supplement orally in tablet form. Three tablets were 
consumed each day (one tablet at each meal) during the 6 month intervention.  Each tablet 
weighed 1350 mg.  The tablet containing the active flaxseed lignan complex provided 550 mg 
flax extract composed of 32.9% SDG, 13.9% cinnamic acids, 11.8% protein, 10.0% 3-hydroxy-
3-methyl glutaric acid, 3.5% fat, 3.3% moisture, and 1.0% ash (Archer Daniels Midland Co., 
Decatur, IL).  In place of the flaxseed lignan complex the placebo tablet contained 550 mg of 
90% maltodextrin and 10% caramel color.  The subjects randomized to the flaxseed lignan 
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complex group consumed ~ 543 mg·d
-1
 of SDG.  As no human studies had been performed 
before this study, the dose of flaxseed lignan complex was speculative in nature but based on a 
personal communication with a flaxseed expert (Neil Wescott, personal communication) 
involved in the isolation of the lignan complex from flaxseed.  Recent evidence from a human 
study has found a dose of 600 mg·d
-1
 of SDG to effectively lower total cholesterol, LDL 
cholesterol, and glucose concentrations in hypercholesterolaemic subjects (Zhang et al. 2007).  
Compliance was monitored by asking subjects to return any unused supplements to the primary 
researcher at the end of the study. 
 
2.2.5 Measurements 
Blood assays 
Overnight 12 hour fasting blood samples were obtained at four time-points throughout 
the study (baseline, 2 mo, 4 mo, and 6 mo).  All blood samples were obtained by a certified 
phlebotomist at the Royal University Hospital, University of Saskatchewan test laboratory.  A 
blood sample (~10 mL) was drawn into Vacutainer serum separator tubes for the analysis of 
glucose, total cholesterol (TC), high density lipoprotein cholesterol (HDL), low density 
lipoprotein cholesterol (LDL), triacylglycerol (TAG), interleukin-6 (IL-6), and tumor necrosis 
factor-α (TNF-α).  A second blood sample (~10 mL) was drawn into Vacutainer tubes containing 
ethylendiaminetetraacetic acid (EDTA) for the analysis of hematopoietic parameters (leukocyte 
counts, lymphocytes, granulocytes, and monocytes).  Both blood samples were centrifuged at 
3200 rpm for 10 minutes at 20°C.  A LX20 Beckman Coulter analyzer (Beckman Coulter 
Canada Inc., Mississauga, ON) was used to analyze glucose, TC, HDL, and TAG by enzymatic 
kits.  LDL concentrations were calculated using the Friedwald formula.  A small test tube of 
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serum was also aliquoted and immediately stored at -80 °C until analyzed for cytokines.  
Commercially available enzyme linked immunosorbent assay (ELISA) kits were used to analyze 
the IL-6 and TNF-α concentrations in the serum of the stored samples (Cayman Chemical 
Company, Ann Arbor, Michigan).  Each assay is based on a double-antibody ‗sandwich‘ 
technique with intra and interassay coefficients of variance ≤ 10% as reported by the 
manufacturer.  The detection limit of each kit is 1.5 pg·mL
-1
.  Hematopoietic measurements were 
analyzed using an automated cell counter (Cell Dyne, Abbott Laboratories, Abbott Park, 
Illinois).   
Anthropometrics and body composition 
Height and weight were measured by a standard stadiometer and a scale at baseline and 6 
months and recorded to the nearest 0.1 centimeter and 0.1 kilogram respectively.  Body mass 
index (BMI) was obtained by dividing subject‘s total body mass (kg) to the square of height in 
meters. 
Body composition was assessed at baseline and after 6 months with dual energy X-ray 
absorptiometry (DEXA) with QDR software for Windows XP (QDR Discovery, Hologic, Inc., 
Bedford, Maryland) by a certified radiation technologist.  Abdominal fat was determined from 
DEXA by following the protocol utilized by Svendsen et al. (Svendsen et al. 1993).  Briefly, a 
region of interest was generated with the QDR software for Windows XP between the 1
st
 and 4
th
 
intervertebral lumbar disks and the inter-costal margins of the whole body scan.  The region of 
interest was then analyzed by the QDR software to assess abdominal fat mass.  The coefficient of 
variation for DEXA derived abdominal fat mass was assessed by having the same research 
assistant create a region of interest on a total of n = 30 DEXA scans in older men and women at 
two different time points (one day apart).  For each DEXA scan a coefficient of variation was 
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determined from the two time-points using the following formula: Coefficient of Variation = 
(Standard Error of the Mean/Absolute Mean Value) × 100.  The coefficient of variation of this 
technique was 4.7%.  Blood measures were assessed every two months throughout the study 
because they were expected to change quickly; whereas body composition was assessed only at 
baseline and 6 months.  This part of the thesis was part of a larger study that also measured bone 
mineral and the DEXA measure was only done at 6 months as bone would not be expected to 
change before this. 
Dietary assessment 
For dietary assessment a food frequency questionnaire (FFQ) was completed by the 
subjects at baseline and after the 6 month study intervention.  This FFQ is a 110 item survey 
designed to estimate the customary dietary intake for a wide variety of food items and nutrients 
in adults (Block Dietary Data Systems - Block 98.2, Berkeley, California).  The FFQ was 
modified by the addition of foods unique to Canada.  Portion size pictures were provided to 
subjects to aid in estimation of foods consumed.  As a control, all subjects were informed at the 
beginning of the study to avoid ingesting any supplement or food product containing flaxseed or 
supplements that contain flaxseed (i.e. combination ω-3 fatty acid supplements) while they were 
enrolled in the study. 
Blood pressure 
After 5 minutes of sitting, resting blood pressure was measured at baseline and 6 months 
with a standard sphygmomanometer by a trained exercise specialist (Certified Exercise 
Physiologist – Canadian Society for Exercise Physiology) at the same time of day on each 
occasion. 
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Total exercise time 
Subjects were instructed to record the amount of time, in minutes, they completed in 
terms of the walking program on forms given to them at the initiation of the intervention.  All the 
time was summed to determine total walking time, in minutes, for the entire 6 months.  This data 
was converted to an estimate of energy expenditure per week by following the guidelines set 
forth by Ainsworth et al. (Ainsworth et al. 1993).  This was done in an attempt to control for any 
differences in estimated energy expenditure between the treatment groups over the 6 month 
intervention.  Total walking time in minutes was divided by 26 weeks and then by 60 min·hr
-1
 to 
determine an average total walking time in hr·wk
-1
.  It was assumed that most subjects in the 
study would walk at approximately 5.6 km·hr
-1
 which corresponds to a estimated energy 
expenditure of 3.3 kcal·kg
-1
·hr
-1
 (Ainsworth et al. 1993).  The estimate of energy expenditure 
was determined by the following formula: 3.3 kcal·kg
-1
·hr
-1
 × average hours of walking·wk
-1
 × 
subject body mass (kg) at baseline. 
 
2.2.6 Metabolic Syndrome Risk Factors 
The secondary dependent variable for the study was a composite score of metabolic 
syndrome.  The metabolic syndrome composite score was calculated by determining the sex-
specific Z-scores of each of the following variables: glucose, HDL, TAG, blood pressure (i.e. 
mean of Z-scores for systolic and diastolic blood pressure), abdominal fat mass (as assessed by 
dual energy x-ray absorptiometry), and inflammatory markers (mean of Z-scores for the 
cytokines IL-6 and TNF-α).  Once the Z-score for each variable was calculated, the mean of the 
inverse of the Z-score for HDL and the five other Z-scores was determined and termed the 
metabolic syndrome composite score for each individual.  The inverse of the Z-score for HDL 
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was used because higher levels of HDL cholesterol are considered beneficial for cardiovascular 
health.  Each subject‘s individual Z-score was calculated by subtracting the mean of the entire 
group‘s variable of interest at baseline from the individual subject‘s value and dividing this value 
by the standard deviation of the entire group‘s variable of interest at baseline.  The baseline 
values were used as representative of values from a normal healthy older adult sample. Once a Z-
score was calculated for each variable of interest (i.e. inflammatory markers, abdominal fat mass, 
glucose, HDL, TAG, and blood pressure), a composite score was calculated for each individual 
subject by summing the six Z-score variables and dividing by six to achieve an average Z-score 
for each individual subject.  This average Z-score was termed the metabolic syndrome composite 
score and was then utilized in statistical analyses of metabolic syndrome.  Previous research has 
used a similar composite score of metabolic syndrome in accordance with Adult Treatment Panel 
III and World Health Organization guidelines (Brage et al. 2004; Eisenmann et al. 2004; Franks 
et al. 2004).   
 
2.2.7 Statistical Analyses 
Covariates 
 Baseline characteristics of the subjects were assessed by a 1 factor (group) ANOVA.  It 
was decided a priori that if group statistical differences existed at baseline that the variable or 
variables showing significant differences would be entered as covariates in the statistical 
analysis.  Also, the dietary data (baseline and 6 months) was analyzed by a 2 (group) × 2 (sex) × 
2 (time) ANOVA with repeated measures on the last factor to determine if differences existed in 
self-reported dietary intake at the beginning and end of the study.  If there were significant 
changes between groups in dietary intake over the 6 month intervention, the nutrient indicating 
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significant differences was entered as a covariate.  Further, a 1 factor (group) ANOVA was used 
to evaluate differences in estimated energy expenditure (from self-reported data) between 
groups; if a significant difference between groups was found, this variable was entered as a 
covariate in the analysis. 
Main analyses 
If there was a significant difference between baseline characteristics, nutrients, or 
estimated energy expenditure, these variables were entered as covariates in a 2 (group) × 2 (sex) 
× 4 (time) ANCOVA with repeated measures on the last factor analyzing the cytokines, 
leukocytes, glucose, HDL, LDL, TC, and TAG.  Also, a 2 (group) × 2 (sex) × 2 (time) 
ANCOVA with repeated measures on the last factor was used to analyze the metabolic syndrome 
composite score.  If no covariates were found, the data was analyzed using a 2 (group) × 2 (sex) 
× 4 (time) ANOVA with repeated measures on the last factor for the cytokines, leukocytes, 
glucose, HDL, LDL, TC, and TAG; while a 2 (group) × 2 (sex) × 2 (time) ANOVA with 
repeated measures on the last factor was used to analyze the metabolic syndrome composite 
score.  When a significant interaction was indicated Tukey‘s post-hoc test was used to detect 
differences between means.  If a significant interaction was not found, main effects were 
assessed for significance.  All results are expressed as means ± standard error of the mean (SE).  
The alpha level was set at p ≤ 0.05.  All statistical analyses were completed using Statistica 
version 7 (StatSoft Inc., Tulsa, Oklahoma).  The data was analyzed with an ANOVA as opposed 
to a MANOVA as the hypothesis of Experiment I has not been evaluated in the population 
tested.   
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2.3 Results 
 Nineteen of the original one hundred subjects enrolled in the study dropped out.  This 
included nine subjects in the female placebo group, four subjects in the female lignan group, five 
subjects in the male placebo group, and one subject in the male lignan group.  Reasons for 
dropping out included lack of time (n = 9), exacerbation of osteoarthritis (n = 2), study 
dissatisfaction (n = 1), commencement of lipid-lowering medication (n = 1), leg amputation (n = 
1), and loss to follow-up (n = 5). Eleven of the 19 had measurements of blood parameters at 
baseline and one or more other time points and these were carried over and included in the final 
analysis.  Thus, total subject number analyzed for the blood parameters was 92 and baseline 
characteristics of these subjects are presented in Table 2.1.  Of the 92 subjects recruited, six 
females and eight males were defined as having metabolic syndrome while forty-seven females 
and thirty-one males were not defined as having metabolic syndrome according to Adult 
Treatment Panel III guidelines (Lorenzo et al. 2007).  Separate sub-analyses of this group 
indicated no substantial alteration to the results reported below (data not shown).  The changes in 
the group defined as having metabolic syndrome were similar to the rest of the group.  It is 
probable that this sub-analysis lacked statistical power due to the low number of subjects defined 
as having metabolic syndrome; therefore, finding significant changes was unlikely. 
There were no differences between groups for age, mass, height, BMI or blood pressure 
at baseline (p > 0.05; see Table 2.1).  There were no differences between groups for baseline 
dietary habits (p > 0.05; see Table 2.2).  No differences were found between groups for 
macronutrient intake throughout the study (p > 0.05; see Table 2.2) but, there were significant 
differences between sexes for total kilocalories, protein, and fat with men consuming more when 
compared to women.  There were no differences between groups for the estimated energy 
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expenditure from the walking program (placebo: 809±96 kcal·wk
-1
 versus SDG: 1033±92 
kcal·wk
-1
; p > 0.05). 
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Table 2.1  Baseline characteristics of subjects randomized to supplement orally with either 
flaxseed lignan complex (4050 mg·d
-1
) or placebo (4050 mg·d
-1
) before 6 months of 
cardiovascular exercise training (n=92). 
 Placebo 
(n = 44) 
Lignan Complex 
(n = 48) 
Age (y) 62.9±1.0 60.7±1.0 
Body Mass (kg) 82.8±2.4 78.7±2.3 
Height (cm) 168.2±1.3 168.1±1.3 
BMI (kg/m
2
) 29.3±0.7 27.7±0.7 
SBP (mmHg) 127±2 128±2 
DBP (mmHg) 80±1 83±1 
 
Mean ± SE.  BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. 
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Table 2.2  Dietary intake of subjects randomized to supplement orally with either flaxseed 
lignan complex (4050 mg·d
-1
) or placebo (4050 mg·d
-1
) during 6 months of 
cardiovascular exercise training (n=75). 
 
 Placebo Lignan Complex 
 
 Female (n=20) 
 
Male (n=15) Female (n=21) Male (n=19) 
Energy (kcal·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
1738±150 
 
1646±134 
 
 
*1777±173 
 
1677±155 
 
 
1828±146 
 
1609±130 
 
 
*2176±154 
 
2074±138 
Protein (g·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
73±6 
 
68±6 
 
 
*75±7 
 
67±6 
 
 
70±6 
 
63±5 
 
 
*86±7 
 
80±6 
Carbohydrate (g·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
202±18 
 
197±16 
 
 
*186±21 
 
185±18 
 
 
227±17 
 
210±16 
 
 
*241±19 
 
233±16 
Fat (g·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
72±8 
 
68±7 
 
 
*80±9 
 
72±8 
 
 
75±7 
 
61±7 
 
 
*97±8 
 
92±7 
Saturated Fat (g·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
20±2 
 
19±2 
 
 
21±2 
 
18±2 
 
 
24±3 
 
20±2 
 
 
28±3 
 
27±3 
MUFA (g·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
27±2 
 
26±3 
 
 
29±3 
 
23±2 
 
 
33±3 
 
28±3 
 
 
39±3 
 
37±3 
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ω-6 Fatty Acid (g·d-1) 
 
     Baseline 
 
     6 month 
 
 
 
18±2 
 
17±2 
 
 
19±2 
 
15±2 
 
 
21±2 
 
18±2 
 
 
21±2 
 
21±2 
ω-3 Fatty Acid (g·d-1) 
 
     Baseline 
 
     6 month 
 
 
 
1.9±0.2 
 
1.6±0.2 
 
 
2.0±0.3 
 
1.8±0.2 
 
 
2.0±0.2 
 
1.7±0.2 
 
 
1.9±0.2 
 
1.8±0.2 
Vitamin A (I.U.) 
 
     Baseline 
 
     6 month 
 
 
 
16580±1999 
 
15128±1639 
 
 
14294±1855 
 
14091±1665 
 
 
9918±1555 
 
11014±1635 
 
 
12385±1497 
 
12893±1528 
Vitamin B6 (mg·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
1.96±0.12 
 
1.92±0.19 
 
 
1.80±0.13 
 
1.87±0.13 
 
 
1.89±0.20 
 
1.74±0.21 
 
 
2.20±0.17 
 
2.02±0.14 
Folate (mg·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
389±28 
 
361±29 
 
 
364±32 
 
363±29 
 
 
340±41 
 
328±38 
 
 
418±37 
 
431±35 
Vitamin C (mg·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
127±11 
 
110±11 
 
 
126±10 
 
128±9 
 
 
92±14 
 
89±16 
 
 
126±10 
 
127±13 
Vitamin D (I.U.) 
 
     Baseline 
 
     6 month 
 
 
 
194±27 
 
194±31 
 
 
145±20 
 
165±25 
 
 
218±42 
 
167±32 
 
 
191±30 
 
168±22 
Vitamin E (mg·d
-1
) 
 
     Baseline 
 
 
11±1 
 
 
11±1 
 
 
10±1 
 
 
12±1 
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     6 month 
 
 
10±1 
 
 
9±1 
 
9±1 
 
12±7 
Zinc (mg·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
13±1 
 
12±1 
 
 
11±1 
 
11±1 
 
 
12±1 
 
11±1 
 
 
14±1 
 
14±1 
Iron (mg·d
-1
) 
 
     Baseline 
 
     6 month 
 
 
 
14±1 
 
13±1 
 
 
 
13±1 
 
12±1 
 
 
14±2 
 
12±1 
 
 
16±1 
 
16±1 
 
Mean±SE.  * Indicates significant sex main effect from 2 factor analysis of variance (p < 0.05) at 
baseline (males > females). 
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2.3.1 Cytokines and Leukocytes 
No main effects or interactions for either IL-6 or TNF-α were observed (see Figures 2.1-
2.4).  No interactions were noted for any of the leukocyte sub-sets analyzed (p > 0.05).  There 
was a main effect of time for basophils (p < 0.05) with basophil numbers higher at the 2 month, 4 
month, and 6 month time-point when compared to baseline counts (see Tables 2.3 and 2.4). 
 
2.3.2 Blood Lipids and Glucose 
The blood lipid and glucose data are presented in Tables 2.5 and 2.6 for men and women, 
respectively.  No differences between groups were observed at baseline except the lignan group 
had a higher concentration of HDL than the placebo group (p = 0.031).  Males had higher 
glucose concentrations than females (p = 0.002) and females had higher concentrations of HDL 
than males at baseline (p = 0.001).  There was a significant group × sex × time interaction for 
TAG (p = 0.017).  Post-hoc analyses indicated no differences between any pair of individual 
means. The interaction was due to a trend for the males on placebo to increase TAG over time 
relative to males on flaxseed lignan complex (see Table 2.5). Time main effects were found for 
high-density lipoprotein cholesterol (p < 0.0001) which decreased over the intervention and the 
ratio of total cholesterol to high-density lipoprotein cholesterol (p < 0.0001) which increased 
over the intervention.  There were main effects for group on HDL (p = 0.049) and total 
cholesterol to HDL ratio (p = 0.032) with the lignan group having a higher HDL and lower total 
cholesterol to HDL ratio than the placebo group.  No main effects or interactions for total 
cholesterol or LDL were found. 
 
 
80 
 
2.3.3 Metabolic Syndrome Composite Score 
 No baseline differences between the flaxseed lignan polymer and placebo groups for 
metabolic composite score were found. Changes for the metabolic composite Z-score from 
baseline to 6 months are presented in Figures 2.5 and 2.6 for males and females, respectively.  A 
significant group × sex × time interaction (p = 0.037) was found.  Post-hoc analysis indicated 
that only the men on placebo increased their metabolic composite score (Figure 2.5).  
 
2.3.4 Abdominal Fat and Blood Pressure 
 The analysis of abdominal fat indicated no differences between the flaxseed lignan 
complex (females: 17.4±1.7 to 17.8±1.8 kilograms; males: 26.0±1.8 to 25.2±1.9 kilograms) and 
placebo (females: 20.6±1.8 to 21.0±1.9 kilograms; males: 26.0±2.0 to 26.7±2.1 kilograms) 
groups.   No difference in systolic blood pressure was found between the flaxseed lignan 
complex (females: 128±3 to 128±3 mmHg; males: 130±3 to 130±3 mmHg) or placebo (females: 
123±3 to 122±3 mmHg; males: 129±3 to 127±4 mmHg) groups (p > 0.05).  There was a 
significant group × sex × time interaction for diastolic blood pressure (p < 0.05).  Post hoc 
analysis did not suggest any significant differences between the individual means (females 
flaxseed lignan complex: 81±2 to 82±2 mmHg; males flaxseed lignan complex: 85±2 to 81±2 
mmHg; females placebo: 77±2 to 76±2 mmHg; males placebo: 82±2 to 82±2 mmHg).  Again, 
the interaction was due to a trend for males on the flaxseed lignan complex to decrease diastolic 
blood pressure over the 6 months when compared to the female flaxseed lignan complex and 
male placebo groups. 
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Figure 2.1  Male serum interleukin-6 concentration for each group over 6 month cardiovascular 
exercise program with either placebo (PLA; n = 17; 4050 mg·d
-1
) or flaxseed lignan complex 
(SDG; n = 20; 4050 mg·d
-1
) oral supplementation.  Values are reported as means ± SE. 
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Figure 2.2  Male serum tumor necrosis factor-α concentration for each group over 6 month 
cardiovascular exercise program with either placebo (PLA; n = 17; 4050 mg·d
-1
) or flaxseed 
lignan complex (SDG; n = 20; 4050 mg·d
-1
) oral supplementation.  Values are reported as means 
± SE. 
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Figure 2.3  Female serum interleukin-6 concentration for each group over 6 month 
cardiovascular exercise program with either placebo (PLA; n = 23; 4050 mg·d
-1
) or flaxseed 
lignan complex (SDG; n = 25; 4050 mg·d
-1
) oral supplementation.  Values are reported as means 
± SE. 
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Figure 2.4  Female serum tumor necrosis factor-α concentration for each group over 6 month 
cardiovascular exercise program with either placebo (PLA; n = 23; 4050 mg·d
-1
) or flaxseed 
lignan complex (SDG; n = 25; 4050 mg·d
-1
) oral supplementation.  Values are reported as means 
± SE. 
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Figure 2.5  Male metabolic syndrome composite score for each group over 6 month 
cardiovascular exercise program with either placebo (PLA; n = 19; 4050 mg·d
-1
) or flaxseed 
lignan complex (SDG; n = 20; 4050 mg·d
-1
) oral supplementation.  Values are reported as means 
± SE.  *Significant difference between baseline and 6 month values for the male placebo group p 
< 0.05. 
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Figure 2.6  Female metabolic syndrome composite score for each group over 6 month 
cardiovascular exercise program with either placebo (PLA, n = 25; 4050 mg·d
-1
) or flaxseed 
lignan complex (SDG; n = 28; 4050 mg·d
-1
) oral supplementation.  Values are reported as means 
± SE. 
Baseline 6 months
-0.25
0.00
0.25
0.50
0.75
PLA
SDG
F
e
m
a
le
 m
e
ta
b
o
li
c
 s
y
n
d
ro
m
e
 s
c
o
re
87 
 
Table 2.3  Leukocyte cell counts (× 109) from male participants over 6 month cardiovascular 
exercise intervention supplementing orally with either placebo (n = 18; 4050 mg·d
-1
) or flaxseed 
lignan complex (n = 20; 4050 mg·d
-1
). 
Variable Baseline 2 month 4 month 6 month 
WBC     
     Placebo 5.44±0.33 5.36±0.27 5.40±0.31 5.24±0.30 
     Lignan 5.78±0.76 5.48±0.23 5.82±0.27 5.68±0.26 
Neutrophil     
     Placebo 3.17±0.22 3.14±0.15 3.08±0.20 3.02±0.21 
     Lignan 3.14±0.31 2.89±0.17 3.09±0.21 2.97±0.17 
Lymphocyte     
     Placebo 1.60±0.09 1.61±0.11 1.60±0.10 1.57±0.10 
     Lignan 2.00±0.11 2.00±0.09 2.05±0.11 2.07±0.11 
Monocyte     
     Placebo 0.44±0.03 0.44±0.02 0.44±0.02 0.43±0.03 
     Lignan 0.45±0.03 0.44±0.03 0.48±0.03 0.46±0.03 
Eosinophil     
     Placebo 0.22±0.06 0.22±0.05 0.26±0.08 0.19±0.05 
     Lignan 0.16±0.02 0.16±0.02 0.18±0.03 0.15±0.02 
Basophil*     
     Placebo 0.01±0.01 0.03±0.01 0.03±0.01 0.03±0.01 
     Lignan 0.02±0.01 0.02±0.01 0.03±0.01 0.02±0.01 
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Values are mean ± SE.  *Indicates significant time main effect (increasing over time, p < 0.05) 
from 3 factor analysis of variance.   
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Table 2.4  Leukocyte cell counts (× 109) from female participants over 6 month cardiovascular 
exercise intervention supplementing orally with either placebo (n = 22; 4050 mg·d
-1
) or flaxseed 
lignan complex (n = 27; 4050 mg·d
-1
).  
Variable Baseline 2 month 4 month 6 month 
WBC     
     Placebo 5.31±0.32 5.50±0.29 5.39±0.31 5.64±0.31 
     Lignan 5.87±0.25 5.51±0.20 5.70±0.20 5.58±0.24 
Neutrophil     
     Placebo 2.95±0.18 3.15±0.20 3.00±0.18 3.17±0.18 
     Lignan 3.32±0.21 3.08±0.15 3.26±0.16 3.11±0.19 
Lymphocyte     
     Placebo 1.73±0.13 1.73±0.13 1.77±0.14 1.78±0.13 
     Lignan 1.88±0.08 1.80±0.09 1.81±0.09 1.82±0.09 
Monocyte     
     Placebo 0.45±0.03 0.43±0.03 0.45±0.03 0.47±0.03 
     Lignan 0.49±0.03 0.47±0.02 0.47±0.02 0.47±0.02 
Eosinophil     
     Placebo 0.18±0.02 0.18±0.02 0.17±0.02 0.19±0.02 
     Lignan 0.15±0.01 0.15±0.01 0.15±0.01 0.15±0.01 
Basophil*     
     Placebo 0.01±0.01 0.01±0.01 0.03±0.01 0.03±0.01 
     Lignan 0.00±0.00 0.01±0.01 0.01±0.01 0.01±0.01 
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Values are mean ± SE.  *Indicates significant time main effect (increasing over time, p < 0.05) 
from 3 factor analysis of variance.
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Table 2.5  Blood glucose and lipid concentrations of male participants over 6 month 
cardiovascular exercise intervention supplementing orally with either placebo (4050 mg·d
-1
) or 
flaxseed lignan complex (4050 mg·d
-1
).  
 
Variable Baseline 2 months 4 months 6 months 
 
Glucose (mmol·L
-1
) 
 
    
     Placebo (n=19) 
 
5.69±0.11 5.59±0.18 5.55±0.12 5.51±0.12 
     Lignan (n=20) 
 
5.55±0.19 5.55±0.19 5.54±0.11 5.63±0.21 
TC (mmol·L
-1
) 
 
    
     Placebo (n=19) 
 
5.68±0.31 5.72±0.39 5.76±0.39 5.67±0.40 
     Lignan (n=20) 
 
5.66±0.23 5.43±0.26 5.40±0.21 5.52±0.26 
TAG (mmol·L
-1
) 
 
    
     Placebo (n=19) 
  
1.58±0.25 1.77±0.37 1.83±0.38 1.74±0.38 
     Lignan (n=20) 
 
1.48±0.17 1.28±0.17 1.34±0.13 1.35±0.17 
HDL (mmol·L
-1
) 
 
    
     Placebo (n=19) 
 
1.26±0.05 1.27±0.04 1.16±0.04 1.15±0.04 
     Lignan (n=20)* 
 
1.43±0.09 1.37±0.08 1.24±0.07 1.28±0.07 
LDL (mmol·L
-1
) 
 
    
     Placebo (n=18) 
 
3.59±0.17 3.47±0.19 3.61±0.18 3.57±0.18 
     Lignan (n=20) 
 
3.56±0.20 3.47±0.22 3.55±0.19 3.63±0.20 
TC:HDL 
 
    
     Placebo (n=19) 
 
4.59±0.26 4.45±0.34 5.05±0.33 4.98±0.32 
     Lignan (n=20)* 
 
4.25±0.27 4.15±0.27 4.55±0.25 4.52±0.25 
92 
 
Values are mean ± SE.  TC, total cholesterol; TAG, triacylglycerol; HDL, high-density 
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.  *Indicates significant group 
main effect (p < 0.05) from 3 factor analysis of variance.   
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Table 2.6  Blood glucose and lipid concentrations for female participants over 6 month 
cardiovascular exercise intervention supplementing orally with either placebo (4050 mg·d
-1
) or 
flaxseed lignan complex (4050 mg·d
-1
).  
Variable Baseline 2 months 4 months 6 months 
 
Glucose (mmol·L
-1
) 
 
    
     Placebo (n=25) 
 
5.19±0.08 5.22±0.08 5.18±0.08 5.25±0.08 
     Lignan (n=27) 
 
5.17±0.11 5.21±0.09 5.20±0.08 5.27±0.10 
TC (mmol·L
-1
) 
 
    
     Placebo (n=25) 
 
6.14±0.21 6.27±0.28 6.09±0.24 6.20±0.24 
     Lignan (n=27) 
 
5.87±0.17 5.84±0.17 5.86±0.18 5.77±0.17 
TAG (mmol·L
-1
) 
 
    
     Placebo (n=25) 
 
1.77±0.22 1.93±0.30 1.75±0.21 1.71±0.22 
     Lignan (n=27) 
 
1.19±0.13 1.12±0.10 1.28±0.16 1.28±0.13 
HDL (mmol·L
-1
) 
 
    
     Placebo (n=25) 
 
1.54±0.08 1.52±0.09 1.36±0.06 1.39±0.06 
     Lignan (n=27)* 
 
1.74±0.08 1.63±0.09 1.60±0.08 1.56±0.08 
LDL (mmol·L
-1
) 
 
    
     Placebo (n=24) 
 
3.77±0.16 3.80±0.23 3.91±0.20 4.01±0.19 
     Lignan (n=27) 
 
3.60±0.17 3.71±0.16 3.68±0.15 3.63±0.15 
TC:HDL 
 
    
     Placebo (n=25) 
 
4.27±0.27 4.46±0.34 4.69±0.31 4.71±0.32 
     Lignan (n=27)* 
 
3.53±0.17 3.81±0.19 3.88±0.20 3.88±0.19 
94 
 
Values are mean ± SE.  TC, total cholesterol; TAG, triacylglycerol; HDL, high-density 
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol. *Indicates significant group 
main effect (p < 0.05) from 3 factor analysis of variance. 
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2.3.5 Adverse Events and Compliance  
There were no serious adverse events that occurred during the study that were considered 
related to the intervention.  One female subject taking the placebo experienced constipation 
(classified as mild) which resolved without incident.  One male subject from the placebo group 
had a lower leg amputation (classified as severe) during the study due to pre-existing peripheral 
arterial disease.  Also, one female subject experienced a flare up of osteoarthritis in her ankle 
joint (mild) and one female subject experienced an exacerbation of osteoarthritis symptoms in a 
knee joint (moderate) due to the walking program.  Compliance monitoring indicated that the 
placebo group ingested 88 ± 2 % of their tablets while the flaxseed lignan group ingested 91 ± 1 
% of their tablets.    
  
2.4 Discussion 
The data from this study indicate that flaxseed lignan complex supplementation has no 
effect on the cytokine concentration of IL-6 and TNF-α or on leukocyte cell counts.  As flaxseed 
lignan is a phytoestrogen, it may act in a manner similar to estrogen by up-regulating estrogen 
receptors which have been shown to have reciprocal cross-talk with nuclear factor kappa B 
(NFκB), a transcription factor for many pro-inflammatory cytokines (Evans et al. 2001).  If 
NFκB is down-regulated by increased estrogen receptor number, the possibility of decreased risk 
of inflammation and associated cardiovascular disease is likely (Evans et al. 2001).  
Supplementing a diet with high amounts of soy isoflavones increased the serum concentrations 
of IL-6 in middle-aged women but not men (Jenkins et al. 2002).  An increase in IL-6 may pre-
dispose older adults to a greater risk of many chronic conditions (Dijsselbloem et al. 2004) but it 
is debated whether IL-6 is pro- or anti-inflammatory in nature as it is a negative feedback signal, 
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decreasing the release of TNF-α and reducing the amount of this powerful pro-inflammatory 
cytokine (Pedersen et al. 2003).   Previous work using partially defatted flaxseed as a dietary 
supplement indicated an increase in oxidative stress as measured by a decrease in protein thiol 
groups compared to a control (Jenkins et al. 1999).  Although an increase in oxidative stress 
could induce an up-regulation of pro-inflammatory cytokines, previous work suggests that the 
lignan from flaxseed is either an anti-oxidant (Kitts et al. 1999; Prasad 1997b; Prasad 2000a; 
Prasad 2000c; Prasad 2005b) or has no effect on antioxidant capacity (Hallund et al. 2006a).  The 
results of this study indicate that flaxseed lignan complex had no significant effects on 
inflammation as measured by IL-6 and TNF-α (Figure 2.1 - 2.4) or leukocyte cell count (Table 
2.3 & 2.4). 
The results also indicate that flaxseed lignan complex supplementation may be effective 
for preventing risk of metabolic syndrome in older men but not older women.  This is in 
agreement with several animal models of supplementation with other phytoestrogens such as soy 
isoflavones which reduce metabolic syndrome in both lean and obese male rats (Davis et al. 
2007; Davis et al. 2005).  Also, a recent in vitro study culturing adipocytes in puerarin (another 
phytoestrogen) found that this isoflavone is capable of producing anti-metabolic syndrome 
effects (Xu et al. 2005).  A cross-sectional study utilizing the Framingham Offspring found that 
postmenopausal women with the highest intake of phytoestrogens (either isoflavones or lignans) 
in their diet had the least possibility of metabolic syndrome risk (de Kleijn et al. 2002).  The 
results in this thesis indicate that metabolic syndrome risk is attenuated in older males, but not 
females, taking a flaxseed lignan complex supplement, but the reason for this sex effect is not 
known.  There is a dramatic decrease in estrogen and likely a decrease in the number of estrogen 
receptors at menopause in women (Castelo-Branco and Rostro 2006).  Although speculative, 
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SDG or its metabolites may not have been able to bind as effectively in the women versus the 
men due to a lack of receptors.  Also, evidence suggests that isoflavones from soy may bind with 
greater affinity to estrogen receptor β than does SDG (Turner et al. 2007) which may explain the 
contrasting results between metabolic syndrome risk factors in women from this study versus the 
Framingham Offspring Study.   Finally, enterolactone, a metabolite of SDG,  effectively binds 
with estrogen receptor α and induces transcription both in vitro and in an in vivo animal model 
(Penttinen et al. 2007).  If estrogen receptors are reduced with aging, especially at menopause, 
then the ability of SDG or its metabolites to bind with estrogen receptor α would also be 
compromised and not likely to produce a favorable health effect in post-menopausal women. 
The interaction noted for TAG in this study most likely occurred due to a decrease in 
TAG concentration in men on flaxseed lignan combined with a increase in men on placebo, with 
no change in the female groups (see Tables 2.5 & 2.6).  Previous work in animals suggests that 
SDG or flaxseed consumption will either raise (Prasad et al. 1998) or have no effect (Prasad 
1999) on TAG. The results of this study confirm earlier research indicating no effect of lignan 
supplementation on TAG in postmenopausal women (Hallund et al. 2006a) but suggest that TAG 
concentration may be lowered in older men ingesting a flaxseed lignan supplement.  Further, in 
type II diabetics, TAG was not altered with 12 weeks of flaxseed lignan complex 
supplementation (Pan et al. 2007).  There are several mechanisms by which flaxseed lignan may 
lower TAG.  Other plant lignans (i.e. sesamin) lower TAG levels by modulating the activity of 
acyl CoA cholesterol acetyl transferase, the enzyme involved in packaging cholesterol ester and 
TAG into very low density lipoproteins for export from the liver (Bloedon and Szapary 2004).  
Lignans also increase hepatic fatty acid oxidation and down regulate hepatic lipogenic enzymes 
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thereby decreasing fatty acid availability for TAG synthesis and secretion from the liver (Ide et 
al. 2001).  
This study revealed no changes between groups in lipoprotein concentrations.  This is in 
direct contrast to research in animal models which found a decrease in total cholesterol and LDL 
with a corresponding increase in HDL in animals supplemented with flaxseed lignan (Prasad 
1999; Prasad 2005b).  These studies found SDG had its greatest effect on animals with abnormal 
lipid profiles induced by a high cholesterol diet.  This was recently confirmed in a human study 
where 8 weeks of SDG supplementation in hypercholesterolaemic subjects significantly lowered 
TC, LDL and glucose versus placebo (Zhang et al. 2007).  In the current study subjects had a 
mix of normal and abnormal lipid profiles; however, sub-analyses on those subjects with lipid 
levels outside the normal reference range indicated no effect of flaxseed lignan complex on lipid 
profiles, although the power of this analysis was low due to low subject numbers (data not 
shown).  The current results are in agreement with the outcomes of Hallund et al. (2006a) and 
Pan et al. (Pan et al. 2007) who found no changes in concentrations of lipids in post-menopausal 
women or type II diabetics supplementing with flaxseed lignan complex.  Estrogen is known to 
increase LDL clearance by up-regulating hepatic LDL receptors (Inukai et al. 2000; Parini et al. 
1997).  Enterolactone, a metabolite produced by SDG, may act similarly to estrogen by 
stimulating  hepatic and macrophage cells to increase uptake of LDL (Owen and Abbey 2004; 
Owen et al. 2004).  The results indicate that 6 months of flaxseed lignan complex 
supplementation had no effect on LDL cholesterol concentrations.  It may be that the lignan 
supplementation did not result in a significant metabolic conversion to enterolactone, due to 
decreased intestinal bacteria activity, which could account for the lack of an effect on LDL 
concentration or that the dose of supplementation was not enough to produce a physiological 
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effect.  A peculiar finding of this study is the decrease in HDL and increase in TC:HDL over 
time in all participants.  Each group was instructed to exercise by walking 5-6 d·wk
-1
, a dose of 
exercise recommended as that needed to increase HDL (Durstine et al. 2002; Durstine et al. 
2001).  The unexpected changes in HDL and TC:HDL over time may have been due to seasonal 
effects (Gordon et al. 1987).  HDL is higher and TC:HDL lower in warmer compared to colder 
months of the year. The majority of subjects in the current study started the intervention in a 
warmer month and finished in a colder month. 
This study is limited in its interpretation.  The study lacked a non-exercise flaxseed 
lignan complex and placebo group, was constrained to self-reported methods of dietary analysis 
as well as self-reported amounts of exercise, and, due to participant staggering, may reflect more 
seasonal effects on metabolic syndrome risk factors (i.e. blood lipids) than effects due to flaxseed 
lignan supplementation.  
In conclusion, this study indicates that 6-months of supplementation with flaxseed lignan 
complex (543 mg·d
-1
 of SDG) had no effect on inflammatory cytokines.  Flaxseed lignan 
complex supplementation attenuates the risk of metabolic syndrome in older men while there is 
no effect on metabolic syndrome criteria in older females.  Of the components of the metabolic 
syndrome, flaxseed lignan complex had its greatest effect on TAG and diastolic blood pressure, 
while having no statistical effect on inflammatory cytokines, HDL, abdominal fat, systolic blood 
pressure, or glucose.  More research on the biological health effects of flaxseed lignan complex 
supplementation in humans is warranted. 
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Chapter 3: Experiment II 
3.1 Introduction 
Skeletal muscle loss is a major health concern associated with aging.  Sarcopenia refers to the 
age related loss of muscle mass and strength (Borst 2004).  Recently, it has been determined that the 
costs associated with health-care due to sarcopenia are 1.5% of the total health care costs per year in 
the United States (Janssen et al. 2004).  Also, it is estimated that this cost will continue to rise as the 
population ages.   
Chronic low grade inflammation is one factor contributing to decreased muscle mass and 
strength with age (Roubenoff 2001) but others such as decreased neural function, altered nutrition in 
old age, reduced physical activity as well as decreases in anabolic hormones may all contribute to 
sarcopenia (Alway and Siu 2008).  The inflammatory cytokine interleukin-6 (IL-6) is associated with 
a decrease in muscle mass, strength, and fiber number in older adults (Bautmans et al. 2005; 
Deschenes 2004; Ferrucci et al. 2002; Payette et al. 2003).  A second inflammatory cytokine, tumor 
necrosis factor-α (TNF-α) is considered a catabolic signaling agent and increasing concentrations due 
to the aging process result in a decreased muscle mass and strength (Ladner et al. 2003).  Apoptosis, 
or programmed cell death, has been indicated as a possible contributor to the etiology of sarcopenia 
(Alway and Siu 2008; Leeuwenburgh 2003) and as age increases, TNF-α stimulates the progressive 
deterioration of myocytes via apoptosis (Ladner et al. 2003).  
Alpha-linolenic acid (18:3ω-3; ALA) is an 18 carbon fatty acid considered an essential ω-
3 polyunsaturated fatty acid and the parent to longer carbon chain ω-3 fatty acids.  Flaxseed oil is 
composed of between 45-60% ALA and is considered the most abundant source of ALA 
(Cunnane 2003).  ALA functions as a precursor to other ω-3 fatty acids (eicosapentaeonic acid 
and docosahexaenoic acid) via carbon chain elongation and further desaturation (Burdge 2004).  
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Supplementation with ω-3 fatty acids has been used to decrease the amount of inflammation 
associated with various disease processes (Simopoulos 1999; Simopoulos 2002b).  It has been 
proposed that a high ratio of ω-6 to ω-3 fatty acids in the normal Western diet is associated with 
an increased risk for many chronic diseases (Simopoulos 2002a).  Increasing consumption of 
ALA will increase eicosapentaenoic acid (EPA) concentration in men and women but the 
conversion is lower in men than women (Burdge 2004; Burdge et al. 2003; Burdge and Wootton 
2003).  Theoretically, increasing exogenous consumption of ALA, with the associated increase 
in EPA, will reduce inflammation by competing for the same enzymatic pathways 
(cyclooxygenase and 5-lipoxygenase) as arachidonic acid (Alexander 1998).  Arachidonic acid 
produces an eicosanoid series considered to be more pro-inflammatory than EPA.  The 
eicosanoids, which are lipid mediators of inflammation, secreted by arachidonic acid metabolism 
are considered pro-inflammatory and will up-regulate pro-inflammatory cytokine release while 
the eicosanoids from EPA metabolism are less inflammatory in nature (Alexander 1998). 
The purpose of this study was to evaluate the effectiveness of ALA supplementation on 
markers of inflammation and muscle mass and strength in older adults completing a progressive 
resistance training program.  The main hypothesis of this study was that ALA supplementation 
would decrease inflammation, as measured by IL-6 and TNF-α concentration in blood plasma, which 
in turn would result in a greater increase in muscle mass and strength in older adults completing a 
strength training program. 
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3.2 Subjects and Methods 
3.2.1 Research Design 
A 2 group randomised controlled double blind trial was used to compare the effects of 12 
weeks of resistance training with and without ALA supplementation in older males and females. 
Dependent variables included plasma concentrations of IL-6 and TNF-α, 1-repetition maximum 
(1 RM) chest and leg press strength, muscle thickness of the elbow and knee extensors and 
flexors assessed by ultrasound, and body composition (lean tissue and fat mass) as assessed by 
dual energy X-ray absorptiometry (DEXA).  Subjects were matched for sex and randomly 
assigned by computer to either supplement with ALA or placebo.  Each participant completed a 
progressive resistance training program designed to improve muscle mass and strength.  
 
3.2.2 Subjects, Randomization, and Supplementation 
Untrained male and female participants were recruited from the healthy population 
(n=51; 65.4 ± 0.8 yrs).  Participants were included only if they were 60 years of age or older 
because this is the approximate age at which there is a significant increase in sarcopenia (Castillo 
et al. 2003). Subjects were excluded if they: 1) were taking any medication that may affect 
inflammation; 2) had an inflammatory disease; 3) were taking any flaxseed supplements; or 4) 
were currently participating in a resistance training program ≥2 times/week.  Once participants 
were screened, they were stratified by sex and then randomized to either the ALA or placebo 
group by a research assistant not involved in any other aspect of the research project.  A random 
number generator (Microsoft Excel) was used to randomize individuals to either the ALA or the 
placebo treatment group. This was done in blocks of 2, so if one subject was randomized to 
ALA, the next person was randomized to placebo, and vice versa.  A Physical Activity Readiness 
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Questionnaire (PAR-Q) was completed to ensure there were no other health risks precluding 
their participation in the resistance training program (Thomas et al. 1992).  A sample size of n = 
24 per treatment group was calculated by using previous research (Caughey et al. 1996) 
demonstrating  a decrease in LPS stimulated peripheral blood mononuclear cells TNF-α 
concentration from 30.1±6.2 pg·mL
-1
 to 22.1±5.4 pg·mL
-1
 after 4 weeks of flaxseed oil 
supplementation in healthy young males at 80% power and an alpha level of 0.05 (Statistica 
version 7, StatSoft Inc., Tulsa, Oklahoma).  A baseline TNF-α concentration of 30.1±9.5 pg·mL-
1
 was entered as the population mean and standard deviation respectively.  An increased standard 
deviation was used as it was expected that the variation in older adults would be greater than 
young adults.  The post-intervention TNF-α concentration of 22.1 pg·mL-1 was entered as the 
expected mean in the intervention group after supplementation.  Recruitment was increased to n 
= 30 per group due to an expected drop-out rate of 25%.    Ethical approval was granted for the 
study through the University of Saskatchewan‘s Biomedical Research Ethics Board and a 
certificate of approval was issued (Bio# 06-211; see appendix C).  All participants signed a 
consent form before being enrolled into the research project (see appendix D).   
ALA and placebo oil was similar in color and calories.  Subjects received a plastic 
opaque bottle of oil after baseline testing and were instructed to store the bottle in a refrigerator 
to reduce the chance of the oil oxidizing.  Participants supplemented their regular diets with 
either 30 mL of flaxseed oil (containing ~14 grams of ALA) or 30 mL of placebo oil (corn oil) 
per day throughout the 12 week trial. This dose was chosen as previous research using ALA 
found a significant decrease in inflammatory cytokines with the same approximate dose 
(Caughey et al. 1996).  Also, this is the maximum dose allowed by Health Canada.  Participants 
were asked to return the bottles at the end of the study for compliance monitoring. 
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3.2.3 Resistance Training 
 Resistance training was 3 days per week with at least one day of rest between training 
days, for 12 weeks. The resistance training sessions included exercises for all major muscle 
groups with the following 13 exercises: chest press, lateral pull down, shoulder press, biceps 
curl, triceps push down, back extension, hip extension, hip flexion, hip adduction and hip 
abduction using Lever equipment (Pulse Fitness Systems; Winnipeg, MB, Canada) and leg press, 
knee extension, and knee flexion using Hammer Strength equipment (Life Fitness; Franklin Park, 
IL, U.S.A.).  A periodized resistance training program involving 4 blocks was utilized for this 
study.  The first block included 6 training sessions and was devoted to anatomical adaptation 
with subjects performing 3 sets of 10-12 repetitions at 60-65% of their 1RM.  Block two was 
devoted to higher volume training designed to stimulate muscle hypertrophy and had subjects 
complete 6 training sessions utilizing 4 sets of 10-12 repetitions at 65-70% of their 1RM.  Block 
three included12 training sessions and was devoted to strength development with the subjects 
performing 3-4 sets of 6-10 repetitions at 70-85% of their 1RM.  The fourth block included 12 
training sessions and was devoted to maintenance of the strength and hypertrophy gains with 
subjects performing 3 sets of 10-12 repetitions at 65-80% of their 1RM.  This program was 
similar to a program previously utilized which demonstrated significant increases in strength and 
lean tissue mass in older men (Newton et al. 2002).  Participants were allowed to progress in 
load when they were able to successfully complete all prescribed sets and repetitions with proper 
form.  
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3.2.4 Data Collection 
 Subjects were required to attend the laboratory for testing over 3 days at baseline and 
after the 12 week intervention.  Before and after the 12 week intervention subjects were required 
to give blood samples for cytokine analysis (Day 1), complete tests of muscle thickness and then 
maximum chest press and leg press strength (Day 2), and provide measurements of body 
composition, as well as complete a food frequency questionnaire (Day 3). 
Cytokines 
Overnight fasting (12 hour) blood samples, of approximately 10 mL were drawn by 
venipuncture from the antecubital vein into cooled (4˚C) vacutainer tubes containing EDTA.  
After inversion, the tubes were kept on ice for ~ 15 minutes and then centrifuged at 2300 rpm for 
12 minutes at 4˚C.  Approximately 4 mL of plasma was aliquoted into Eppendorf microtubes (~1 
mL per tube × 4 tubes) and immediately frozen at -80˚C until analyzed.  An enzyme linked 
immunosorbent assay (ELISA) was used to analyze IL-6 and TNF-α concentration in the plasma 
(Cayman Chemical Company, Ann Arbor, Michigan, U.S.A.) according to the manufacturer‘s 
instructions.  Each assay is based on a double-antibody ‗sandwich‘ technique.  The intraassay 
coefficients of variation for IL-6 were less than 4% and for TNF-α were less than 6%.  The 
detection limit of each kit is 1.5 pg·mL
-1
.  Completed assays were read for absorbance on a 
Synergy HT microplate reader (BioTek Instruments, Winooski, Vermont, U.S.A.) at a 
wavelength of 405 nm.  All samples of each subject (i.e. both at baseline and after 12 weeks) 
were assayed in triplicate within the same microplate to reduce variation. 
Anthropometrics and Body Composition 
Height was measured utilizing a standard stadiometer and weight was measured using a 
calibrated scale.  Body composition was assessed by DEXA (Discovery W version 12.3, Hologic 
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Inc., Bedford, Maryland).  Coefficients of variation for repeated measures in our lab were 0.5% 
for lean tissue mass, and 3% for fat mass. 
Muscle Thickness 
Muscle thickness was evaluated on the elbow and knee flexors and extensors on the right 
limbs by B-mode ultrasound using a 5 MHz scanning transducer (Aloka SSD-500, Tokoyo, 
Japan) as has been previously described in detail (Candow and Chilibeck 2005; Farthing and 
Chilibeck 2003).  The coefficients of variation for repeated muscle thickness measurements were 
2.5% (elbow flexors), 2.2% (elbow extensors), 3.6% (knee flexors), and 2.1% (knee extensors). 
Muscle Strength 
One-repetition maximum (1-RM) strength was assessed by using the same chest press 
and leg press equipment used with training, by a protocol previously described in detail (Chrusch 
et al. 2001). Briefly, all 1-RM strength testing was performed by a qualified exercise 
professional (Certified Exercise Physiologist) who gave proper instruction on exercise technique 
before beginning the testing session and made it clear to the subjects that a maximal effort was 
required for the two strength tests.  One-repetition maximum strength was assessed by using 
standard chest press (Pulse Fitness Systems Inc., Winnipeg, Manitoba) and leg press (Life 
Fitness; Franklin Park, IL, U.S.A.) equipment.  Subjects performed a very light warm up set of 
10 repetitions on the equipment being used for the test and then 1-2 minutes of static stretching 
exercises for the muscle groups being tested.  Then another warm-up set of 5 repetitions was 
performed with a higher load.  The equipment was then loaded with more weight and the subject 
was instructed to make a 1 repetition attempt.  If the attempt was successful, the research 
assistant loaded more weight on to the equipment.  This was repeated until the subject was 
unable to perform one repetition with the load on the equipment.  Subjects rested quietly between 
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1RM attempts for between 30-60 seconds.  If the subject was unsuccessful on the first attempt 
the load was lowered and the same protocol was followed (i.e. 1RM attempts were made until 
the subject was unable to lift the load).  The coefficients of variation for chest and leg press 1-
RM were 3.6% and 3.0%, respectively.  
Dietary Assessment 
Typical dietary intake was evaluated by a food frequency questionnaire (FFQ). The FFQ 
used was a 110 item survey, with modifications made for the typical Canadian diet, designed to 
estimate the customary dietary intake for macronutrients and micronutrients in adults (Block 
98.2, Block Dietary Data Systems, Berkeley, California).  The FFQ utilizes portion size pictures 
to increase the accuracy of dietary intake estimation. 
 
3.2.5 Statistical Analyses 
 
Covariates 
 
Baseline characteristics of the subjects were assessed by a 1 factor (group) ANOVA.  It 
was decided a priori that if group statistical differences existed at baseline that the variable(s) 
showing significant differences would be entered as covariates in the statistical analysis. Also, 
the dietary data (baseline and 12 weeks) was analyzed by a 2 (group) × 2 (sex) × 2 (time) 
ANOVA with repeated measures on the last factor to determine if differences existed in self-
reported dietary intake at the beginning and end of the study.  If there were significant changes in 
dietary intake between groups over the 12 week intervention, the nutrient indicating a significant 
difference was entered as a covariate. 
Main analyses 
  A 2 (groups) × 2 (sex) × 2 (time, before and after 12 weeks of supplementation) 
ANOVA with repeated measures on the last factor was used to analyze the data in relation to 
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changes in cytokine concentration, 1 repetition maximum strength, muscle thickness, body 
composition and dietary status.  Relative change scores for dependent variables were analyzed 
with a 2 (groups) × 2 (sex) factorial ANOVA.  Relative change scores were determined by 
subtracting baseline from final results, dividing by baseline and multiplying by 100 to derive a 
percentage.  If a significant interaction was found an LSD post hoc test was performed to 
determine differences between means.  A more liberal post hoc analysis was used in this study as 
the number of subjects was not as large as in Experiment I which would reduce the power of our 
analysis.  If a significant interaction was not found, main effects were assessed for significance.  
The alpha level for the study was set at p ≤ 0.05.  All data is displayed as mean ± standard error 
(SE).    All statistical analyses were performed using Statistica version 7 (Statsoft, Tulsa, OK).  
The data was analyzed with an ANOVA as opposed to a MANOVA as the hypothesis of 
Experiment II had not been evaluated in the population tested.   
 
3.3 Results 
 The number of individuals that responded to the media advertisement was one hundred 
and forty.  Seventy-seven were excluded from the study after the initial interview.  Three 
individuals decided not to participate after the initial interview.  Sixty individuals were enrolled 
in the study at baseline, which included baseline testing.  Nine of the sixty original subjects 
dropped out during the study, leaving fifty-one to complete the intervention.  Reasons given for 
drop out included: lack of time (n = 5), medical problems unrelated to the study intervention (n = 
2), family medical problems (n = 1), and unable to tolerate supplement consumption (n = 1).  Of 
the fifty-one remaining, twenty-five were in the ALA group and twenty-six were in the placebo 
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group.  According to returned portions of oil, the placebo group was 78.2 ± 4.1 % compliant 
while the ALA group was 83.6 ± 2.9 % compliant with the supplementation protocol. 
There were no differences between ALA and placebo groups at baseline (Table 3.1) 
except that females on placebo had a greater elbow extensors muscle thickness than the females 
on ALA (p = 0.027).   
 
3.3.1 Dietary Intake 
There were no differences between groups from baseline to 12 wk for intake of 
kilocalories, protein, total fat, monounsaturated fat, polyunsaturated fat, or carbohydrate (see 
Table 3.2).  There were time main effects for protein (decreasing, p < 0.05), total fat (decreasing, 
p < 0.05), saturated fat (decreasing, p < 0.05), and monounsaturated fat (decreasing, p < 0.05). 
 
3.3.2 Cytokines   
A significant group × sex × time interaction for IL-6 was found (p = 0.05; Figure 3.1).  
Post-hoc analysis indicated that the male ALA group had a significant reduction in IL-6 
concentration from baseline to 12 weeks (p = 0.003) while the male placebo group and female 
groups did not change significantly over time.  The ALA and placebo groups did not differ over 
time for TNF-α concentration (Figure 3.2).  Analysis did reveal a significant sex × time 
interaction for the absolute changes in TNF-α concentration (p = 0.03) with males decreasing 
(7.80 ± 0.67 to 6.98 ± 0.65 pg·mL
-1
) and females increasing (4.42 ± 0.74 to 5.72± 0.71pg·mL
-1
) 
over the 12 weeks.  
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3.3.3 Muscle Strength 
One-repetition maximum strength did not differ between ALA and placebo groups over 
time. There was a significant sex × time interaction for chest press strength (p = 0.006) with 
females increasing (27.6 ± 3.5 to 42.2 ± 3.9 kg) less than males (73.5 ± 3.1 to 96.8 ± 3.6 kg), see 
Figure 3.3.  Also, a main effect of time (p < 0.01) for leg press strength was found (see Figure 
3.4).   
 
3.3.4 Body Composition   
Body composition measures did not differ between ALA and placebo groups over time. 
There were main effects of time with lean tissue mass increasing (see Figure 3.5; p < 0.05).  
Also, percent body fat (29.7 ± 0.8 to 29.0 ± 0.7 %) and total body mass (75.8 ± 1.9 to 74.7 ± 1.8 
kg) decreased significantly over time (both p < 0.01).  It was determined that neither the 
interaction for differences in fat mass were significant (p > 0.05) nor were main effects for fat 
mass significant (p > 0.05).  
 
3.3.5 Muscle Thickness 
   
There was a significant group × sex × time interaction (p ≤ 0.05) for knee flexor muscle 
thickness with the female placebo group and male ALA group increasing from baseline to 12 
weeks with no other significant changes in the other groups over time.  Main effects of time were 
observed for elbow flexor, elbow extensor, and knee extensor thicknesses (all p < 0.01; see Table 
3.3). 
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Table 3.1  Baseline characteristics of older adults randomized to supplement orally with either 
flaxseed oil (ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) for 12 weeks while completing a 
strength training exercise program (n = 51). 
 
 ALA (n = 25) 
 
PLA (n = 26) 
Age (yr) 65±1 
 
66±1 
Height (cm) 168±2 
 
169±2 
Mass (kg) 75±3 78±3 
 
Fat (%) 29±2 30±2 
 
Fat Mass (kg) 22±2 23±2 
 
LTM (kg) 51±2 52±2 
 
 
Data are means ± SE.  ALA, alpha-linolenic acid group; PLA, placebo group; LTM, lean tissue 
mass. 
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Table 3.2  Dietary intake of older adults randomized to supplement orally with either flaxseed 
oil (ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) for 12 weeks while completing a strength 
training exercise program not including the supplement ingested (n = 51). 
 
 Male 
 
(n = 14 PLA; n = 14 ALA) 
 
Female 
 
(n = 12 PLA; n = 11 ALA) 
 
Baseline 12 weeks Baseline 12 weeks 
Energy(kcal·d
-1
) 
 
     PLA 
 
     ALA 
 
 
2121±157 
 
1671±157 
 
 
1949±148 
 
1517±148 
 
 
1633±170 
 
1628±177 
 
 
1611±159 
 
1514±167 
Protein (g·d
-1) † 
 
     PLA 
 
     ALA 
 
 
79±7 
 
64±7 
 
 
73±7 
 
62±7 
 
 
66±8 
 
66±8 
 
 
61±7 
 
57±8 
Carbohydrate (g·d
-1
) 
 
     PLA 
 
     ALA 
 
 
274±20 
 
186±20 
 
 
251±18 
 
168±18 
 
 
199±22 
 
195±23 
 
 
199±19 
 
190±20 
Total Fat (g·d
-1
)† 
 
     PLA 
 
     ALA 
 
 
81±8 
 
71±8 
 
 
74±8 
 
62±8 
 
 
67±9 
 
70±9 
 
 
66±8 
 
63±9 
Saturated Fat (g·d
-1
) † 
 
     PLA 
 
     ALA 
 
 
23±2 
 
22±2 
 
 
21±2 
 
19±2 
 
 
19±3 
 
19±3 
 
 
19±3 
 
17±3 
MUFA (g·d
-1
) † 
 
     PLA 
 
     ALA 
 
 
33±3 
 
28±3 
 
 
29±3 
 
24±3 
 
 
25±4 
 
28±4 
 
 
25±3 
 
26±4 
ω-6 Fatty Acid (g·d-1) 
 
     PLA 
 
 
19±2 
 
 
17±2 
 
 
18±2 
 
 
18±2 
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     ALA 
 
15±2 
 
14±2 
 
17±2 
 
15±2 
ω-3 Fatty Acid (g·d-1) 
 
     PLA 
 
     ALA 
 
 
 
1.8±0.2 
 
1.4±0.2 
 
 
1.8±0.2 
 
1.3±0.2 
 
 
1.7±0.2 
 
1.6±0.2 
 
 
1.8±0.2 
 
1.4±0.2 
Vitamin A (I.U.) 
 
     PLA 
 
     ALA 
 
 
 
14646±2507 
 
7724±2507 
 
 
13710±1897 
 
8009±1897 
 
 
15213±2708 
 
14254±2829 
 
 
12807±2049 
 
12207±2140 
Vitamin B6 (mg·d
-1
) 
 
     PLA 
 
     ALA 
 
 
 
2.2±0.2 
 
1.8±0.2 
 
 
2.1±0.2 
 
1.7±0.2 
 
 
1.8±0.2 
 
1.7±0.2 
 
 
1.8±0.2 
 
1.7±0.2 
Folate (mg·d
-1
) 
 
     PLA 
 
     ALA 
 
 
 
448±37 
 
330±37 
 
 
407±37 
 
303±37 
 
 
391±40 
 
370±42 
 
 
375±40 
 
337±41 
Vitamin C (mg·d
-1
) 
 
     PLA 
 
     ALA 
 
 
 
143±16 
 
99±16 
 
 
138±14 
 
91±13 
 
 
139±18 
 
116±19 
 
 
129±15 
 
117±16 
Vitamin D (I.U.) 
 
     PLA 
 
     ALA 
 
 
 
181±35 
 
158±35 
 
 
170±30 
 
173±30 
 
 
158±38 
 
229±40 
 
 
128±32 
 
156±34 
Vitamin E (mg·d
-1
) 
 
     PLA 
 
     ALA 
 
 
 
11.6±1.3 
 
8.3±1.2 
 
 
10.4±1.0 
 
7.6±1.0 
 
 
10.8±1.3 
 
10.8±1.3 
 
 
10.5±1.1 
 
10.0±1.1 
Zinc (mg·d
-1
) 
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     PLA 
 
     ALA 
 
13.4±1.3 
 
11.0±1.3 
13.0±1.5 
 
10.4±1.5 
11.3±1.4 
 
11.5±1.5 
10.8±1.6 
 
10.2±1.7 
Iron (mg·d
-1
) 
 
     PLA 
 
     ALA 
 
 
 
15.9±1.3 
 
13.3±1.3 
 
 
14.6±1.3 
 
12.5±1.3 
 
 
12.7±1.5 
 
12.5±1.5 
 
 
11.8±1.4 
 
11.9±1.5 
 
Data are means ± SE.  ALA, alpha-linolenic acid.  † Significant main effect of time (p < 0.05). 
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Figure 3.1  IL-6 concentration at baseline and 12 weeks of oral supplementation with flaxseed 
oil (ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) in older adults completing a strength training 
program.  * Male ALA value at 12 wk significantly lower than baseline (p < 0.01).  Values are 
group means ± standard error. 
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Figure 3.2  TNF-α concentration at baseline and 12 weeks of oral supplementation with flaxseed 
oil (ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) in older adults completing a strength training 
program.  Values are group means ± standard error. 
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Figure 3.3  Chest press 1 repetition maximum at baseline and 12 weeks of oral supplementation 
with flaxseed oil (ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) in older adults completing a 
strength training program.  * Significant time × sex interaction, females increased less than males 
(p < 0.01).  Values are group means ± standard error. 
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Figure 3.4  Leg press 1 repetition maximum at baseline and 12 weeks of oral supplementation 
with flaxseed oil (ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) in older adults completing a 
strength training program.  *Significant time main effect, increasing strength in whole group (p < 
0.01).  Values are group means ± standard error. 
* 
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Figure 3.5  Lean tissue mass at baseline and 12 weeks of oral supplementation with flaxseed oil 
(ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) in older adults completing a strength training 
program.  * Significant time main effect, increasing lean tissue mass in whole group (p < 0.05).  
Values are group means ± standard error. 
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Table 3.3.  Muscle thickness measurements for the flexor and extensor muscles surrounding the 
elbow and knee joints of older adults randomized to supplement orally with either flaxseed oil 
(ALA; 30 ml·d
-1
) or corn oil (PLA; 30 ml·d
-1
) for 12 weeks while completing a strength training 
exercise program (n = 51). 
    
 Male 
 
(n = 14 PLA; n = 14 ALA) 
Female 
 
(n = 12 PLA; n = 11 ALA) 
 
 
Baseline 
 
12 week 
 
Baseline 
 
12 week 
 
Elbow flexors (cm) †     
 
     PLA 
 
3.5 ± 0.2 3.7 ± 0.1 3.6 ± 0.3 3.8 ± 0.3 
     ALA 
 
3.6 ± 0.1 4.0 ± 0.2 2.9 ± 0.2 3.2 ± 0.2 
Elbow extensors (cm) † 
 
    
     PLA 
 
4.4 ± 0.3 4.5 ± 0.3 3.5 ± 0.4 4.6 ± 0.4 
     ALA 
 
4.4 ± 0.3 5.2 ± 0.3 3.7 ± 0.4 4.6 ± 0.2 
Knee flexors (cm) 
 
    
     PLA 
 
5.1 ± 0.4 5.3 ± 0.5 4.5 ± 0.5 5.8 ± 0.5* 
     ALA 
 
5.2 ± 0.4 6.1 ± 0.3* 5.1 ± 0.5 5.1 ± 0.5 
Knee extensors (cm) † 
 
    
     PLA 
 
3.6 ± 0.2 3.9 ± 0.2 3.6 ± 0.3 3.9 ± 0.1 
     ALA 
 
3.4 ± 0.1 3.4 ± 0.1 3.5 ± 0.2 4.0 ± 0.2 
 
Data are means ± SE.  PLA (placebo); ALA (alpha-linolenic acid).  *Group × sex × time, 
females on placebo and males on ALA increased over time with no changes in the other groups 
(p ≤ 0.05).  †Significant main effect of time (p < 0.01). 
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3.3.6 Adverse Events   
Three subjects in the placebo group reported adverse events that were deemed related to 
the supplement which included upset stomach/nausea (n = 1) and diarrhea (n = 2).  Two subjects 
experienced adverse events that resulted in a reduced resistance training volume.  One subject in 
the placebo group was diagnosed as having a first degree sprain in the left ACL ligament due to 
pre-existing joint laxity and ‗over-exertion‘ on the knee flexion machine and one subject in the 
ALA group fractured her patella in an accident unrelated to the study intervention.  These two 
subjects did not complete the leg press 1-RM post-testing due to these injuries and were unable 
to complete all the lower body exercises in the exercise program. 
 
3.4 Discussion 
 It was hypothesized that ALA supplementation would reduce inflammation and that this 
would be beneficial for increasing muscle mass and strength.  The results of this study indicate 
that older men supplementing with ALA for 12 weeks decreased the concentration of 
interleukin-6 with no effect in women, but this did not appear to have beneficial effects on 
muscle mass or strength.  ALA acts as a substrate for the longer chain fatty acids EPA and DHA 
and it has been shown that women convert higher amounts of ALA to the longer chain fatty acids 
because the conversion is mediated by estrogen (Burdge 2006).  As the women recruited in this 
study were all post-menopausal, the conversion of ALA to the longer chain fatty acids may have 
been inhibited due to the decrease in the estrogen production after menopause (Ottosson et al. 
1984; Silfverstolpe et al. 1981; Stark et al. 2003).  Earlier data has indicated that estrogen intake 
during menopause stimulates delta-6 desaturase and inhibits delta-5 desaturase activity which 
would result in an increased conversion of ALA to EPA but a reduction in DHA (Stark et al. 
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2003).  Further, research in lactating women, who have increased estrogen concentrations, 
indicated that EPA was significantly increased while DHA was not in the plasma (Francois et al. 
2003).  These observations indicate that estrogen has a mediating role in the conversion of ALA 
to the longer chain fatty acids and that post-menopausal women may therefore have a different 
response to ALA supplementation.  Previous research evaluating the effects of either dietary 
supplementation or dietary modification to include more ALA in humans has shown a decrease 
(Caughey et al. 1996; Mantzioris et al. 2000; Nelson and Hickey 2004) or no change (Kew et al. 
2003; Wallace et al. 2003) in various pro-inflammatory cytokines including IL-6, TNF-α, IL-1β, 
and the acute phase protein C-reactive protein.  The changes in TNF-α concentration mirrored 
the same pattern as IL-6 but did not reach statistical significance for differences between groups.  
It is well established that TNF-α is responsible for the release of IL-6 and that the two cytokines 
are highly correlated (Pedersen et al. 2000).   Likely, this study lacked statistical power to detect 
significant differences between ALA and placebo for TNF-α.  Nevertheless, these results seem to 
further substantiate the anti-inflammatory effect of ALA in older men but not in older women.   
 The results indicate that progressive resistance training is effective for increasing muscle 
thickness, muscle strength, and lean tissue mass in older adults. The addition of ALA to the 
strength training program resulted in a significantly greater increase in knee flexor muscle 
thickness in men but not women.  There was no greater improvement in the other muscle 
thickness measures, lean tissue mass, or muscle strength with ALA.  Interventions that decrease 
the amount of pro-inflammatory cytokines such as TNF-α and IL-6 may be effective at 
decreasing the amount of myocyte apoptosis in older adults thus preserving muscle mass and 
strength into older age (Dirks and Leeuwenburgh 2006; Pistilli et al. 2006).  It has been 
suggested that older adults are at increased risk of sarcopenia due to the hyper-inflammatory 
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state associated with aging and increased concentrations of TNF-α will act as a catabolic agent 
for death-cell receptors on myocytes signaling an increase in apoptosis (Dirks and 
Leeuwenburgh 2006) and a decrease in total skeletal muscle mass and consequently strength 
(Pistilli et al. 2006).  The ALA only resulted in increased muscle thickness of the knee flexors in 
the older men, with no greater increase in other measures of muscle thickness, muscle strength or 
lean tissue mass compared to placebo. This indicates that, even though ALA supplementation 
seemed to be beneficial for lowering IL-6 concentration, ALA resulted in only minimal changes 
in muscle mass with no changes in strength.  Although there were no statistical differences 
between groups in protein intake, the men consuming ALA consumed, on average, a lower 
amount of protein in their diets than the current RDA (~0.76 g·d
-1
).  This may have influenced 
the results by putting these men at a disadvantage for inducing skeletal muscle hypertrophy as 
protein consumption beyond the RDA is usually recommended (Andrews et al. 2006; Campbell 
and Geik 2004).   
Unexpectedly, the women in the placebo group increased knee flexor muscle thickness 
while the women in the ALA group did not.  This conflicts with the study hypothesis.  Muscle 
regeneration has been inhibited in animal models utilizing non-steroidal anti-inflammatory 
medication which inhibits cyclooxygenase activity and decreases the regenerative ability of 
muscle (Bondesen et al. 2004; Bondesen et al. 2006).  Also, ibuprofen (1200 mg·d
-1
) 
administration to young men resulted in a blunted postexercise fractional synthesis rate of 
skeletal muscle and decreased prostaglandin F2α, indicating a decrease in muscle protein 
synthesis, while having no effect on prostaglandin E2, which if up-regulated would result in 
increased skeletal muscle degradation (Trappe et al. 2001; Trappe et al. 2002).  This research 
also suggested that there was no change in inflammatory cell response to skeletal muscle tissue 
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injury with or without ibuprofen ingestion (Peterson et al. 2003).  This proposes that 
cyclooxygenase (COX) inhibition may be deleterious to muscle hypertrophy.  Specifically, it 
seems that inhibition of the COX-2 isoform results in the greatest decrease in muscle 
regenerative ability (Bondesen et al. 2004; Bondesen et al. 2006; Mendias et al. 2004).  Recently, 
ALA has been found to act on COX-2 in a similar manner which could explain the results of an 
increase in knee flexor thickness in the female placebo group and no increase in the female ALA 
group but does not provide evidence for the effect observed on knee flexor thickness in men on 
ALA in this study (Ren and Chung 2007; Ren et al. 2007). 
Cross-sectional research in older adults has indicated that physical activity is anti-
inflammatory in nature (Colbert et al. 2004; McFarlin et al. 2006) which may decrease the risk of 
chronic health conditions (Bruunsgaard and Pedersen 2003).  Relatively little prospective 
research has been performed in older adults to evaluate the effects of progressive resistance 
training exercise on markers of inflammation.  Twelve weeks of progressive resistance training 
was found to have no effect on markers of inflammation in older healthy and frail elderly 
subjects (Bruunsgaard et al. 2004; Rall et al. 1996) but a 6 week intensive resistance training 
program was able to decrease heat shock protein 70 and eliminate the decrease in IL-10 (an anti-
inflammatory cytokine) after an acute bout of exercise in older adults (Bautmans et al. 2005).  
Our results would suggest that resistance training is unable to alter inflammatory markers; 
however, our study is limited because it did not include a non-training control group.  
In conclusion, the results of this study suggest that ALA supplementation for 12 weeks 
reduces the plasma concentration of IL-6 in older men but not older women while progressive 
resistance training remains an effective method for reducing the risk of sarcopenia in older 
adults.  High doses of ALA may reduce skeletal muscle regenerative ability by inhibiting the 
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COX-2 enzyme but more research on the mechanistic differences between men and women 
ingesting ALA is warranted. 
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Chapter 4: General Discussion 
4.1 Summary of Major Findings 
 The constituents of flaxseed used in these experiments seem to exert some favorable 
health effects in older men while having no effect in older women when all subjects were 
completing standardized exercise programs.  The change in hormonal status experienced by 
older women (i.e. post-menopause) may moderate the effects of supplementing diets with 
components of flaxseed.  Decreasing estrogen (estrone, estradiol, estrione) concentrations may 
influence the effectiveness of flaxseed supplementation on inflammation in older women. 
The results of Experiment I indicate that a composite score of metabolic syndrome may 
be attenuated in older men consuming a flaxseed lignan complex (containing SDG) supplement 
during 6 months of cardiovascular exercise training with no effect on the concentration of the 
cytokines IL-6 and TNF-α.  Further, the attenuation of the metabolic syndrome score was 
accompanied by a decrease in TAG and diastolic blood pressure in the men consuming the 
flaxseed lignan complex supplement.  The flaxseed lignan complex supplement appears to have 
no effect on metabolic syndrome or cytokines in older women.  This experiment is unique as no 
other study to date has evaluated the effects of flaxseed lignan complex supplementation on 
blood lipids, metabolic syndrome, leukocytes, and inflammatory cytokines in older men and 
women completing standardized cardiovascular exercise.  Further, this experiment in humans is 
the longest intervention, to date, evaluating the cardiovascular health effects of combined 
cardiovascular exercise and flaxseed lignan complex supplementation.   
Experiment II indicates that older men supplementing with flaxseed oil (ALA) during 12 
weeks of strength training have a significant decrease in the concentration of IL-6 but not in 
TNF-α while there was no effect in older women.  Further, the hypothesized greater increase in 
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lean tissue mass, muscle strength, and muscle size did not occur in the subjects supplementing 
their diet with ALA.  Experiment II is unique to the literature as no study has evaluated the 
effects of ALA supplementation in older adults completing a standardized resistance training 
program. 
 
4.2 Inflammation and Flaxseed 
 The immune system is responsible for coordinating and controlling the overall health of 
an organism.  Components of flaxseed have exhibited some beneficial health modifying effects 
via their positive influence on the inflammatory response controlled by the immune system, but 
more knowledge in regards to safety, efficacy, and dosing with components of flaxseed is 
required to establish the actual influence of flaxseed on human health.  Evidence from the two 
experiments conducted suggests that components of flaxseed may exert some positive health 
effects, beyond the beneficial effects of exercise training, in older men but not older women. 
 
4.2.1 Inflammation and Secoisolariciresinol Diglucoside 
The data from the first experiment indicate that flaxseed lignan complex supplementation 
during cardiovascular exercise training has no effect on the cytokines IL-6 and TNF-α.  The 
theory of the first experiment was that SDG would act as an anti-oxidant, by increasing the 
scavenging of the hydroxyl radical, which in turn would result in a decreased amount of systemic 
inflammation.  The research is scarce on the effects of the lignan component of flaxseed on the 
immune system and inflammation.  The effects of a flaxseed lignan complex on the 
hematopoietic system has been evaluated in rabbits (Prasad 2005a).  This research concluded that 
the lignan complex had no adverse effects on the counts of leukocytes, granulocytes, 
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lymphocytes, or monocytes in healthy or hyper-cholesterolaemic rabbits.  The results of the first 
experiment confirmed this in humans (see Tables 2.3 & 2.4).  Likely, the health benefits 
associated with flaxseed lignan consumption are through another mechanism.  SDG seems to 
possess good potential for modifying immune function as it possesses anti-carcinogenic effects 
in some hormone and non-hormonal cancers (Bergman Jungestrom et al. 2007; Li et al. 1999; 
Serraino and Thompson 1991; Sung et al. 1998; Thompson et al. 2005) but the mechanism(s) 
remain poorly understood.  It has been speculated that the anti-oxidant ability of SDG may be 
responsible for decreasing development of cancer but the anti-estrogenic effects of SDG may 
also be involved (Bergman Jungestrom et al. 2007).  Other types of phytoestrogens affect 
immune system function and markers of inflammation.  In humans, studies with soy isoflavones 
are contradictory. One study indicated that IL-6 was increased in postmenopausal women, with 
no effect on men (Jenkins et al. 2002), while a second study indicated IL-6 and TNF-α in the 
blood of postmenopausal women were decreased with soy isoflavone (phytoestrogen) 
supplementation (Huang et al. 2005).  Monocytes cultured with genistein and daidzein (the two 
main phytoestrogens from soy) from the women in this study were subjected to endotoxin and 
exhibited an increased response of TNF-α.  Recently, in vitro analysis indicated that NFκB is 
blocked by isoflavones independent of estrogen activity (Vanden Berghe et al. 2006) suggesting 
that isoflavones have effects on this inflammatory transcription factor via a mechanism other 
than cross-talk with estrogen receptors.  A study evaluating the effects of flaxseed lignan 
complex on health was done in post-menopausal women (Hallund et al. 2006a; Hallund et al. 
2006b).  Supplementation for 6 weeks had no effect on anti-oxidant capacity, blood lipids or 
endothelial function.  The study is limited due to a small sample size, a short duration of 
supplementation, and it only included women in the sample.  Another study evaluated the effects 
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of flaxseed lignan complex supplementation in type II diabetic patients over 12 weeks and found 
no effect on blood lipids but improved glucose control as measured by HbA1c (Pan et al. 2007).  
These results are limited in interpretation as the majority of the subjects were taking oral 
hypoglycemic agents, antihypertensives or hypolipidemics.  Efficacy in lowering LDL, TC, and 
glucose has been demonstrated for flaxseed lignan supplementation in hypercholesterolaemic 
subjects (Zhang et al. 2007).  It is premature to speculate on all the effects that phytoestrogens 
have on immune system function and inflammation.  More research in this area, especially with 
flaxseed lignan, is required.  The results of Experiment I indicate that oral supplementation with 
a flaxseed lignan complex during 6 months of cardiovascular exercise training had no significant 
effect on IL-6, TNF-α or leukocyte cell number. 
 As Experiment I was done over different seasons, the effects that the environmental 
conditions during varying times of the year have on cytokine concentrations is of interest.  A 
substantial amount of evidence from Antarctic exploration indicates that cold exposure changes 
cytokine concentrations and immune function (Francis et al. 2002; Muller et al. 1995; Shearer et 
al. 2002; Shirai et al. 2003; Tingate et al. 1997; Tringali et al. 2000).  Exposure to Antarctic 
isolation suppresses anti-inflammatory cytokines and stimulates pro-inflammatory cytokines 
(Shearer et al. 2002).  Further, cold exposure combined with strenuous exercise may combine to 
produce an increased suppression of immune function (Shephard 1998; Shephard and Shek 
1998).  It is theorized that cold exposure promotes a hypothalamic-pituitary-adrenal stress 
response which influences the immune response (Shephard 1998; Shephard and Shek 1998).  It 
is unlikely that subjects involved in this study were exposed to the same extremes in 
environment as an Antarctic winter or that they participated in exercise strenuous enough to 
130 
 
cause immunosuppression. Thus, it is unlikely that there was an effect of season on cytokine 
concentrations in this group of older adults. 
 A seasonal effect on blood lipid concentrations is not a new phenomenon (Gordon et al. 
1987).  HDL is higher and TC:HDL lower in warmer compared to colder months of the year. 
Also, LDL and TAG have been shown to be elevated in colder months in the elderly 
(Woodhouse et al. 1993).  The majority of subjects in the current study started their intervention 
in a warmer month and finished in a colder month.  The change in blood lipids with season may 
be explained by changes in plasma volume (Frohlich et al. 1997).  Plasma volume is expanded in 
summer months to aid with thermoregulation and possibly due to increased physical activity 
levels, and this could dilute lipid concentrations (Ockene et al. 2004).  Experiment I is limited in 
its interpretation as the time of year was not controlled during the intervention.  The confounding 
factor of season was controlled for in Experiment I by randomly assigning subjects to the 
treatment groups. 
 
4.2.2 Inflammation and Alpha-Linolenic Acid 
The results of the Experiment II indicate that older men supplementing with ALA during 
12 weeks of strength training decreased the concentration of interleukin-6 with no effect in older 
women.  Also, this experiment indicated that TNF-α was modified in a similar pattern as IL-6 
although the results were not significant.  As supplementation with ALA did not result in a 
significant decrease in the cytokines measured in older women it is possible that the conversion 
of ALA to the longer ω-3 fatty acids was inhibited due to the decrease in the estrogen production 
after menopause (Burdge 2006).  Data indicates that delta-6 desaturase activity (i.e. the enzyme 
responsible for the conversion of ALA to EPA) is increased in postmenopausal women on 
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hormone replacement therapy (Stark et al. 2003) and lactating women (Francois et al. 2003).  
This evidence suggests that postmenopausal women not on hormone replacement therapy would 
have decreased amounts of ALA conversion to EPA due to decreased estrogen concentrations.  
Earlier research with ALA in humans has shown a decrease (Caughey et al. 1996; Mantzioris et 
al. 2000; Nelson and Hickey 2004) or no change (Kew et al. 2003; Thies et al. 2001a; Wallace et 
al. 2003) in pro-inflammatory cytokines including IL-6, TNF-α, IL-1β, and the acute phase 
protein C-reactive protein.  There are a few methodological differences between the studies to 
explain varying results.  The dose of ALA given in each study varied substantially.  In the 
studies indicating a decrease in inflammatory markers a minimum dose of 9 g·d
-1
 (range 9.0 – 
13.7 g·d
-1
) was used, while the studies indicating no effect used doses ranging from 2.0 to 9.5 
g·d
-1
.  A recent review on ALA metabolism to the longer chain fatty acids concluded that ALA 
conversion to EPA is approximately 5% while its conversion to DHA is never more than 1% 
(Plourde and Cunnane 2007).  Subsequently, studies evaluating the anti-inflammatory effect of 
ALA supplementation using smaller doses are unlikely to see an effect as conversion to the 
longer chain metabolites, which likely mediate the inflammatory reaction, will not be as great.  
Assuming that there was 5% conversion of ALA to EPA, our study would result in an increase of 
approximately 700 mg of EPA per day.  Recent reviews suggest that  EPA and DHA fatty acids 
have positive beneficial effects with doses less than 1 g·d
-1
 on risk factors for cardiovascular and 
inflammatory disease (Breslow 2006; Ergas et al. 2002).  Further there may be a sex effect with 
ALA supplementation.  All of the studies that showed a decrease in inflammatory markers were 
completed in men (Caughey et al. 1996; Mantzioris et al. 2000; Nelson and Hickey 2004) while 
two of the studies indicating no effect of ALA supplementation on inflammatory markers were 
done in mixed populations of women and men (Kew et al. 2003; Thies et al. 2001a) and the 
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statistical analyses used did not account for a sex effect.  Thus, there may have been a sex 
difference present in these studies, but it could not be determined with the analysis utilized.  One 
of these studies (Kew et al. 2003) evaluated a sample population with a large age range (25-72 
years) and did not determine whether there was a beneficial effect on inflammation in relation to 
different age groups.  Older adults are at an increased risk of inflammation while healthy 
younger adults are not likely ―hyper-inflamed‖, unless there is underlying pathology.  The results 
from Experiment II suggest that IL-6 and possibly TNF-α are decreased in older men but not 
older women supplementing with ALA during 12 weeks of strength training exercise. 
 
4.3 Other Mechanisms 
The first experiment indicated that flaxseed lignan complex supplementation during 
cardiovascular exercise has no effect on IL-6, TNF-α, or leukocyte cell count but may have an 
effect on metabolic syndrome risk factors, mainly by lowering TAG concentrations in older men.  
Previous in vitro research in macrophages has indicated that savinin, another type of lignan, is 
able to reduce TNF-α formation and T-cell propagation (Cho et al. 2001).  Thus, although 
Experiment I did not demonstrate efficacy in lowering markers of inflammation, there seems to 
remain potential for phytoestrogens to impact immune system function.  The most possible 
mechanisms for control of metabolic syndrome by phytoestrogens seem to be the ligand binding 
activity of various phytoestrogens to nuclear receptors involved in fat and glucose metabolism 
(PPARs) (Kwon et al. 2006; Ricketts et al. 2005; Shen et al. 2006), while the effects of 
phytoestrogens on inflammation or immune system function are most likely regulated through 
NFκB (Dijsselbloem et al. 2004; Evans et al. 2001; Garcia Palacios et al. 2005; Harnish et al. 
2000; Kang et al. 2005; Vanden Berghe et al. 2006).  Interestingly, some in vitro research has 
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demonstrated reciprocal cross-talk between PPARγ and NFκB suggesting a novel pathway for 
the reduction of metabolic syndrome due to exacerbation of inflammation (Takada et al. 2005). 
The results of Experiment I did demonstrate an attenuation of metabolic syndrome risk 
along with a decrease in TAG concentration in older men.  Research on other phytoestrogens has 
indicated that the favorable modification of blood lipids and cholesterol is due to the ligand 
binding ability of phytoestrogens to perioxisome proliferator-activated receptors (PPAR).  Up-
regulation of PPARα and PPARγ, which would result in increased fatty acid β-oxidation via 
increased enzyme activity and enhanced glucose control, has been demonstrated with isoflavones 
in vitro (Kwon et al. 2006; Shen et al. 2006).  A recent human study in hypercholesterolaemic 
subjects indicated that 8 weeks of supplementation with flaxseed lignan complex lowered TC, 
LDL, and fasting glucose to a greater extent than placebo (Zhang et al. 2007).  Thus, flaxseed 
lignan complex may be effective in altering blood lipids in those with an increased risk of 
cardiovascular disease while having minimal effect in those without health risk due to abnormal 
blood lipids.  Likely, the effects observed in Experiment I on older men were mediated by one of 
the aforementioned mechanisms.  No direct measure of mRNA or protein content of the PPARs 
was done in this study so this mechanism remains speculative. 
Experiment II demonstrated that ALA supplementation was effective at lowering IL-6 
concentration in older men.  The conversion of ALA to the longer chain fatty acids may be but 
one mechanism whereby ALA exerts its anti-inflammatory effects.  Recent in vitro and animal 
data indicate ALA is effective at inhibiting gene expression of iNOS, COX-2, and TNF-α by 
blocking NFκB and mitogen activated protein kinases (Ren and Chung 2007; Ren et al. 2007).  
Thus, although the metabolic conversion of ALA to EPA and DHA may be one mechanism 
whereby ALA is anti-inflammatory, ALA may have direct effects via other mechanisms 
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resulting in a decreased amount of inflammation.  More research should be completed to 
establish the mechanism(s) by which ALA reduces inflammation.  Also, more randomized 
controlled trials evaluating ALA effects on inflammation in various ages, genders, and diseased 
conditions is warranted.  In agreement with the above research, the results of the second 
experiment suggest that ALA supplementation during strength training reduces IL-6 in older men 
but has no effect in women. 
 
4.4 Limitations 
 Although the research conducted in Experiment I and II was done in a randomized, 
controlled fashion there are limitations associated with the studies.  Each experiment was lacking 
a non-exercise control group.  The sample reflects the attributes of largely urban, socio-
economically middle class, healthy, Caucasian older adults and thus, would only be 
generalizable to this demographic.  Also, the participants recruited for the studies were highly 
motivated to exert health change or improvement by the dietary and exercise protocols used in 
the research.  Thus, the results may only be generalizable to older individuals who are health 
conscious.  The food frequency questionnaires utilized reflect self-reported data of typical 
dietary habits which may under or over-predict characteristic nutrient intake.  In the second 
experiment subject motivation could have influenced the 1-RM strength testing.  Also, a stress 
response could be associated with drawing blood in some individuals which might affect the 
cytokine concentration. 
 Another limitation of this thesis is that the intensity of exercise prescribed between the 
two studies was different.  In the first experiment, intensity would be considered light to 
moderate while in the second experiment, intensity would be considered moderate to vigorous.  
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Nieman (Nieman 2003) has suggested that there is a J-curve relationship between exercise 
intensity and immune function.  This theory states that sedentary individuals may be at an 
increased risk of immune function abnormalities as opposed to those who are moderately active.  
Also, the theory states that heavy physical exertion, such as that type of exercise observed in 
highly trained athletes (over-reaching, over-training), will reduce immune system function and 
could leave an individual immuno-compromised.  Although the intensity of exercise was 
different between the two studies in this thesis, it is unlikely that the intensity of exercise was 
high enough in either study to promote immunosuppression.  The difference between low and 
moderate intensity exercise in terms of immune function is not known, especially in older 
exercising adults.  The current recommendations for health benefits associated with physical 
activity in older adults include accumulating at least 30 minutes of moderate intensity activity on 
most days of the week or a volume of exercise corresponding to 1000 kcal·wk
-1
 of energy 
expenditure (1998; Nelson et al. 2007; Paterson et al. 2007).  Nieman (Nieman 2003) argues that 
this dose of exercise has health benefits and that it is likely effective for improving immune 
function.  The strategy employed in Experiment I was to prescribe enough exercise to elicit a 
minimum of 1000 kilocalories of energy expenditure for each week of the study intervention.  
Although there is evidence to support the J-curve theory, especially in highly trained athletes, 
there is a shortage of clinical evidence suggesting that moderate intensity activity is able to 
enhance immune function.  An analysis of the scientific evidence supporting the positive role of 
moderate intensity exercise in reducing inflammation is only beginning to emerge.  More long-
term clinical and basic research is needed to establish how the type, intensity, duration, and 
frequency of exercise will influence inflammation, especially in populations that are already 
immunocompromised such as the elderly. 
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4.5 Future Research 
 Some, (de Kleijn et al. 2002; Kreijkamp-Kaspers et al. 2004), but not all (van der Schouw 
et al. 2005) epidemiological data suggests a positive association between dietary phytoestrogen 
consumption and risk factors for metabolic syndrome and cardiovascular disease in post-
menopausal women.  Also, phytoestrogen supplementation has been found to alter markers of 
inflammation in prospective research (Huang et al. 2005; Jenkins et al. 2002).  The current 
research shows potential for the effectiveness of phytoestrogens to exert positive health effects in 
older men.  Longer, prospective randomized trials utilizing various types of phytoestrogens are 
needed to elucidate which type(s) is/are most valuable for improving the health of older adults.  
However, more research on the possible negative health effects of high amounts of 
phytoestrogen consumption is warranted as some data indicates negative effects on the immune 
system in animal models (Selvaraj et al. 2005; Yellayi et al. 2002; Yellayi et al. 2003).  Finally, 
it is suggested that further basic research on the mechanisms involved in the beneficial or 
detrimental effects of phytoestrogens on health be intensified to determine the usefulness of 
phytoestrogens in health maintenance. 
 Higher intakes of ALA in the diet are consistently associated with lower amounts of 
inflammatory mediators in epidemiological data (Ferrucci et al. 2006; Lopez-Garcia et al. 2004; 
Yoneyama et al. 2007).  Prospective interventional research on ALA is limited and demonstrates 
conflicting results in relation to ALA‘s effectiveness in lowering inflammatory markers.  Data 
from Experiment II suggests ALA may have a negative effect on muscle, especially in older 
women.  Further research evaluating the effects of ALA supplementation on skeletal muscle is 
needed.  Different inflammatory modification mechanisms may be at work with ALA 
supplementation in older men versus women; this problem needs to be addressed more fully.  
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Age differences with respect to ALA supplementation should also be addressed.  Although 
Dietary Reference Intake values are developed for essential polyunsaturated fatty acids, the 
establishment of an appropriate dietary balance between ω-3 and ω-6 fatty acids requires further 
investigation especially in specific groups (inflammatory conditions, aging, and frailty).  
Ultimately, the issue of dietary ratio between essential fatty acids is not a new research debate, 
but it is a problem that requires intensive investigation to establish the necessary equilibrium 
between these essential nutrients for optimal health. 
 
4.6 General Conclusion 
The results of these two experiments suggest that the components of flaxseed used as 
supplements were effective at alleviating some of the risk factors associated with chronic disease 
in older men.  It is unknown why flaxseed did not have a similar effect in older women.  It is 
suggested that older men ingest flaxseed or its components to produce favorable effects in 
reducing disease risk.  Older women should not follow the same recommendation until more 
research is done to determine the underlying mechanism whereby flaxseed may be ineffective in 
reducing disease risk in older women.  From this research, one can conclude that the lignan 
component of flaxseed will attenuate an increase in metabolic syndrome risk observed with 
aging and that the oil component of flaxseed will reduce inflammatory markers in older men.  
Further, it can be concluded that the lignan component has no effect on inflammation whereas 
the oil component is effective at reducing inflammation.  Those older male individuals interested 
in reducing inflammation should choose flaxseed oil as an effective means of doing so.  Those 
older female individuals interested in supplementing with flaxseed components would be prudent 
to refrain from doing so as the lignan or oil from flaxseed did not demonstrate efficacy in this 
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research and thus, represents an unnecessary cost for older females interested in nutritional 
supplementation for improving health.   
Although there was no true control group to compare results to in this research, the 
evidence from the placebo groups in both experiments suggest that cardiovascular exercise 
training or resistance training in older adults was not effective for reducing inflammation as 
assessed by inflammatory cytokines.  This is in contrast to previous research which suggests that 
exercise may be effective in lowering inflammation in older adults.  Although speculative, it may 
be that the intensity or volume of exercise was either not enough or too much to elicit an anti-
inflammatory effect.  Further research on the mechanisms and clinical evidence for or against the 
anti-inflammatory nature of exercise in older adults is warranted.
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Glossary 
 
 
Term Explanation 
Acute phase protein Early inflammatory proteins made by hepatocytes in response to IL-
6, TNF and IL-1β.  Acute phase proteins (particularly C-reactive 
protein) bind to cell wall components of microbes and activate 
complement. 
 
Aglycone Is the noncarbohydrate group (as a phenol or alcohol) combined with 
the sugar portion of a glycoside. 
 
Antibody Secreted immunoglobulin that is produced by B lineage plasma cells 
and binds to specific antigens.  Able to recognize antigens that are 
either soluble or fixed in a tissue or on a cell surface. 
 
Antigen Entity (such as an element of an infectious pathogen, cancer, or inert 
injurious material, or of a self-tissue) that can bind to the antigen 
receptor of a T or B cell.  This binding does not necessarily lead to 
lymphocyte activation. 
 
Apoptosis The controlled death of a cell mediated by certain intracellular 
proteases (including caspases) that cause the orderly breakdown of 
the cell nucleus and its DNA.  Death occurs without the release of 
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internal contents and without triggering inflammation.  The intrinsic 
apoptotic pathway involves the release of mitochondrial cytochrome 
c, while the extrinsic apoptotic pathway is triggered by the 
engagement of death receptors such as Fas and TNFR.  Apoptosis is 
also called ―programmed cell death‖. 
 
Arachidonic Acid Arachidonic acid is a ω-6 polyunsaturated fatty acid that is present in 
the phospholipids (especially phosphatidylethanolamine, 
phosphatidylcholine and phosphatidylinositides) of membranes of the 
body's cells, and is highly enriched in the brain. It is a precursor in 
the production of eicosanoids: the prostaglandins, thromboxanes, 
prostacyclin and the leukotrienes (through enzymes including 
cyclooxygenase, lipoxygenase and peroxidase). The production of 
these derivatives, and their action in the body, are collectively known 
as the arachidonic acid cascade which affects inflammation and other 
cellular functions. 
 
Basophil Circulating granulocyte with an irregularly shaped nucleus.  Contains 
granules that stain a dark blue color with basic dyes.  Basophil 
granules contain heparin and vasoactive amines, as well as many 
enzymes capable of promoting inflammation. 
 
B-cell Lymphocytes that have antibody molecules on the surface and 
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comprise the antibody-secreting plasma cells when mature; also 
known as B-lymphocyte.  B-cells are distinguished phenotypically by 
the cell surface expression of B-cell receptors. 
 
 
Bradykinin One of a family of small peptide inflammatory mediators that 
circulate in inactive form in the blood until cleaved by blood clotting 
enzymes or enzymes released from damaged cells.  These peptides 
cause increased vascular permeability, smooth muscle contraction, 
and pain. 
 
Cachexia Wasting of the body due to uncontrolled cellular catabolism.  
Cachexia is usually induced by high levels of TNF. 
 
Chemokine Chemotactic cytokines.  Structural families include the C, CC, CXC, 
and CX3C subgroups.  See also chemotaxis. 
 
Chemotactic factors Factors derived from either host or bacterial metabolism that can 
induce chemotaxis.  Includes chemokines, kallikrein, platelet 
activating factor, thrombin, and the anaphylatoxin C5a. 
 
Chemotaxis The directed movement of cells along the concentration gradient of a 
chemotactic factor.  Serves to draw neutrophils, lymphocytes, and 
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other leukocytes from the circulation into an injured or infected 
tissue. 
 
Cluster of differentiation 
(CD) 
 
A CD number in the unique designation given to a cell surface 
protein identified serologically by the binding to that protein of a 
cluster of different antibodies.  That is, the CD number points to the 
specific collection of serological epitopes furnished by the protein. 
 
CD3 The CD3 antigen protein complex is composed of three distinct 
chains (CD3γ, CD3δ and CD3ε) in mammals, that associate with 
molecules known as the T cell receptor (TCR) and the δ-chain to 
generate an activation signal in T lymphocytes. The TCR, δ-chain 
and CD3 molecules together comprise the TCR complex. 
 
CD4 Glycoprotein found on the surface of helper T-cells which usually 
functions to facilitate recognition by T cell receptors of antigens 
complexed with molecules of a class that are found on the surface of 
antigen presenting cells (as B cells and macrophages) and are the 
product of genes of the major histocompatibility complex class II 
proteins. 
 
CD8 Glycoprotein found on the surface of cytotoxic T-cells which usually 
functions to facilitate recognition of cytotoxic T cell receptors of 
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antigens complexed with molecules of a class that are found on the 
surface of most nucleated cells and are the product of genes of the 
major histocompatibility complex class I proteins 
 
CD16 Alson known as Fc receptor.  A transmembrane glycoprotein that is a 
member of the immunoglobulin superfamily which exists in two 
isoforms that 1) functions to mediate phagocytosis and antigen 
dependent cell-mediated cytotoxity and 2) does not mediate 
phagocytosis or antigen dependent cell-mediated cytotoxity but 
serves as a trap for immune complexes. 
 
CD56 Also known as neural cell adhesion molecule.  A membrane 
glycoprotein and member of the immunoglobulin superfamily that 
has various isoforms on a variety of cell lines which functions as an 
adhesion molecule in neuronal tissue and NK cells but its function in 
T-cells is not known. 
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Complement A series of thirty serum and membrane proteins that are involved in 
humoral immunity and inflammation. 
 
C-reactive protein An acute phase protein released by hepatocytes into the blood in 
response to stimulation by TNF and IL-6 usually in response to 
various abnormal states including inflammation.  Its release will 
result in activation of the complement cascade of events. 
 
Cyclooxygenase An enzyme that catalyzes the conversion of arachidonic acid to 
prostaglandins which has three isoforms (COX-1, COX-2, and COX-
3) of which COX-2 is involved in the cascade of events producing 
pain and inflammation while COX-1 is not involved in this cascade 
of events.  COX-1 is considered a constitutive enzyme, being found 
in most mammalian cells. More recently it has been shown to be 
upregulated in various carcinomas and to have a central role in 
tumorigenesis. COX-2, on the other hand, is undetectable in most 
normal tissues. It is an inducible enzyme, becoming abundant in 
activated macrophages and other cells at sites of inflammation.  Both 
COX-1 and -2 also oxygenate two other essential fatty acids – DGLA 
(ω-6) and EPA (ω-3) – to give the series-1 and series-3 prostanoids, 
which are less inflammatory than those of series-2. DGLA and EPA 
are competitive inhibitors with AA for the COX pathways. This 
inhibition is a major mode of action in the way that dietary sources of 
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DGLA and EPA (e.g. borage, fish oil) reduce inflammation. 
 
Cytotoxicity Having the ability to kill cells. 
 
Dendritic cells (DCs) Irregularly shaped phagocytic leukocytes with finger-like processes 
resembling the neuronal dendrites.  DC subsets arise from both the 
myeloid and lymphoid lineages and include conventional and 
plasmacytoid DCs.  Immature DCs in the tissues capture antigen.  
DCs activated by pro-inflammatory cytokines migrate to the draining 
lymph node and mature, upregulating expression of costimulatory 
molecules.  Mature DCs are the only antigen presenting cell capable 
of activating naïve T-cells. 
 
Eicosapentaenoic acid 
(EPA) 
 
A ω-3 polyunsaturated fatty acid found especially in fish oils. 
Endotoxic shock A sometimes fatal collapse of circulatory and metabolic systems 
induced by an overwhelming amount of cytokines (particularly IL-1 
and TNF) released into the circulation by macrophages in response to 
infection with gram-negative bacteria or their components (especially 
lipopolysaccharide).  Also known as septic shock. 
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Eosinophils Connective tissue granulocytes with bilobed nuclei and granules that 
stain reddish with acidic dyes.  The granules contain highly basic 
proteins and enzymes effective in the killing of larger parasites.  
Eosinophils also play a role in allergy. 
 
Erythrocytes 
 
Red blood cells. 
Extravasation To exude from a vessel (such as blood or lymph) into the surrounding 
tissue. 
 
Fibrin A white insoluble fibrous protein formed from fibrinogen by the 
action of thrombin especially in the clotting of blood. 
 
Fibroblasts A connective tissue cell of mesenchymal origin that secretes proteins 
and especially molecular collagen from which the extracellular 
fibrillar matrix of connective tissue forms. 
 
Fibrosis The formation of excessive fibrous tissue, as in a reparative or 
restorative process. 
Glycoprotein A conjugated protein in which the nonprotein group is a 
carbohydrate.  Also known as a glucoprotein. 
 
Granulocytes Myeloid leukocytes that harbor large intracellular granules containing 
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 microbe-destroying hydrolytic enzymes.  Include neutrophils, 
basophils, and eosinophils. 
 
Granulocyte-colony 
stimulating factor 
(G-CSF) 
A colony stimulating factor produced by macrophages, endothelial 
cells, and fibroblasts that acts to promote the maturation of precursor 
cells into granulocytes. 
 
Hematopoietic cells Red and white blood cells. 
 
Heparin A glycosaminoglycan sulfuric acid ester that occurs especially in the 
liver and lungs, that prolongs the clotting time of blood by preventing 
the formation of fibrin. 
 
Hepatocyte Cells of the liver. 
 
Histamine A nitrogen containing compound in mammalian tissues that causes 
dilatation of capillaries, contraction of smooth muscle, and 
stimulation of gastric acid secretion, that is released during allergic 
reactions, and that is formed by the decarboxylation of histidine. 
 
5-Hydroxy Tryptamine 
 
Serotonin.  A monoamine neurotransmitter synthesized in 
serotonergic neurons in the central nervous system (CNS) and 
enterochromaffin cells in the gastrointestinal tract. 
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Interferons (IFN) Family of cytokines produced by cells upon infection by virus.  Type 
I (IFN α, β, and ω) are important in inhibiting proliferation and 
establishing an antiviral state in bystander cells.  Type II IFN (IFNγ) 
has multiple immunoregulatory and pro-inflammatory effects in 
addition to its anti-proliferative and anti-viral activities, and is 
essential for a hyperactivated macrophage. 
 
IL-1ra Interleukin-1 receptor antagonist; will bind to IL-1 receptors but will 
not produce an effect thus reducing the ability of IL-1 to exert an 
effect. 
 
Ig isotype switching During the initial stages of a B-cell‘s primary response to antigen, it 
produces and secretes IgM.  Later in the primary response of during 
subsequent responses, different heavy chain isotypes may be 
expressed by the progeny of the original IgM-producing clone.  Such 
―switching‖ occurs at the DNA level, resulting in the production of 
an Ig protein with the capability of producing antibodies of the same 
specificity but different isotypes. 
 
Immuoglobulin (Ig) Y-shaped antigen binding protein expressed by B lineage cells.  An 
Ig monomer is composed of two identical light and two identical 
heavy chains.  In its plasma membrane-bound form, an Ig is the 
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antigen-binding component of the B-cell receptor complex.  In its 
secreted form, an Ig is an antibody.  Igs were originally named for 
both their involvement in immunity and their presence in the gamma 
globulin fraction of plasma proteins. 
 
Immunosenescence The process whereby the immune system diminishes its functional 
ability as a result of the aging process or some other 
immunological/inflammatory disease. 
 
Inducible nitric oxide 
synthase (iNOS) 
Enzyme induced mainly in phagocytes by the presence of microbial 
products or pro-inflammatory cytokines.  Converts arginine to 
citrulline and nitric oxide, which is toxic to endocytosed cells. 
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Intercellular adhesion 
molecule (ICAM) 
Molecules that promote adhesion between cells.  There are several 
different forms of ICAM. ICAM-1 is continuously present in low 
concentrations in the membranes of leukocytes and endothelial cells. 
Upon cytokine stimulation, the concentrations greatly increase. 
ICAM-1 can be induced by IL-1 and TNFα and is expressed by the 
vascular endothelium, macrophages and lymphocytes. 
 
Kupffer cells Macrophage-like cells in liver sinusoids. 
 
Leukocytes White blood cells, including lymphocytes, granulocytes, monocytes, 
macrophages, NK, and NKT cells. 
 
Leukotrienes Lipid inflammatory mediators whose formation is initiated when 
phospholipids in the membranes of macrophages, monocytes, 
neutrophils, and mast cells are degraded and converted to arachidonic 
acid.  Metabolism of arachidonic acid via the lipoxygenase pathway 
then produces leukotrienes. 
 
Lignan A chemical compound found in plants. Lignans are one of the two 
major classes of phytoestrogens, which are antioxidants found in a 
variety of plants which includes flaxseeds, pumpkin seeds, sesame 
seeds, rye, soybeans, broccoli, beans, and some berries. The other 
class of phytoestrogens is the isoflavones. Plant lignans are 
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polyphenolic substances derived from phenylalanine via dimerization 
of substituted cinnamic alcohols to a dibenzylbutane skeleton. 
 
Lipopolysaccharide 
(LPS) 
Component of gram-negative bacteria bacterial cell walls that 
generates endotoxin and induces endotoxic shock.  Will bind to toll 
like receptor-4. 
 
Lipoxygenase Are iron-containing enzymes that catalyse the dioxygenation of 
polyunsaturated fatty acids. 5-lipoxygenase (5-LO), which transforms 
EFAs into leukotrienes. Substrates and leukotriene products of 5-LO 
include: 1) Arachidonic acid yields the 4-series leukotrienes (LTB4, 
LTC4, LTD4, LTE4 — generally proinflammatory); 2) 
Eicosapentaenoic acid  yields the 5-series (LTB5, LTC5, LTD5, 
LTE5 — antiinflammatory); 3) Gamma-linolenic acid yields the 3-
series via the DGLA intermediary. 5-LO catalyzes oxidation of AA at 
the 5-position to yield 5-hydroperoxyeicosatetraenoic acid (5-
HPETE). Two other lipoxygenases, 12-LO and 15-LO, act at the 12- 
and 15-positions, yielding 12- and 15-HPETE. These pathways lead 
to the leukotriene 12-hydroxyeicosatetraenoic acid (12-HETE) and to 
the lipoxins, respectively. 
 
Lymphoid cells Cells that develop from the common lyphoid progenitor, including T 
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and B lymphocytes, NK cells, and NKT cells. 
 
Lysis Refers to the death of a cell by bursting, often by viral or osmotic 
mechanisms that compromise the integrity of the cellular membrane.  
A process of of disintegration or dissolution particularly of cellular 
processes. 
 
Macrophage Powerful phagoctye that also secretes a large array of proteases, 
cytokines, and growth factors and can act as an antigen-presenting 
cell. 
 
Macrophage activating 
factor 
 
Factors secreted by stimulated lymphocytes that prime macrophages 
to become nonspecifically cytotoxic to tumors and modulate the 
expression of macrophage cell surface Ig antigens. 
 
Macrophage 
inflammatory protein 
 
A chemokine of the CC subgroup produced by monocytes, 
macrophages, neutrophils, and endothelium 
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Major histocompatibility 
complex (MHC) 
Region of the genome containing genes encoding the chains 
composing the MHC class I, class II, and class III proteins.  
Originally defined as a cluster of genes encoding proteins controlling 
tissue compatibility between individuals.  The function of the 
proteins encoded in the MHC class I and class II regions is to 
combine with antigenic peptides, both self and nonself, and display 
them on the surface of host cells for perusal by T-cells.  MHC class I 
molecules are expressed on most nucleated cells and present peptides 
to CD8-expressing Tc cells.  MHC class II molecules are expressed 
only on antigen presenting cells that present peptides to CD4-
expressing Th cells.  The class I and class II MHC genes are highly 
polymorphic in many species, including mice and humans.  The class 
III MHC genes encode various protiens important in complement 
activation, inflammation, and stress responses. 
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Mast cells Granule-containing leukocytes with non-lobed nucleus derived from 
a lineage seprate from that giving rise to other granulocytes.  The 
cytoplasmic granules of mast cells stain like those of basophils and 
also contain heparin and histamines, but are more numerous and 
smaller than those of basophils.  Mast cells are found in both mucosal 
and non-mucosal tissues and their degranulation is important for 
inflammation and allergy. 
 
Monocytes Myeloid cells in the blood.  Monocytes circulate in the blood for 
approximately 1 day before entering the tissues and serous cavities 
and maturing into macrophages. 
 
Myeloid cells Cells that develop from the common myeloid progenitor, including 
erythrocytes, neutrophils, monocytes/macrophages, eosinophils, 
basophils, and megakaryocytes. 
 
  
203 
 
Natural killer cells (NK-
cells) 
Lymphoid lineage cells that recognize nonself entities with broad 
specificity.  NK cells are activated when a target cell expresses 
ligands that bind to NK activatory receptors but lacks MHC class I to 
engage NK inhibitory receptors.  NK cells bear cytoplasmic granules 
that allow them to kill targets such as virus-infected and tumor cells 
by natural cytotoxicity.  NK cells also secrete inflammatory 
cytokines and carry Fc receptrs mediating antibody dependent cell-
mediated cytotoxicity. 
 
Neutrophils Most common leukocytes in the body.  Respond immediately in great 
numbers to tissue injury or pathogen attack.  Neutrophils are both 
granulocytes and phagocytes, and are distinguished by their 
irregularly shaped multi-lobed nuclei and cytoplasmic granules that 
stain neutrally.  Also called ―polymorphonuclear cells‖ (PMNs). 
 
Neutrophilia Greatly increased number of neutrophils in the circulation. 
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Nuclear factor kappa B 
(NF-κB) 
A family of heterodimeric transcription factors.  NF-κB activation is 
induced by engagement of the B-cell receptor, T-cell receptor, and 
many cytokine/growth factor receptors.  In resting cells, NF-κB is 
held inactive in the cytoplasm by binding to the IκB inhibitor.  
Receptor engagement stimulates intracellular signaling that activates 
the IKK kinase, which phosphorylates IκB, triggering its degradation.  
Free NF-κB enters the nucleus and binds to the κB DNA binding 
motif, initiating new gene transcription. 
 
Nutraceutical A combination of "nutritional" and "pharmaceutical" and refers to 
foods thought to have a beneficial effect on human health. It can also 
refer to individual chemicals which are present in common foods 
(and therefore may be delivered in a non-drug form). Many such 
nutraceuticals are phytonutrients.  Sometimes called functional foods. 
 
Opsonization Enhanced phagocytosis of a pathogen or macromolecule due to the 
binding of molecules that interact with cell surface receptors on 
phagocytes. 
 
Phagocytosis The engulfing and ingesting of bacteria and other foreign particles by 
phagocytes. 
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Pleiotropic Usually used in genetics to refer to the ability of one gene to express 
multiple phenotypic characteristics.  In relation to immunology and 
cytokines, the word refers to a cytokine that is able to produce an 
effect in multiple cell types. 
 
PMNL Polymorphonuclear leukocytes.  A type of white blood cell (e.g., 
neutrophil) containing more than one nucleus. PMNL are phagocytes 
(scavenger cells) important in immune defense, particularly against 
cell-free organisms such as fungi. 
 
Prostaglandin Any of various oxygenated unsaturated cyclic fatty acids of animals 
that are formed as cyclooxygenase metabolites especially from 
unsaturated fatty acids (as arachidonic acid) composed of a chain of 
20 carbon atoms and that perform a variety of hormonelike actions 
(as in controlling blood pressure or smooth muscle contraction). 
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Reactive oxygen species 
(ROS) 
Species such as superoxide, hydrogen peroxide, and hydroxyl radical 
that contain unpaired electrons and are associated with cell damage.  
ROS will ‗steal‘ electrons from nearby tissue (such as lipid 
membranes or proteins) to increase their stability. If the ability to 
neutralize increased amounts of ROS is compromised it may result in 
increased cellular damage via apoptosis.  
 
Septic shock See endotoxic shock. 
 
T-cell Also known as T-lymphocyte generally concentrated in the 
secondary lymphoid tissue in a resting state.  T-cells can be 
distinguished phenotypically by the cell surface expression of T-cell 
receptors. 
 
T-cytotoxic cells  
(Tc cells) 
Cytotoxic T-cells that recognize nonself-peptide presented on MHC 
class I molecules expressed by a target cell.  Upon activation, Tc 
cells differentiate into cytotoxic T lymphocyte effector cells that kill 
target cells by perforin/granzyme-mediated cytotoxicity or by 
secretion of cytotoxic cytokines.  Tc cells generally express the CD8 
coreceptor. 
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TGF-β Transforming growth factor β.  A cytokine with three isoforms that 
has multiple roles including adhesion, proliferation, differentiation, 
transformation, chemotaxis, and immunoregulation.  Particularly 
important for stimulating angiogenesis. 
 
Th1 An isoform of Th cells.  See T-helper cells. 
 
Th2 An isoform of Th cells.  See T-helper cells. 
 
T-helper cell T-cells that express the CD4 glycoprotein and are involved in 
stimulating and directing the immune system by aiding antibody cell 
switching, activating cytotoxic T-cells, and by supporting the 
bactericidal action of macrophages and phagocytes. 
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Thromboxane A member of the family of lipids known as eicosanoids. It is 
produced in platelets by thromboxane-A synthase, which is produced 
from the endoperoxides by the cyclooxygenase (COX) enzyme from 
arachidonic acid.  Thromboxane is a vasoconstrictor and a potent 
hypertensive agent, and it facilitates the clumping of platelets. It is in 
homeostatic balance in the circulatory system with prostacyclin, a 
related compound. 
 
Thymus gland A small bilobed organ located above the heart, consisting of the 
medulla, the inner and outer cortex, and the subcapsule.  The thymus 
is the primary lymphoid tissue in which thymocytes develop into 
mature T-cells. 
 
ω-3 fatty acid A polyunsaturated fatty acid that has the final double bond in the 
hydrocarbon chain between the third and fourth carbon atoms from 
the end of the molecule opposite that of the carboxylic acid group.  
Predominantly found in fish oils, vegetable oils, and green leafy 
vegetables. 
 
 
Compiled from Mak & Saunders, 2006 
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University of Saskatchewan 
Biomedical Research Ethics Board (Bio-REB) 02-Feb-
2005 
Certificate of Approval 
  
PRINCIPAL INVESTIGATOR DEPARTMENT                                                                                          Bio # 
Philip D. Chilibeck                                                     Kinesiology                                                                               04-169 
INSTITUTION (S) WHERE RESEARCH WILL BE CARRIED OUT 
College of Kinesiology Royal University Hospital 
105 Gymnasium Place 103 Hospital Drive 
Saskatoon SK S7N 5C2 Saskatoon SK S7N OW8 
SUB-INVESTIGATOR(S) 
JayBiem 
Punam Pahwa 
Susan J. Whiting 
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HEART AND STROKE FOUNDATION OF SASKATCHEWAN 
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Protocol Flaxseed Lignan and Exercise Training for Improving Blood Lipid Levels 
ORIGINAL APPROVAL DATE CURRENT EXPIRY DATE 
08-Sep-2004 Ol-Sep-2005 
CERTIFICATION UPDATE APPROVED ON 
Consent Form (28 Jan 05) 02-Feb-2005 
CERTIFICATION 
The University of Saskatchewan Biomedical Research Ethics Board (Bio- REB) has reviewed the above-named research project including 
the protocol and consent form, where applicable. The proposal was found to be acceptable on ethical grounds. The principal investigator 
has the responsibility of ensuring that the authorized research is carried out according to governing law. This Approval is valid for the 
above time period provided there is no change in experimental protocol or in the consent process. 
ONGOING REVIEW REQUIREMENT(S) / REB ATTESTATION 
In order to receive annual renewal, a status report must be submitted to the Chair for Committee consideration within one month of the 
current expiry date each year the study remains open, and upon study completion. Please refer to the following website for further 
instructions: http://www.usask.ca/research/ethics.shtml. In respect to clinical trials, the University of Saskatchewan Research Ethics 
Board complies with the membership requirements for Research Ethics Boards defined in Division 5 of the Food and Drug Regulations 
and carries out its functions in a manner consistent with Good Clinical Practices. This approval and the views of this REB have been 
documented in writing. 
J7 °      ' I /   \ 
Barry D. McLennan, Ph.DC, Chair 
University of Saskatchewan 
Biomedical Research Ethics Board (Bio-REB) 
  
Please send all correspondence to: 
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of
 Research Services, University of Saskatchewan 
Room 3403, 110 Gymnasium Place Box 5000 
RPO University Saskatoon, SK S7N 4J8 Phone: 
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Consent Form 
 
Title: Effectiveness of flax lignan and exercise training for improving lipid 
profiles    
 
Names of Researchers: Philip D. Chilibeck, Ph.D., Associate Professor, College 
of Kinesiology, University of Saskatchewan (966-1072 or 343-6577), role: 
principal researcher; H. Jay Biem, M.D., Department of Medicine, Royal 
University Hospital, University of Saskatchewan (966-7951), role: clinical trials 
consultant, Susan Whiting, Ph.D., Professor, College of Pharmacy and Nutrition, 
University of Saskatchewan (966-5837), role: nutritional analyses, Punam Pahwa, 
Assistant Professor, Department of Community Health and Epidemiology, 
University of Saskatchewan (966-7941), role: statistical consultant, Stephen 
Cornish, M.Sc. (student researcher supervised by Dr. Chilibeck), College of 
Kinesiology, University of Saskatchewan, phone: 966-6505. 
 
Sponsor: Heart and Stroke Foundation of Saskatchewan; Archer Daniels Midland 
(supplier of the flax lignan nutritional supplement) 
 
You are being asked to participate in a research study because you are of the age 
where you may be at risk for high cholesterol levels. This study involves the use of 
a dietary supplement derived from flaxseed (flax lignan) and exercise training 
(brisk walking or slow jogging) for improving cholesterol levels. Exercise training 
is thought to raise the levels of ―good‖ cholesterol (high density lipoproteins) while 
the flax supplement is thought to lower the level of ―bad‖ cholesterol (low density 
lipoproteins). 
 
Before you decide, it is important for you to understand what the research involves.  
This consent form will tell you about the study, why the research is being done, 
what will happen to you during the study and the possible benefits, risks and 
discomforts.  If you wish to participate, you will be asked to sign this form.  Your 
participation is entirely voluntary, so it is up to you to decide whether or not to take 
part in this study. If you do decide to take part in this study, you are free to 
withdraw at any time without giving any reasons for your decision nor will you 
lose the benefit of any medical care to which you are entitled or are presently 
receiving. Please take time to read the following information carefully and to 
discuss it with your family, friends, and doctor before you decide. 
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Purpose of the study: The purpose of the study is to determine the effectiveness 
of combining exercise training and flax lignan supplementation for improving 
blood cholesterol levels in individuals who are at risk for high cholesterol levels. 
 
Possible benefits of the study: You may improve you blood cholesterol levels and 
lower your body fat level. These results are not guaranteed. 
 
Procedures: You will initially be given a questionnaire that asks whether you are 
at risk for performing exercise. This will take several minutes to complete. If it is 
determined you are at risk, we will ask you to obtain permission from your family 
physician before entering the study. 
 
You will be randomized by chance to one of two groups (i.e. There will be an 
equal chance of being assigned to either group). You will have an equal (one in 
two) chance of being assigned to either group. The first group will receive flax 
lignan dietary supplement (500 mg per day) and will participate in an exercise 
program of brisk walking or slow jogging six days per week, 60 minute per day, 
for 6 months. The second group will receive a placebo (i.e. an inactive substance 
that looks identical to the flax lignan dietary supplement but contains no active 
ingredients) and will participate in the same exercise training program. The study 
is ―double blind‖, that is, neither you nor the investigators will know whether you 
are on the flax lignan supplement or placebo until the study is over. In case of 
emergency, the code on the double blind can be broken so we can tell whether you 
are on the flax lignan or placebo. If you agree to be in the study, we will do the 
following measurements on you: 
 
1) Blood cholesterol, and glucose levels will be measured at the start of the 
study, after 2 months, after 4 months, and after 6 months. Approximately 11 
mL of (about 2.5 teaspoons) blood will be collected at each time point, after 
a 12 hour fast. This procedure will take about 5 minutes. 
2) Body composition (i.e. lean tissue, fat, and bone mass) will be assessed at 
the start of the study and 6 months by dual energy X-ray absorptiometry. 
This involves lying still on a table for approximately 10 minutes while your 
body composition is assessed. Dual energy X-ray absorptiometry uses X-ray 
beams that are absorbed differently by fat, muscle, and bone. From this we 
can determine your fat, muscle, and bone mass. 
3) Body mass, height, waist girth, and two skinfolds from your trunk area 
(measured with calipers, that is, an instrument which pinches your fat 
skinfold) will be assessed at the start of the study and after 6 months. This 
procedure takes about 5 minutes. 
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4) Your diet will be assessed at the start of the study and after 6 months by a 
food frequency questionnaire. This will take about 30 minutes to complete. 
5) Your aerobic fitness will be assessed at the start of the study and after 6 
months with a ―step test‖. This involves stepping up and down a set of 2 
steps at a rate which increases every 3
 
minutes. The test stops when you 
reach a heart rate level corresponding to 85% of your age-predicted maximal 
heart rate. This test can last between 3 and 20 minutes, depending on your 
fitness level. 
 
With your permission, your family physician will be informed of your enrolment 
and of your test results. 
 
Foreseeable risks, side effects or discomfort: There is radiation exposure from 
the dual energy X-ray absorptiometry but this is considered minimal. This is about 
the same amount of radiation as you would be exposed to during a return airplane 
flight from Saskatoon to Toronto, and is less than the amount of radiation you 
would be exposed to during a regular X-ray. 
 
There is a risk of injury during exercise testing or training. This will be minimized 
by proper warm-up procedures and supervision by qualified exercise trainers. 
 
There will be some discomfort when blood is drawn for testing cholesterol levels. 
Bruising or infection at the sight of the blood draw is a possibility, but care will be 
taken to minimize these risks. 
 
The side effects of flax lignan are unknown.  
 
There may be unforeseen and unknown risks during the study, or after the study 
has been completed. 
 
Alternatives to this study: 
You do not have to participate in this study to improve your cholesterol levels or 
body composition. Your cholesterol levels can be improved by altering your diet 
(i.e. lowering saturated fat intake) or by a variety of drugs that may be prescribed 
by your family physician. Your body composition can also be improved by altering 
your diet. You can discuss these options with your doctor before deciding whether 
or not to participate in this research project. 
 
Research-Related Injury: There will be no cost to you for participation in this 
study. You will not be charged for the study nutritional supplements or any 
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research procedures. In the event you become ill or injured as a result of 
participating in this study, necessary medical treatment will be made available at 
no additional cost to you. By signing this document you do not waive any of your 
legal rights. 
 
Confidentiality: Precautions will be taken to protect your anonymity during the 
study. All data collected will be stored in a locked office in the College of 
Kinesiology. While absolute confidentiality cannot be guaranteed, every effort will 
be made to ensure that the information you provide for this study is kept entirely 
confidential.  Your name will not be attached to any information, nor mentioned in 
any study report, nor be made available to anyone except the research team.  It is 
the intention of the research team to publish results of this research in scientific 
journals and to present the findings at related conferences and workshops, but your 
identity will not be revealed. 
 
If you have questions concerning the study you can contact Dr. Philip Chilibeck at 
966-1072 or 343-6577 or Stephen Cornish (student researcher) at 966-6505. 
 
If you have any questions about your rights as a research subject or concerns about 
the study, you should contact the Chair of the Biomedical Research Ethics Board, 
c/o the Office of Research Services, University of Saskatchewan at (306) 966-
4053. 
 
If, during the course of this study, new information becomes available that may be 
related to your willingness to continue to participate, this information will be 
provided to you by the investigator. 
 
Your participation in the research is entirely voluntary. You are free to withdraw 
from this study at any time and this withdrawal will not affect your access to health 
care or other services. If you choose to enter the study and then decide to withdraw 
at a later time, all data collected about you during your enrolment in the study will 
be retained for analysis.  If you do withdraw from the study you will be informed 
of the treatment you were receiving (i.e. flax lignan or placebo). 
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Please read the following before signing this consent form: 
 
 I have read or have had this read to me and understood the research subject 
information and consent form.  
 I have had sufficient time to consider the information provided and to ask for 
advice if necessary.  
 I have had the opportunity to ask questions and have had satisfactory 
responses to my questions.  
 I understand that all of the information collected will be kept confidential 
and that the result will only be used for scientific objectives.  
 I understand that my participation in this study is voluntary and that I am 
completely free to refuse to participate or to withdraw from this study at any 
time without changing in any way the quality of care that I receive.  
 I understand that I am not waiving any of my legal rights as a result of 
signing this consent form.  
 I understand that there is no guarantee that this study will provide any 
benefits to me (if applicable).  
 I have read this form and I freely consent to participate in this study.   
 I have been told that I will receive a dated and signed copy of this form.   
 
Please notify my primary care physician of my participation in this study:  
Yes_____ 
No______ 
 
Research Subject‘s Signature:___________________   
 
 
Signature of the Individual responsible for conducting the consent process: 
 
______________________  
 
 
Date: ______________________ 
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Determining Your Heart Rate 
 
There are two simple ways to take your heart rate.  The first way is on your radial artery 
(on the side of your wrist closet to the thumb).  You will want to press down with the 
index and middle finger to find the “beating” of the artery.  You will count the number of 
“beats” you feel with this method in 15 seconds.  Always start counting at zero (0).  
Once you determine the number of beats in 15 seconds multiply the number by 4.  This 
will give you the number of beats per minute (bpm) that your heart is beating.  The 
second way to take your heart rate is on your carotid artery (on the neck).  The 
procedure is the same as above.  Use whatever method is easiest for you.  You are 
also able to determine your heart rate with a heart rate monitor.  This will display your 
heart rate on a watch that is worn on the wrist. 
 
Determining Your Training Zone 
 
When performing aerobic activity, a good way to monitor your progression in fitness is 
by utilizing target heart rate “zone” training.  This is the method of exercise prescription 
that we will use in prescribing exercise intensity in this study.  When using the target 
heart rate (THR) zone method of training, each individual will need to determine their 
maximum heart rate (MHR).  MHR is calculated from the following formula: 
MHR = 220-age 
 
Once you determine your maximum heart rate you will then be able to insert this value 
into the following table to determine what intensity (i.e. number of beats per minute) you 
should strive for in each of your exercise training sessions. 
 
Zone Type of Training Percent of MHR 
I Health Zone* 50-55% MHR 
II Base Fitness Zone* 55-65% MHR 
III Aerobic Zone (Extensive)* 65-70% MHR 
IV Aerobic Zone (Intensive)☻ 70-85% MHR 
V Anaerobic Zone (Sport 
Training)☻ 
85-90% MHR 
VI Maximum Zone (Sport 
Training)☻ 
90-100% MHR 
* These are the only three zones that will be used in this study. 
☻These zones are used for sport and elite fitness training and will not be used in this 
study. 
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TRAINING ZONES 
 
*Zone I: Health Zone (Warm up) --- 50 - 55% of maximum heart rate: The easiest zone 
and probably the best zone for people just starting a fitness program. It can also be 
used as a warm up for more serious walkers. This zone has been shown to help 
decrease body fat, blood pressure and cholesterol. It also decreases the risk of 
degenerative diseases and has a low risk of injury. 85% of kilocalories burned in this 
zone are fats. 
 
*Zone II: Base Fitness Zone (Fat Burning) --- 55 - 65% of maximum heart rate: This 
zone provides the same benefits as the healthy heart zone, but is more intense and 
burns more total kilocalories. The percent of fat kilocalories is still 85%. 
 
*Zone III: Aerobic Zone (Extensive Training) --- 65-70% of maximum heart rate: The 
extensive aerobic zone will improve your cardiovascular and respiratory system AND 
increase the size and strength of your heart. This is the preferred zone if you are 
training for an endurance event. More kilocalories are burned with 50% from fat. 
 
☻Zone IV: Aerobic Zone (Intensive Training) --- 70-85% of maximum heart rate:  The 
intensive aerobic zone will improve VO2 maximum (the highest amount of oxygen one 
can consume during exercise), increase the efficiency of the cardiovascular system, and 
elevate your ability to sustain more intense activity.  The difference between the 
extensive and intensive zones is the amount of time an individual would be able to 
sustain the activity.  More kilocalories are used in this zone with less of the energy 
derived from fat than the extensive zone. 
 
☻Zone V: Anaerobic Zone (Sport Training) --- 85 - 90% of maximum heart rate: 
Benefits of this zone include an improved VO2 maximum (the highest amount of oxygen 
one can consume during exercise) and thus an improved cardiorespiratory system, and 
a higher lactate tolerance ability which means your endurance will improve and you'll be 
able to fight fatigue better. This is a high intensity zone burning more kilocalories, 15 % 
from fat. 
 
☻Zone VI: Maximum (Sport Training) --- 90 - 100% of maximum heart rate: Although 
this zone burns the highest number of calories, it is very intense. Most people can only 
stay in this zone for short periods. You should only train in this zone if you are in very 
good shape and have been cleared by a physician to do so. 
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Week Prescriptio
n 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
1 Duration 5'/20'/5' 5'/20'/5' 5'/22'/5' 5'/22'/5' 5'/24'/5' 5'/24'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual 
Time 
              
Distance/S
teps 
              
2 Duration 5'/24'/5' 5'/24'/5' 5'/26'/5' 5'/26'/5' 5'/28'/5' 5'/28'/5'   
 Intensity I/II/
I 
I/II/I I/II/
I 
I/II/I I/II/I I/II/I   
 Actual 
Time 
              
Distance/S
teps 
              
3 Duration 5'/28'/5' 5'/28'/5' 5'/30'/5' 5'/30'/5' 5'/32'/5' 5'/32'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual 
Time 
              
Distance/S
teps 
              
4 Duration 5'/32'/5' 5'/32'/5' 5'/34'/5' 5'/34'/5' 5'/36'/5' 5'/36'/5'   
 Intensity I/II/
I 
I/II/I I/II/
I 
I/II/I I/II/I I/II/I   
 Actual 
Time 
              
Distance/S
teps 
              
5 Duration 5'/36'/5' 5'/36'/5' 5'/38'/5' 5'/38'/5' 5'/40'/5' 5'/40'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual 
Time 
              
Distance/S
teps 
              
6 Duration 5'/40'/5' 5'/40'/5' 5'/42'/5' 5'/42'/5' 5'/44'/5' 5'/44'/5'   
 Intensity I/II/
I 
I/II/I I/II/
I 
I/II/I I/II/I I/II/I   
 Actual 
Time 
              
Distance/S
teps 
              
7 Duration 5'/44'/5' 5'/44'/5' 5'/46'/5' 5'/46'/5' 5'/48'/5' 5'/48'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual 
Time 
              
Distance/S
teps 
              
8 Duration 5'/48'/5' 5'/48'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
 Intensity I/II/
I 
I/II/I I/II/
I 
I/II/I I/II/I I/II/I   
 Actual               
221 
 
Time 
Distance/S
teps 
              
9 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual 
Time 
              
Distance/S
teps 
              
10 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
 Intensity I/II/
I 
I/II/I I/II/
I 
I/II/I I/II/I I/II/I   
 Actual 
Time 
              
Distance/S
teps 
              
11 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual 
Time 
              
Distance/S
teps 
              
12 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
 Intensity I/II/
I 
I/II/I I/II/
I 
I/II/I I/II/I I/II/I   
 Actual 
Time 
              
Distance/S
teps 
              
13 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual 
Time 
              
Distance/S
teps 
              
Duration: 5' = 5 mintues 
Intensity = Your target heart rate (see other handout) 
Actual Time = for you to record the actual amount of time walked each day. 
Distance = distance in kilometers and/or number of steps taken from pedometer 
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Week Prescription Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
14 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
15 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
16 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
17 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
18 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
19 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
20 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
21 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
22 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
23 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
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24 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
25 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
 Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
 Actual Time               
Distance/Steps               
26 Duration 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5' 5'/50'/5'   
Intensity I/II/I I/II/I I/II/I I/II/I I/II/I I/II/I   
Actual Time               
Distance/Steps               
Duration: 5' = 5 mintues 
Intensity = Your target heart rate (see other handout) 
Actual Time = for you to record the actual amount of time walked each day. 
Distance = distance in kilometers and/or number of steps taken from pedometer 
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UNIVERSITY OF SASKATCHEWAN 
Certificate of Approval 
  
PRINCIPAL INVESTIGATOR
 DEPARTME
NT 
Philip D. Chilibeck                                                            
Kinesiology 
INSTITUTION(S) WHERE RESEARCH WILL BE 
CARRIED OUT College of Kinesiology 105 
Gymnasium Place Saskatoon  SK   S7N 5C2 
STUDENT 
RESEARCHER(S) 
Stephen Cornish 
SPONSORING AGENCIES 
GATORADE SPORTS SCIENCE INSTITUTE 
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CERTIFICATION 
The University of Saskatchewan Biomedical Research Ethics Board has reviewed the above-named research project at a full-board meeting 
(any research classified as minimal risk is reviewed through the expedited review process). The proposal was found to be acceptable on 
ethical grounds. The principal investigator has the responsibility for any other administrative or regulatory approvals that may pertain to this 
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above time period provided there is no change in experimental protocol or in the consent process. 
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Consent Form 
 
Title: The combined effects of resistance training and flax oil 
supplementation upon inflammation in older adults 
 
Names of Researchers: Philip D. Chilibeck, Ph.D. (principal investigator), 
Associate Professor, College of Kinesiology, University of Saskatchewan 
(966-1072 or 343-6577); Lisa Paus-Jensson, M.D., Department of Medicine, 
University of Saskatchewan (966-7951) Stephen Cornish, M.Sc. (student 
investigator supervised by Dr. Chilibeck), College of Kinesiology, 
University of Saskatchewan, phone: 966-1123 or 978-5735 
 
You are being asked to participate in a research study because you are of the 
age where you may be at risk for increased inflammation and reduced 
muscle strength and mass. This study involves the use of a dietary 
supplement derived from flaxseed (flax oil) and exercise training (weight 
training) for improving blood markers of inflammation, muscle strength, and 
muscle mass. Exercise training is thought to increase muscle mass and 
strength while the flax supplement is thought to lower the level of blood 
markers of inflammation. 
 
A total of 60 subjects are expected to participate in this trial. 
 
Before you decide, it is important for you to understand what the research 
involves.  This consent form will tell you about the study, why the research 
is being done, what will happen to you during the study and the possible 
benefits, risks and discomforts.  If you wish to participate, you will be asked 
to sign this form.  Your participation is entirely voluntary, so it is up to you 
to decide whether or not to take part in this study. If you do decide to take 
part in this study, you are free to withdraw at any time without giving any 
reasons for your decision nor will you lose the benefit of any medical care to 
which you are entitled or are presently receiving. Please take time to read the 
following information carefully and to discuss it with your family, friends, 
and doctor before you decide. 
 
Purpose of the study: The purpose of the study is to determine the 
effectiveness of combining exercise training and flax oil supplementation for 
reducing inflammation, and increasing muscle mass and strength, in those at 
risk of having a higher amount of inflammation.  
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Possible benefits of the study: You may improve your blood inflammatory 
status, increase your muscle mass, increase your muscle strength, and lower 
your body fat level. These results are not guaranteed. 
 
Procedures: You will initially be given a questionnaire that asks whether 
you are at risk for performing exercise. This will take several minutes to 
complete. If it is determined you are at risk, we will ask you to obtain 
permission from your family physician before entering the study. 
 
You will be randomized by chance (i.e. by a computer program) to one of 
two groups (i.e. There will be an equal chance of being assigned to either 
group). The first group will receive flax oil dietary supplement (30 mL or 2 
Tablespoons per day) and will participate in an exercise program of 
resistance training (weight training) 3 days per week, 60 minutes per day for 
12 weeks. The second group will receive a placebo (i.e. a substance that 
looks identical to the flax oil dietary supplement but does not contain the 
active ingredients of flax oil. The placebo we are using in our study is corn 
oil) and will participate in the same exercise training program. The study is 
―double blind‖, that is, neither you nor the investigators will know whether 
you are on the flax oil supplement or placebo until the study is over. In case 
of emergency, the code on the double blind can be broken so we can tell 
whether you are on the flax oil or placebo. If you agree to be in the study, we 
will do the following measurements on you: 
 
6) Blood (to assess markers of inflammation) will be taken at the start of 
the study and after 12 weeks.  Approximately 11 mL of (about 2.5 
teaspoons) blood will be collected at each time point, after a 12 hour 
fast. This procedure will take about 5 minutes. 
7) Body composition (i.e. lean tissue, fat, and bone mass) will be 
assessed at the start of the study and after 12 weeks by dual energy X-
ray absorptiometry. This involves lying still on a table for 
approximately 10 minutes while your body composition is assessed. 
Dual energy X-ray absorptiometry uses X-ray beams that are absorbed 
differently by fat, muscle, and bone. From this we can determine your 
fat, muscle, and bone mass. 
8) Body mass, height, waist girth, and two skinfolds from your trunk 
area (measured with calipers, that is, an instrument which pinches 
your fat skinfold) will be assessed at the start of the study and after 12 
weeks. This procedure takes about 5 minutes. 
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9) Muscle thickness will be determined using ultrasound on your arm 
and leg at the start of the study and after 12 weeks.  This procedure 
takes about 10 minutes. 
10) Your diet will be assessed at the start of the study and after 12 weeks 
by a food frequency questionnaire. This will take about 30 minutes to 
complete. 
11) Your muscle strength will be assessed at the start of the study and 
after 12 weeks by completing a one repetition maximum strength test 
(i.e. determining the maximal amount of weight you can lift).  One 
test (chest press) will be done to assess your upper body strength and 
another test (leg press) will be done to assess your lower body 
strength.  These tests involve progressively increasing the amount of 
weight you lift for one repetition until you are no longer able to 
complete a full repetition of the specific exercise. 
 
All of the above measurements will be done at one visit, both before and 
after the 12 weeks of flax oil/placebo supplementation and training, except 
for the muscular strength assessment. This will be done on a separate day so 
that you are not fasted.  
 
With your permission, your family physician will be informed of your 
enrolment and of your test results. 
 
You will be asked to maintain a consistent diet throughout the study. 
 
You will be prohibited from taking the following during the trial: Flax oil 
(besides that given as part of the trial), any other flaxseed product (i.e. whole 
or ground flaxseed), fish oil, evening primrose oil supplements, other marine 
oil supplements (i.e. seal oil), foods that are supplemented with omega-3 
fatty acids (i.e. omega-3 supplemented dairy and eggs) and prescription or 
over-the counter medication (non-steroidal anti-inflammatory drugs, 
prednisone etc.) or natural health products (i.e. bromelain) that are anti-
inflammatory in nature. 
 
Foreseeable risks, side effects or discomfort: There is radiation exposure 
from the dual energy X-ray absorptiometry but this is considered minimal. 
This is about the same amount of radiation as you would be exposed to 
during a return airplane flight from Saskatoon to Toronto, and is less than 
the amount of radiation you would be exposed to during a regular X-ray. 
 
 230 
There is a risk of injury during exercise testing or training. This will be 
minimized by proper warm-up procedures and supervision by qualified 
exercise trainers. 
 
There will be some discomfort when blood is drawn for testing inflammation 
levels. Bruising or infection at the sight of the blood draw is a possibility, 
but care will be taken to minimize these risks. 
 
One study reported that flax oil supplementation induced diarrhea or loose 
stools in 20% of individuals; however, this study used four times the dose to 
be used in the current study.   
 
Increased bleeding time is a possible risk associated with use of flax seed 
oil. If you have a bleeding disorder or are taking blood thinners you should 
consult a health care practitioner before using the investigational product. 
 
There may be other side effects of flax oil supplementation which are 
unknown. 
 
There may be unforeseen and unknown risks during the study, or after the 
study has been completed. 
 
Alternatives to this study: 
You do not have to participate in this study to improve your inflammatory 
status or body composition. Your level of inflammation can be improved by 
altering your diet (i.e. lowering saturated fat intake and increasing the 
amount of essential fatty acids) or by a variety of drugs that may be 
prescribed by your family physician. Your body composition can also be 
improved by altering your diet or participating in an alternative fitness 
program. You can discuss these options with your doctor before deciding 
whether or not to participate in this research project. 
 
Research-Related Injury: There will be no cost to you for participation in 
this study. You will not be charged for the study nutritional supplements or 
any research procedures. In the event you become ill or injured as a result of 
participating in this study, necessary medical treatment will be made 
available at no additional cost to you. By signing this document you do not 
waive any of your legal rights. 
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Confidentiality: Precautions will be taken to protect your anonymity during 
the study. All data collected will be stored in a locked office in the College 
of Kinesiology. While absolute confidentiality cannot be guaranteed, every 
effort will be made to ensure that the information you provide for this study 
is kept entirely confidential.  Your name will not be attached to any 
information, nor mentioned in any study report, nor be made available to 
anyone except the research team.  Health Canada may be granted direct 
access to your original medical records for verification of clinical trial 
procedures and/or data. It is the intention of the research team to publish 
results of this research in scientific journals and to present the findings at 
related conferences and workshops, but your identity will not be revealed. 
 
If you have questions concerning the study you can contact Stephen Cornish 
(student researcher) at 966-1123 or 978-5735 or Dr. Philip Chilibeck at 966-
1072, 343-6577, or 230-3849 (24 hour number). Any adverse events you 
experience during the study should be reported immediately by calling one 
of the above numbers. 
 
If you have any questions about your rights as a research subject or concerns 
about the study, you should contact the Chair of the Biomedical Research 
Ethics Board, c/o the Office of Research Services, University of 
Saskatchewan at (306) 966-4053. 
 
If, during the course of this study, new information becomes available that 
may be related to your willingness to continue to participate, this 
information will be provided to you by the investigator. 
 
Your participation in the research is entirely voluntary. You are free to 
withdraw from this study at any time and this withdrawal will not affect your 
access to health care or other services. If you choose to enter the study and 
then decide to withdraw at a later time, all data collected about you during 
your enrolment in the study will be retained for analysis.   
 
Unused study product must be returned to the Investigator for the purpose of 
compliance monitoring and product accountability. 
 
Please read the following before signing this consent form: 
 I have read or have had this read to me and understood the research 
subject information and consent form.  
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 I have had sufficient time to consider the information provided and to 
ask for advice if necessary.  
 I have had the opportunity to ask questions and have had satisfactory 
responses to my questions.  
 I understand that all of the information collected will be kept 
confidential and that the result will only be used for scientific 
objectives.  
 I understand that my participation in this study is voluntary and that I 
am completely free to refuse to participate or to withdraw from this 
study at any time without changing in any way the quality of care that 
I receive.  
 I understand that I am not waiving any of my legal rights as a result of 
signing this consent form.  
 I understand that there is no guarantee that this study will provide any 
benefits to me (if applicable).  
 I have read this form and I freely consent to participate in this study.   
 I have been told that I will receive a dated and signed copy of this 
form.   
 
Please notify my primary care physician of my participation in this study:  
Yes_____ 
No______ 
 
Research Subject‘s Signature:___________________   
 
Signature of the Individual responsible for conducting the consent process: 
 
______________________  
 
 
Date: ______________________ 
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 Week 1:  3 Sets of 12 Repetitions @ 65% 1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 Week 1:  3 Sets of 12 Repetitions @ 65% 1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
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Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
     
     
 Week 1:  3 Sets of 12 Repetitions @ 65% 1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 Week 2:  3 Sets of 10 Repetitions @ 70% 1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
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Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
     
     
 Week 2:  3 Sets of 10 Repetitions @ 75% 1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
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Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 Week 2:  3 Sets of 10 Repetitions @ 70% 1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
     
     
 Week 3:  4 Sets of 12 Repetitions @ 65% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
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Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
 Week 3:  4 Sets of 12 Repetitions @ 75% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
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Leg Curl         
Other:         
     
     
     
 Week 3:  4 Sets of 12 Repetitions @ 70% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
 Week 4:  4 Sets of 10 Repetitions @ 75% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
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Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
     
     
 Week 4:  4 Sets of 10 Repetitions @ 75% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
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Other:         
 Week 4:  4 Sets of 10 Repetitions @ 75% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
     
     
 Week 5:  3 Sets of 8 Repetitions @ 80% 1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
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Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 Week 5:  3 Sets of 8 Repetitions @ 75% 1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
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 Week 5:  3 Sets of 8 Repetitions @ 80% 1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 Week 6:  3 Sets of 10 Repetitions @ 75% 1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
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Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
     
     
     
 Week 6:  3 Sets of 10 Repetitions @ 80% 1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 Week 6:  3 Sets of 10 Repetitions @ 75% 1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
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Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
RE-TEST STRENGTH THIS WEEK 
 
 
 
 Week 7:  4 Sets of 8 Repetitions @ 80% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
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Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
 Week 7:  4 Sets of 8 Repetitions @ 75% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
     
     
     
 Week 7:  4 Sets of 8 Repetitions @ 80% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
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Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
 Week 8:  4 Sets of 6 Repetitions @ 85% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
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Leg Curl         
Other:         
     
     
     
 Week 8:  4 Sets of 6 Repetitions @ 80% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
 Week 8:  4 Sets of 6 Repetitions @ 85% 1RM  
Date: 
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3 
Reps/Weight 
Set 4 
Chest Press         
Lat Pulldown         
Trunk 
Flexion/Extension         
 249 
Leg Press         
Shoulder Press         
Bicep Curl         
Hip 
Flexion/Extension         
Tricep Press         
Hip 
Abduction/Adducti
on         
Leg Extension         
Leg Curl         
Other:         
     
     
     
 Week 9:  3 Sets of 12 Repetitions @ 75% 1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
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Leg Curl        
Other:        
 Week 9:  3 Sets of 12 Repetitions @ 75% 1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
     
     
     
 Week 9:  3 Sets of 12 Repetitions @ 75% 1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
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Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 
Week 10:  3 Sets of 10 Repetitions @ 80% 
1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
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Other:        
     
     
     
 
Week 10:  3 Sets of 10 Repetitions @ 70% 
1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 
Week 10:  3 Sets of 10 Repetitions @ 80% 
1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
 253 
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
     
     
     
 
Week 11:  3 Sets of 10 Repetitions @ 70% 
1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
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Leg Curl        
Other:        
 
Week 11:  3 Sets of 10 Repetitions @ 80% 
1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
     
     
     
 
Week 11:  3 Sets of 10 Repetitions @ 70% 
1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
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Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 
Week 12:  3 Sets of 12 Repetitions @ 70% 
1RM  
Date:  
Day 1 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
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Leg Curl        
Other:        
     
     
     
 
Week 12:  3 Sets of 12 Repetitions @ 70% 
1RM  
Date:  
Day 2 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
 
Week 12:  3 Sets of 12 Repetitions @ 70% 
1RM  
Date:  
Day 3 
Reps/Weight 
Set 1 
Reps/Weight 
Set 2 
Reps/Weight 
Set 3  
Chest Press        
Lat Pulldown        
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Trunk 
Flexion/Extension        
Leg Press        
Shoulder Press        
Bicep Curl        
Hip 
Flexion/Extension        
Tricep Press        
Hip 
Abduction/Adducti
on        
Leg Extension        
Leg Curl        
Other:        
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ANOVA Covariate Analysis at Baseline (Age) 
 
 
 
ANOVA Covariate Analysis at Baseline (Body Mass) 
 
 
 
ANOVA Covariate Analysis at Baseline (Height) 
 
 
 
ANOVA Covariate Analysis at Baseline (BMI) 
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ANOVA Covariate Analysis at Baseline (Systolic blood pressure) 
 
 
 
ANOVA Covariate Analysis at Baseline (Diastolic blood pressure) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Kilocalorie) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Total Fat) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Saturated Fat) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (MUFA) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Omega-6) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Omega-3) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Carbohydrate) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Protein) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin A) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin B6) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin C) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Folate) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin D) 
 
 
 
 
 
 
 265 
Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin E) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Iron) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Zinc) 
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ANOVA Covariate Analysis (Kilocalories of energy expenditure) 
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Repeated Measures ANOVA for IL-6 Experiment I 
 
 
_ 
 
Repeated Measures ANOVA for TNF-α Experiment I 
 
Repeated Measures ANOVA for Metabolic Syndrome Score Experiment I 
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Repeated Measures ANOVA for TAG Experiment I 
 
Repeated Measures ANOVA for HDL Experiment I 
 
Repeated Measures ANOVA for glucose Experiment I 
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Repeated Measure ANOVA for abdominal fat Experiment I 
 
Repeated Measures ANOVA for systolic blood pressure Experiment I 
 
Repeated Measures ANOVA for diastolic blood pressure Experiment I 
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Repeated Measures ANOVA for leukocytes Experiment I 
 
Repeated Measures ANOVA for lymphocytes Experiment I 
 
Repeated Measures ANOVA for monocytes Experiment I 
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Repeated Measures ANOVA for eosinophils Experiment I 
 
Repeated Measures ANOVA for basophils Experiment I 
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Appendix H ANOVA Tables from Flaxseed Oil Study 
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ANOVA Covariate Analysis (Age) 
 
 
 
ANOVA Covariate Analysis (Height) 
 
 
 
ANOVA Covariate Analysis (Body Mass) 
 
 
 
ANOVA Covariate Analysis (Chest Press Muscle Strength) 
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ANOVA Covariate Analysis (Leg Press Muscle Strength) 
 
 
 
ANOVA Covariate Analysis (Lean Tissue Mass) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Kilocalories) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Total Fat) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (MUFA) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (omega-6) 
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Repeated Measures ANOVA Dietary Covariate Analysis (omega-3) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Carbohydrate) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Protein) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin A) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin B6) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin C) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin D) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Vitamin E) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Folate) 
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Repeated Measures ANOVA Dietary Covariate Analysis (Iron) 
 
 
 
Repeated Measures ANOVA Dietary Covariate Analysis (Zinc) 
 
 
 
Repeated Measures ANOVA for IL-6 Experiment II 
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Repeated Measures ANOVA for TNF-α Experiment II 
 
Repeated Measures ANOVA for chest press strength Experiment II 
 
Repeated Measures ANOVA for leg press strength Experiment II 
 
 
 
 
 
 
 
 
 
 
 281 
Repeated Measures ANOVA for elbow flexor muscle thickness Experiment II 
 
Repeated Measures ANOVA for elbow extensor muscle thickness Experiment II 
 
  
 282 
Repeated Measures ANOVA for knee extensor muscle thickness Experiment II 
 
Repeated Measures ANOVA for knee flexor muscle thickness Experiment II 
 
Repeated Measures ANOVA for lean tissue mass Experiment II 
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Repeated Measures ANOVA for percent body fat Experiment II 
 
Repeated Measures ANOVA for fat mass Experiment II 
 
